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Abstract 
The results presented herein represent a concerted experimental programme focussed 
on producing a deracemisation system for hydroxlyamines. A number of different 
avenues have been explored. An attempt to engineer the monoamine oxidase N 
enzyme (MAO-N) which displayed no activity towards the substrates of interest was 
made. The rationale behind this was the close relationship between the amines 
known to be substrates and their hydroxylamine analogues. 
Following the initial engineering efforts two different courses of action were 
undertaken. Modification of the substrates being studied led to success in discovering 
novel substrates for the MAO-N enzyme. The enantioselective oxidation of 
hydroxylamine ethers by MAO-N is a novel discovery. A further development is the 
engineering of a MAO-N which displayed improved catalytic activity for a model 
hydroxylamine ether substrate compared with the parental enzyme. 
A second research programme lead to the discovery of the applicability of a 
laccase:mediator system to the oxidation of hydroxylamines. This represents a 
further novel discovery. 
An experimental programme investigating the reduction of oximes under conditions 
suitable for the biocatalysts described above was also performed. 
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Hydroxylamines, of the general structure 1, are a class of compounds found in many 
different areas of chemistry, from drugs' to pesticide s 2 , narcotic metabolites 3 to 
heavy metal sequestration. 4  In addition they are precursors to hydroxamic acids 5 ' 6 
and may also be regarded as masked amines. For biological studies to be performed 
and synthetic routes devised hydroxylamines have been synthesised and a relatively 





R', R 2 , R3 = alkyl, aryl 
Figure 1: General structure ofhydroxylamines. 
1.2 	Synthesis of hydroxylamines and derivatives 
1.2.1 .Racemic synthetic methods 
A number of avenues have been explored for the synthesis of hydroxylamines. 
Inspection of the literature shows that the standard method is a two step synthesis 
starting from the ketone 2 to the hydroxylamine 4, via the reduction of oxinie 
intermediate 3 (Figure 2). 
Q 	 U2NOH.F]Ci 	HOW, 	 Na(CN)BU3 	
HONNH 
	
1 	R2 	Na2SO4 	 Me011 / HC! 
Figure 2: Standard hydroxylamine synthetic route. 
The nature of the reducing agent, solvent and reaction conditions vary across the 
literature. 8 '9  Good to excellent yields are generally achieved and a wide variety of 
parental ketones have been employed.' 0"' It is for these reasons that this route is 
found across the literature. The limitation inherent in this synthetic route is the 
racernic nature of the final product. For pharmaceutical and agriculture applications 
enantiopurity may be an essential factor. 
Amines 5 may also be used as the starting materials for hydroxylamine synthesis. 
Direct oxidation of the amine to the hydroxylamine 4 using oxone / Si0 2 12 or 2,2-
dimethyldioxirane (DMD)' 3  has been reported with varying results. The DMD 
oxidation has also been reported to oxidise amines to the corresponding nitrone 6, 
which was hydrolysed to the hydroxylamine 4. Amines may also be converted to aryl 
irnines 7, thence to hydroxylamines via oxaziridines 8.14,15 A further method is the 
alkylation of amines, followed by m-CPBA oxidation to the nitrone derivative 9 and 
subsequent treatment with hydroxylamine hydrochloride (Figure 3). 16 
Oxone 
5102 





R- 'NH2 	ArCF4O R,- N Ar 	
0 m-cPBA 	
R'N-\ 	
H30t 	RNHOH -  
5 	 7 	 BAr 
1.XCH2CN, base 	 -'-, 	 RNCN — H2N0H 
2. m-CPBA 	 0_ 
9 
Figure 3: Flydroxylamine synthesis from amine starting material. 
VA 
Generally, the oxidation methods described used primary amine starting materials 
and stereoselectivity was not addressed in any of the reports. 
1.2.2 Stereoselective synthetic methods 
Chirality is a key issue concerning the production of a number of classes of fine 
chemicals. In 1992 the FDA and European Committee for Proprietary Medicinal 
Products confirmed the requirement for manufacturers to research and characterise 
all stereoisomers in chiral drugs proposed to be marketed as a mixture. Thus the 
necessity to synthesise enantiomerically pure compounds was magnified. Sales of 
chiral drugs in single enantiomer dosage continue to grow at more than 11.4% 
annually with the market estimated to be worth $14.94 billion by the end of 2009.' 
An adjunct to the possibility of using hydroxylamine derivatives as drug substances 
is the role hydroxylamines may play as drug substance metabolites. As an example, it 
has been reported that oxidation of amphetamines to a hydroxylamine derivatives is a 
crucial step on the pathway of amphetamine detoxification .3  When considering the 
roles that hydroxylamine metabolites may play in biological systems, once again the 
different reactivities of enantiomers may be crucial to the understanding of the 
metabolic pathways involved. The need for enantiopure synthetic metabolites is thus 
obvious. 
As with pharmaceuticals, chiral agrochemicals are increasingly sold as single 
enantiomer formulations. Enantiomerically enriched hydroxylamine derivatives 
have also been reported in the literature as useful as chiral auxiliaries in organic 
synthesis. The production of these fine chemicals provides a further rationale for 
developing enantioselective synthetic routes to this class of compounds. 
The mechanisms by which enantiopurity may be introduced to a synthetic route 
comprise: enantiomerically pure precursors, synthesis or resolution of a racemic 
3 
mixture. The methods mentioned above have appeared to one extent or another 
numerous times in the literature. 
The modification of enantiomerically pure starting materials has been exploited by 
Wovkiulich and Uskokovié to produce a simple synthesis of enantiomerically pure 
hydroxylamines (5)- and (R)-4 from the corresponding amines (Figure 4)•19 
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Figure 4: Synthesis of enantiopure hydroxylaniines from corresponding amines. 
This synthetic route has a number of attractive features but the foundation is the 
availability of enantiomerically pure amines, thus the route merely defers the 
difficulties of accessing enantiopure materials. The cost and availability of the 
starting materials is a key limitation of this route. The same limitation applies to 
another synthetic route which could employ single enantiomer alcohols as the 
starting material. A Milsunobu reaction, leading to inversion of stereochemistry, has 
been performed using a number of different alcohols and NO-doubly protected 
hydroxylamines. Z, Abc, True and Teoc flinctionalities have been used to protect the 
hydroxylamine and the hydroxylamine afforded in good to high yield (Figure 5) 20 
Racemic alcohols were employed in this case but it may be predicted that the use of 
single enantiomer alcohols could allow access to single enanliomer hydroxylamines 
of the opposite stereoconfiguration. 
4 
0 
OH 	PPh3 HNOR1 
OORi 	+ y R2 	R3 	
DIAD 
0 
12a-d (1?)- I(S)-la 
R1= 	>CPh 
>Z'CCI S >çSiMea 
0 
R loN 0y0R 1  deprotect 	HNOH RIO-I 
(F?)- I (S)-14 
	
(F?)- / (S)-4 
Figure 5: Synthesis of hydroxylamines via the Mitsunobu reaction. 
The resolution of hydroxylamines has also been described in the literature. The use 
of enantiomerically pure tartaric or mandelic acid to form a diastereomeric mix of the 
hydroxylamine acid followed by selective crystallisation afforded enantiomerically 
pure hydroxylamines. 2 ' The disadvantage of this technique is the inherent limitation 
to the reaction yield. No greater than 50% yield can be achieved for the desired 
enantiomer. The reaction is poorly atom-efficient and yields high quantities of waste 
material (Figure 6). 
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Figure 6: Selective crystallisation to access single enantiomer hydroxylamines. 
Perhaps the most elegant, but often the most expensive, solution to the problems of 
synthesising enantiomerically pure products is that of asymmetric synthesis. A 
reaction that modifies an achiral moiety to produce an enantiomerically enriched 
chiral centre opens the possibility for an efficient synthetic route. The asymmetric 
reduction of an oxime 15 to the corresponding hydroxylamine derivative 16 is just 
such a reaction (Figure 7). 
	
R30, N 	Asymmetric reduction catalyst! reagent 	
R30NH 
 
15 	 (R)-I(S)-16 
Figure 7: Asymmetric reduction of oximes. 
A number of authors have reported reactions of this nature in the literature. The 
results are variable with the enantiomeric excesses reported ranging from poor to 
good. There are a number of disadvantages associated with the published methods 
for asymmetric reduction of oximes. A critical issue is the regularly observed over-
reduction to the amine product, 22  leading to low chemoselectivities and yields. 
Enantioselectivities also are often poor to moderate . 23 Additionally, there is a 
requirement for either chiral auxiliaries or reagents, for example borane-
oxazaborolidine adduct S.22  Chiral auxiliaries often require lengthy synthetic routes, 
as do the asymmetric reducing agents reported. The limitation when reagents are 
acquired from the chiral pool is that the enantiomer desired is not always available. If 
synthesised, then the expense and difficulty in acuiring the species employed to 
induce an enantioselective reduction often over-shadows the success in producing the 
enantioenriched hydroxylamine products. 
An overall assessment of the literature regarding the synthesis of enantiomerically 
enriched hydroxylamine derivatives indicates that the area is significantly under-
developed when compared to methods to make chiral amines and alcohols. It may be 
argued that this is due to the relative importance attached to these moieties in the 
fields of organic synthesis, drug discovery and chemical manufacture. Nevertheless 
there clearly exists an opportunity for the investigation and exploitation of novel 
techniques to access enantiomerically enriched hydroxylamine derivatives. The 
limited nature of the literature reported starkly illustrates the fact that the use of 
biocatalysis, a rapidly expanding are of interest for enantioselective synthesis, has 
not been reported to any significant extent for hydroxylamines. 24 
1.3 	Riocatalysts 
Biocatalysis describes any chemical conversion of substances that is mediated by 
living organisms or enzyme preparations derived there from. Biocatalysis has 
become an increasingly important tool in the industrial synthesis of pharmaceutical 
and agrochemical intermediates and speciality bulk chemicals. A number of 
attractive features are associated with the use of a biocatalyst and the growth in the 
exploitation of biocatalysts can be traced to a combination of driving and enabling 
factors. 
1.3.1 Factors driving the development of biocatalysis 
Factors that have driven the development of biocatalytic synthetic routes include the 
high enantioselectivities regularly exhibited by a wide variety of systems. 25 This has 
been one of the most crucial driving forces. On occasions there has been no rival 
system that can offer comparable enantioselectivity. A further key factor has been the 
drive towards 'greener' chemical processes. 26  The reduction in volume and 
hazardousness of waste streams and the lowering of energy requirements top the list 
of methods to make a process more environmentally benign. Whilst biocatalytic 
systems are no panacea to the problems of synthesis, they may offer significant 
advantages over rival systems on occasions. Biocatalytic processes generally require 
moderate temperatures and pressures, 27  thus lower energy input compared with 
traditional processes. In addition, bulk solvents are often reasonably 'green', water 
and/or non-chlorinated solvent mixtures being most commonly used. Finally, 
biocatalysis may be the only method to perform the reaction in question, in other 
words, no viable alternative methods are available. 
7 
1.3.2 Factors enabling the development of biocatalysis 
Factors that have enabled the development and exploitation of biocatalytic processes 
include the advances in both technological and biological knowledge of recent times. 
A crucial area is that of genomics which has allowed the unravelling of many of the 
secrets of biocatalytic processes. It has also fed into the science of directed enzyme 
evolution. The use of the directed evolution 28, saturation mutagenesis 29 and chemical 
modification of enzymes 30  has provided researchers with the opportunity to tune, 
improve and alter biocatalysts much as has been done with traditional 
chemocatalysts. A second enabling factor has been the sourcing of biocatalysts from 
a far broader range of biodiversity. Organisms and the biocatalysts produced by them 
are now known from a wide range of environments; deep-sea vents 31 , African soda 
lakes 32  and the Antarctic 33  to name but a few. This in turn leads to both novel 
reactions and novel conditions at which reactions may be performed being 
discovered. A third factor is the commercialisation of many biocatalyst preparations 
which has allowed 'off-the-shelf access for researchers. A final, intangible, factor is 
the increasing acceptance of biocatalytic routes as viable and acceptable synthetic 
routes within the community of synthetic chemists. Clearly this builds from the 
factors outlined previously, along greater knowledge transfer 34  and inter-disciplinary 
interactions. The realisation that biocatalysis may offer great benefits and the 
acceptance that they may perform stable, reproducible and understandable reactions 
has led to a recognition that biocatalysis must be taken seriously. 
1.3.3 Biocatalytic routes to enantioenriched products 
Asymmetric synthesis 
The transformation of an achiral substrate to an enantioenriched chiral product is an 
asymmetric synthetic process. Biocatalysts have proved to have many applications in 
this area and the literature covering this area is broad and extensive. Biocatalysts 
employed in asymmetric transformations include transaminases which have been 
used in the production of optically active amines 18 from a carbonyl compound such 










Figure 8: Synthesis of optically active amines using transaminase enzymes. 
Enantiopure lactones have been synthesised using Baeyer-Villigerase enzymes -16  and 
many other biocatalysts have been described to catalyse asymmetric transformations 
including epoxide hydrolases, 37  alcohol dehydrogenases and oxidases 38 and 
reductases 39  to name but a few. It is also noteworthy that the use of biocatalysts is not 
restricted to simple single step transformations; complex cascade reactions may be 
performed .41) 
Enantioconvergent synthesis 
An enantioconvergent transformation describes a process by which a racemic 
mixture is convened to a single enantioi -ner of a product via two different reactions 
for the two substrate enantiomers. One enantiomer is converted with retention of 
configuration and the other enantiomer is converted with inversion of configuration, 
producing a single enantiomer product with 100% theoretical maximum yield. An 
enantioconvergent system often relies on the use of two different biocatalysts, with 
opposite stereoselectivity, in a one-pot system, for example the combination of two 
epoxide hydrolases with opposite hydrolysis specificities. 4 ' interestingly a single 
biocatalyst can perform an enantioconvergent reaction, if it displays opposite 
selectivities on the two different enantiomers of a raceniic mixture. Epoxide 
hydrolase from Novacardia species hydrolyses both enantiomers of cis-2,3-
disubstituted epoxyalkanes however, crucially, hydrolysis is performed at the (8)- 
















Figure 9: Enantioconvergent synthesis of epoxyalkanes. 
Kinetic resolution 
A kinetic resolution is the achievement of partial or complete resolution, by virtue of 
unequal reaction rates, of the enantiomers of a racemate with a chiral agent. Thus 
enantiosejection is based on the different reaction rates of the transformation of 
substrates SR and Ss by a chiral catalyst to PR and P5. Recovery of the product PR and 
the unreacted enantiomer S5 in a non-racemic form constitutes a kinetic resolution. 
Clearly the reaction may progress with opposite enantioselectivity, dependent upon 
the nature of the catalyst (Figure 10). 
10 
- - - - ks 
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5R S5 = substrate enantiomers 
R, s = product enantiomers 





Figure 10: Theoretical basis of  kinetic resolution. 
Biocatalytic kinetic resolutions are extremely common in the literature  .43  The bulk of 
the resolutions presented employ a lipase as the enantioselective catalyst. Most 
commonly the lipase is employed to selectively acylate a hydroxyl moiety on one 
enantiomer using an acyl donor in a transesterification reaction, vinyl acetate being 
the most common choice  .44  The reasons for this include the fact that a number of 
lipases are frilly commercialised products, available in bulk quantities. This means 
that they are a catalyst that may be considered for scale-up and they are readily 
available to researchers worldwide. In addition to simple lipases a number of solid-
supported lipase preparations are also widely available including Novozyme 435 and 
Lipolase, 45 increasing the scope for the lipase-catalysed reactions. The specificity 
and enantioselectivity of lipases has been studied and is predictable, 46 along with the 
stereochemical preference for ester and alcohol substrates, generally found to follow 
Kazlauskas' rule (Figure 1 
Figure 11: Pictorial representation of preferred lipase substrate for Kazlauskas' rule. 
As with any empirical rule, exceptions may be found but as a general guide to the 
stereoselectivity of lipases this rule allows for predictable results to be achieved. The 
11 
factors outlined above contribute to a 'snowball' effect, in which increasing literature 
reports of lipase-catalysed kinetic resolutions stimulate further work. The practical 
requirements48  and techniques needed to perform a biocatalysed kinetic resolution 
have entered the mainstream synthetic chemist's arena. 
A number of different substrate classes, with different chiral flinctionalities have 
been resolved using a lipase catalysed kinetic resolution system. These include a 
wide diversity of compounds with a hydroxyl moiety but also amines . 49 The reverse 
reaction of the transesterification, hydrolysis of one enantiomer of a racemic ester, is 
also regularly reported. Lipases are not the only catalysts successfully used in 
kinetic resolutions; enzymes including epoxide hydrolases 5° and esterases 5 ' have also 
been reported to catalyse the resolution of chiral substrates. Kinetic resolution is a 
powerful technique to access enantioenriched products and, as demonstrated above, 
has been widely adopted and reported in the literature. The key limitation of the 
process is the inherent maximum yield of the desired product. As a racemate contains 
only 50% of the desired enantiomer, a maximum yield of 50% can be achieved. This 
restriction will always apply and only in the rare case when the desired enantiorner of 
the product and the remaining enantiomer of the substrate are both required will the 
reaction be theoretically high yielding. Recognising this crucial deficiency research 
has been directed towards overcoming the maximum yield restriction. The recycling 
or racemisation of the unwanted enantiomer is often the focus for research, 
particularly by process chemists. 
Dynamic kinetic resolution 
A kinetic resolution may be modified by the addition of a second process in which 
the two substrate enantiomers are interconverted (Figure 12). This is named a 
dynamic kinetic resolution (DKR). This leads to the possibility of a maximum 
theoretical yield of 100%. 
12 
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SR 	 R 	 - build.upofPR 
Figure 12: Theoretical basis of a dynamic kinetic resolution. 
The key to a successful DKR is finding conditions which allow an in situ 
racemisation whilst maintaining the activity of the resolution catalyst. Both the 
conditions and catalysts used for the two processes must be mutually compatible. 
Broadly, two techniques have been used for the racemisation process; chemocatalysis 
or a second biocatalytic process. Simple chemocatalysis, such as acid/base catalysed 
enolisation can be used to racemise labile chiral centres. However it is advantageous 
to operate with stable chiral centres, to ensure a stable, non-labile product is formed. 
Alcohols and amines can be racemised by an oxidation and reduction sequence with 
a transition metal catalyst such as Ru, Rh, Ir, Al, or Pd .52  Bäckvall and co-workers 
have developed a process based on the use ofp-chloroacetate as the acyl donor and a 
ruthenium complex as the racemisation catalyst. 53  This was found to be compatible 
with Candida antarlica lipase B catalysed resolution, allowing the construction of a 
DKR (Figure 13). 
CAL-B lipase 
OH p-Cl-C61 ­14-OAc (3 equiv) OAc 
Ru-catalyst (2 mol%) 
rac-21 toluene (0.25 M) (S)-22 
>50% yield 
99% e.e 
Figure 13: Dynamic kinetic resolution of secondary alcohols. 
Deracemisat ion 
Formally, a deracemisation process is one in which a racemate is converted into a 
chiral, non-racemic product with a theoretical maximum e.e. of 100% and with the 
theoretical possibility of 100% yield. No intermediate separation of materials occurs. 
13 
Dynamic kinetic resolutions (DKR), dynamic thermodynamic resolution, 
stereoinversion and enantioconvergent transformations of a racemate are all 
classified as deracemisation processes. However, in the context of this report, a 
deracemisation describes a subset of these processes, specifically the conversion of a 
raceniate to a single enantiomer of a substrate in a maximum theoretical yield of 
100% (Figure 14). 
achiraI 
kR 	 [kp 	k 
SR, Ss = substrate enantiomers 
1acl,iraI = achiral intermediate 
kR>ks 
11 
SR a\  Ss 	• build-up of Ss 
Figure 14: Theoretical basis of a deracemisation. 
As demonstrated in Figure 14, the requirements for the deracemisation process are a 
stereoselective transformation of one enantiomer of the substrate to an achiral 
intermediate. Secondly, a non-stereoselective transformation of the achiral 
intermediate back to the substrate is needed. Critically, these two processes need to 
be mutually compatible in a one-pot situation. Overall a cyclic transformation system 
is set-up and repeated progression of the transformed enantiomer through the cyclic 
leads to an enantioenrichment of the substrate. Depending on the nature of the 
racemic substrate the stereoselective portion may be an oxidation or a reduction. The 
use of a deracemisation process to access enantioenriched products has been reported 
in the literature '54.55  Soda eat al. employed this method for the deracemisation of DL-
proline 56 and DL-pipecolic acid
-57  using D-amino acid oxidase to perform the 
stereoselective oxidation and sodium borohydride to non-stereoselectively reduce the 
achiral imine intermediate (Figure 15). 
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NH 7 	Reduction 
NaBH4 
Build-up of (L)-23 
(L)-23 
Figure 15: Deracemisation of DL-proline. 
The use of these conditions has been expanded to encompass the deracemisation of 
acyclic substrates. The use of sodium cyanoborohydride as the reducing agent has 
also been reported, with some advantages over sodium borohydride. 58 Catalytic 
transfer hydrogenation has also shown to be effective as the reducing agent in the 
deracemisation of amino acids.  59  The stereoselective biocatalytic oxidation coupled 
with borohydnde reagent reduction process has more recently been applied to the 
deracemisation of amines. The deracemisation of a.-methylbenzylamine 24 in 77% 
yield and 93% e.e. has been reported  '60 as has the deracemisation of I-methyl-
1,2,3,44etrahydroisoquinoline 25.61  In the case of the acyclic substrate the yield was 
sub-optimum as a result of intermediate imine hydrolysis. However it has been 
conclusively demonstrated that the deracemisation of amines, as with amino acids, is 
a viable proposition. 
NH2 
(X~ 	 NH 
24 	 25 
Figure 16: Previously demonstrated amine deracemisation substrates. 
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Stereoinversjon 
A stereoinversion process consists of one enantiomer of a substrate being selectively 
converted to an achiral intermediate. The achiral intermediate is in turn converted to 
the opposite enantiomer with a second step. An example of this process is the 
stereoinversion of a chiral secondary alcohol via an achiral ketone. This process has 
been reported in the literature, employing two different enzymes; a dehydrogenase 
which stereoselectively oxidises one enantiomer of the secondary alcohol and a 
redox enzyme which stereoselectivity reduces the ketone with opposite selectivity to 
the dehydrogenase. 62  Crucially the stereoselective reduction of the ketone is 
irreversible, thus a build-up of a single enantiomer occurs. This is important as the 
conversion of the racemate to a single enantiomer in this process is energetically 
disfavoured in thermodynamic terms. 
Dehydrogenase 	 Redox-enzyme 




R226/ \\ 	 / \ 
	 R i R2 
NAD(P) + NAD(P)H 	NAD(P)H 	NAD(P) t 
A 	 4 
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Internal cofactor recycling 
Figure 17: Stereoinversion of secondary alcohols. 
A stereoinversion can be regarded as a more refined version of a deracemisation, 
described above, replacing the second non-stereoselective step of a deracemisation 
with a stereoselective transformation. The combination of two stereoselective steps 
means that the completion of a number of cycles of conversion, as with a 
deracernisation, is unnecessary. 
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1.4 	Conclusion 
The reasons detailed above illustrate the rationale for conducting an investigation 
into possible biocatalytic routes for the synthesis of hydroxylamine derivatives. The 
area is not developed significantly in the literature and both the synthetic products 
and procedures warrant a detailed survey of possible biocatalytic routes that may be 
exploited. Due to the prior success of a deracemisation system in producing 
enantiornerically enriched amine enantiorners from the corresponding racernates 61 ' 63 
the development of an analogous system for hydroxylamines was the focus for the 
project as a whole. The development of the various components necessary for this 
are described further in the chapters that follow. As an alternative to the 
deracemisation, an asymmetric reduction of the achiral oxime substrates to the 
analogous hydroxylamines employing a biocatalyst could be envisaged, and has also 
been explored to some extent. 
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2 	Laccase 
As outlined in Chapter 1 a successful construction of a deracemisation system 
requires a stereoselective conversion, in the case of this report, a stereoselective 
oxidation of a hydroxylamine substrate. With a focus on biocatalytic methods a 
survey of the literature was performed in an effort to identify suitable biocatalyst. 
One such catalyst identified was the laccase family of enzymes. 
2.1 	Laccase enzymes 
Laccases (benzened iol: oxygen oxidoreductases, E.C. 1.10.13.2) are a class of 
oxidoreductase enzymes that participate in the a variety of enzymatic processes. 
They have been found in various plant species, in bacterium 65 , and in a number of 
studied insects. 66  Laccases have been implicated in a number of processes which 
include lignin biosynthesis 67,  plant pathogenicity68 , the degradation of plant cell 
walls69 and insect sclerotisation. 7°  Laccases are also widespread in numerous fungi. 7 ' 
Of relevance to this study is the involvement of white-rot fungi laccases in the multi-
enzymatic process of lignocellulose degradation. 72  The lignocellulose degradation 
process is a crucial step in carbon recycling in terrestrial ecosystems and a number of 
fungi demonstrate the ability to break down the lignin present in the wood they grow 
on, this degradation is achieved via the oxidation of the lignin catalysed by laccase, 
using atmospheric oxygen as the ultimate oxidant. 
Crystal structures for a number of laccases have been published and indicate the 
enzyme contains 4 copper atoms. 64,73 Laccases are described as being type 1, type 2 
and coupled binuclear type 3 centres. These assignments are based on the EPR 
properties exhibited by the Cu atoms. The type 2 Cu atom and the type 3 binucleur 
Cu. atoms form the trinucleur cluster which is thought to represent the active site for 
the binding and reduction of 02 and for the release of water. Mechanistic studies 
indicate that a single-electron transfer mechanism is involved . 74 The 
depolymerisation of lignin requires the oxidation of two general moieties: electron-
rich phenolic fragments and non-phenolic fragments. Studies have showed that the 
substrate specificity range of these enzymes is relatively narrow, with a specificity 
limited to the phenolic fragments of lignin. The reaction mechanism proceeds 
through the generation of the phenoxyl radical, after which a variety of reaction 
pathways have been proposed (Figure I 
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Figure 18: Possible reactions of the phenoxyl radical derived from a lignin subunit; 
A - side-chain oxidation, B -. radical coupling condensation, C - aromatic ring 
cleavage via dioxetane intermediate, D - further oxidation / oxygen addition at C-3 
to yield o-quinones, E - further oxidation at C-I to yield p-quinones. 
It has been shown that the distribution of products from the laccase mediated 
oxidation of vanillyl alcohol, 29, a standard lignin model, is very narrow. Traces of 
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vanillin 30, the product of side-chain oxidation (pathway A) and 31, the radical 
coupling (pathway B) derived product are the only observed products. Much of the 
starting material remained. However, work in a number of publications has 
illustrated how the scope of laccase catalysed oxidations may be expanded 
















Figure 19: Vanillyl alcohol 29 and observed oxidation products 30 and 31. 
The interest and research regarding laccases has been driven chiefly by the 
technological applications that these enzymes have in the wood processing industry. 
Lignin removal, the major step in the degradation of lignocellulose, is the key step in 
the conversion of wood to paper pulp. In addition, the bleaching of paper pulp fibres 
requires further lignin removal. In targeting a totally chlorine-free (TCF) 
manufacturing sequence industrial and academic research groups have exploited a 
number of enzymes, including laccases, as oxidising agents. The use of atmospheric 
oxygen as the stoichiometric oxidant ensures a cheap and unrestricted bulk reagent 
supply. Environmental concerns are reduced with TCF processes and economic 
drivers are high for developing these enzymatic processes. 
2.2 	Laccase:mediator systems 
The use of laccases in paper-processing has exploited the wild type substrate of the 
enzyme, as have a number of other bioremedial and synthetic systems 77,  however 
developments of pulp processing systems 78  have demonstrated that the substrate 
range of laccase can be expanded greatly by the incorporation of a mediator in the 
oxidation system, the so called ]accase:mediator system (LM system). 79 An extra 
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oxidation/reduction cycle is inserted into the reaction sequence which has the effect 
of decoupling the direct oxidation of the substrate from the laccase active site (Figure 
20). 
02 	Laccase 	Mediator - ox 	Substrate 
H20 	Laccase - ox 	Mediator 	Substrate - ox 
Figure 20: Laccase-mediator system. 
After being oxidised the mediator exits the enzyme active site and in turn oxidises 
the substrate, thus the mediator acts as an 'electron shuttle'. This would expand the 
possible substrates to those unable to access the laccase active site. Alternatively, the 
mediator could oxidise the substrate through a mechanism unavailable to the laccase, 
again expanding the substrates able to be oxidised. 80 A combination of both of the 
factors outlined above is possible. 
Research in the area of LM systems has led to a reassessment of the natural lignin 
degradation process. Naturally incorporated mediators would expand the substrate 
range of the laccases and allow an oxidation of the non-phenolic lignin fragments, 
giving the expressed laccase broad spectrum lignin degradation activity. A number of 
compounds, including 3-hydroxyanthranilic acid, have been postulated as a naturally 
occurring mediator of the laccase activity in fungi. The area is still under 
investigation and conflicting results have been reported. 81 ' 82 A key advantage that the 
use of a LM system has allowed is that the range of substrates that may be oxidised is 
broadened significantly. This has been manifested in a number of ways; the 
modification of a paper bleaching system to afford a much improved process or 
product 83,  water treatment 84  and in the decolourisation of recalcitrant dyes 85, 
including a fully comrnercialised process for denim decolourisation sold under the 
trade name Denilite and its reformulated successor Denilite II S. 86 
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A number of different mediators have been described in the literature. 87  The essential 
feature is the ability of the small molecule mediators to undertake redox cycles. 
Whilst many molecules could be suggested that have this feature, prior work has 
generally focused on three categories of mediator; 2,2'-azino-bis(3-
ethylbenzthiazoline-6-sulfonic acid) (ABTS) 32, N-hydroxy compounds such as I-
hydroxybenzotriazole (FIOBt) 33 and species based on the nitroxyl radical containing 
2,2',6,6'-tetramethylpiperidine- N-oxyl (TEMPO) 34. 
N=x(I 
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Figure 21: Mediators previously reported for laccase:mediator systems. 
2.3 	Laccase:mediator reaction mechanisms 
The mechanism for ABTS mediated oxidation has been postulated to be an electron 
transfer (ET) route (Figure 22). It was shown that the reactivity of the mediation 
reaction correlated with the oxidation potentials of a series of analogous substrates, 
based on substituted benzyl alcohols. 88 
CH20H 	 CH2 0H 	 CHOH 	 CHO 
(] 	
Medox 	 -H 	 - 
OMe 	 OMe 	 OMe 	 OMe 
Figure 22: ET route for ABTS mediated reactions. 
The mechanism for N-hydroxy mediators has been extensively investigated and, in 
the case of N-hydroxyphthalimide and l-hydroxybenzotriazole, a radical hydrogen 
atom transfer (FIAT) model has been demonstrated to be the most appropriate 
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explanation. 88 Hydrogen atom abstraction from the benzylic C-H bond was shown to 
be the rate determining step, differing from the ET route for ABTS (Figure 23). 
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Figure 23: HAT route for N-hydroxyl compound mediated reactions. 
The fact that the N-hydroxy compounds are believed to operate through a nitroxyl 
radical • intermediate points to the use of stable nitroxyl compounds as possible 
mediators. The mode of action of these compounds, such as TEMPO, is not, 
however, a simple case. The stable nitroxyl compounds are not, in themselves, active 
oxidising agents; in other words, the nitroxyl is not the active oxidising species in 
these systems. This is easily demonstrated by the fact that laccase is required for the 
system to work, TEMPO alone is not sufficient for an oxidising system. The 
mechanism is proposed to go through the key 
O N 
R1 	R2 
R 1 	R2 
JH+ 
HO 
R i 	 R2 
xoammonium ion (Figure 24). 
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Figure 24: Proposed TEMPO mediated laccase oxidation mechanism for alcohols. 89 
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Of greatest relevance to the studies presented herein is the work of Galli and co-
workers. 89 Over the course of a number of publications this group has shown that the 
use of a LM system can be applied to the oxidation of a number of simple alcohols 
and related substrates. A comprehensive survey of possible mediators and the 
substrate range with respect to substituted alcohols has been reported. The regular 
use of N-hydroxy compounds as mediators suggested that hydroxylamine derivatives 
could be viable targets as the ultimately oxidised substrate in a LM system. In an 
attempt to define a system suitable for the efficient and reproducible oxidation of 
hydroxylamine derivatives to the corresponding oxime derivatives a programme 
investigating the application of a LM system to this transformation was undertaken. 
A number a key variables were identified and a systematic investigation performed 
in an attempt to firstly; assess whether a LM system could be applied to the oxidation 
of hydroxylamine derivatives, and secondly; optimise reaction conditions to 
construct a viable reaction system. The source of the laccase, reaction conditions in 
terms of substrate concentration, solvent and reaction time were key parameters. The 
nature of the mediator was predicted to be a crucial and the experimental program 
reflected this. 
2.4 	Laccase results and discussion 
2.4.1 Laccase source 
A number of sources of laccase are available, both wild-type and recombinant. These 
enzymes have been use in a number of different preparations including immobilised 
on silica and Amberlite IRA-400 resin. 909 Commercial sources were considered as 
the preferred option for reasons of expediency and price and were prioritised for 
investigation and assessment. Two sources were employed for initial testing, laccase 
derived from Rhus vernijicera (the Japanese lacquer tree) and Tramefes versicolor 
(the turkey-tail fungus) and both were supplied as off-white to brown powders. These 
preparations were analysed using SDS-PAGE chromatography and were found to 
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contain multiple bands (Figure 25). The preparations were used in this crude 
formulation, because it was desirable to construct an oxidation system that was 
convenient and transferable. The use of commercially available reagents without 
further purification is hugely advantageous if the process is to be used at large scale. 
If the oxidation was found to be ineffective than re-examination of the system with 
purified laccase would be possible. 
kDa 
R. vern/ict'ra T versicolor Protein Ladder 
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Figure 25: SDS-PAGE gel of Rhus verniflcera and Trametes versicolor laccase 
preparations. 
Initial experiments were focused on a single substrate, l-phenylethylhydroxylamine 
35, to assess the suitability of applying a LM system to hydroxylamine systems and 
in an attempt to define optimised reaction conditions. 
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Figure 26: 1-phenylethylhydroxylamine 35. 
Analysis was performed using GC-MS. This technique provided a number of 
advantages; rapidity, the use of an automated injection system and the development 
of a short run time lead to a high-throughput screen. Also, if the reaction produced 
undesired or unexpected products in the reaction an initial identification of these 
could be achieved from the mass spectrum acquired. 
Initial experiments performed were designed to explore whether laccase would 
directly catalyse the oxidation of hydroxylamines without requiring a mediator, thus 
the laccases were first tested without any mediator added. No conversion of the 
starting material was observed with either Rims verni/Icera or Trarne/es versicolor 
derived laccase. 
Having demonstrated that a non-mediated system was completely ineffectual in the 
attempted oxidation of a hydroxylamine derivative the investigation of possible 
mediators was commenced. 
2.4.2 Mediator 
A large number of possible mediators for use in a LM system have been described by 
previously published work. A comprehensive survey of these possible mediators was 
undertaken. Commercial availably appeared to have driven selection of these 
possible mediators in the literature and this focus was followed in the selection of the 
initial mediator panel to be tested. The target of this experimental programme was to 
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define a simple and practical oxidation system, so the use of mediators that required 
significant synthetic steps to access or were available only from niche sources would 
be a significant limitation. A diverse selection of possible mediators was -assembled 
32-34, 36-39 (Figure 27) and challenged against 35. The laccase preparation from 
Trametes versicolor was selected for the first mediator survey. This was due to 
observations from the initial laccase survey; the laccase preparation derived from 
Rhus vernflcera contained a noticeable amount of insoluble particulates. 
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Figure 27: Possible LM system mediators. 
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• 	 Mediator ? 0.3eq. 	• .•• 	Conversion at t = 180mins I % 
ABTS (32) >99 
HOBt (33) 11 
TEMPO (34) >99 
PROXYL (36) 36 
PROXYLene (37) 45 
Violuric Acid (38) >99 
N-hydroxyphthalimide (39) 5 
Table 2: Survey of possible mediators for LM system. 
Due to the excellent conversion observed, coupled with reasons of economy and ease 
of supply, TEMPO was selected as the mediator of choice for further experiments. 
One might expect the oxidation mechanism for this process to be closely analogous 
to the proposed mechanism for alcohol oxidation using the same system (Figure 28). 
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Figure 28: Proposed mechanism for TEMPO mediator laccase oxidation of 
hydroxylamines. 
To confirm the choice of laccase from Tranietes versicolor as the preferred enzyme 
preparation a TEMPO- Rhus vernjficera LM system was tested and found to produce 
0% conversion. The reason for this is unclear, however the experiment was repeated 
with a new supply of Rhus vern(fIcera laccase and the same negative result obtained. 
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Thus TEMPO / Trameles versicolor laccase was defined as the LM system of choice 
for further work. The test system that was defined was: 3mM (0.3eq.) TEMPO, 100U 
laccase, 10mM substrate in pH 4.5 citrate buffer. 10% v/v MeCN was used for 
systems in which the substrate was not frilly soluble in aqueous buffer. The reaction 
mixture was shaken at 200 rpm at 25 °C. The use of 0.3 eq. TEMPO is regularly 
reported in the literature and suggests a very inefficient catalyst system. A possible 
explanation is that the TEMPO undertakes an oxygen transfer reaction to enzyme 
residues, which results in the corresponding secondary amine being formed (Figure 
29). 





Figure 29: Possible TEMPO degradation reaction. 
Evidence for this is that TEMPO concentration in these reactions can be observed to 
rapidly fall initially, before reaching an equilibrium concentration. Addition of 
further portions of TEMPO results in a rising of this equilibrium concentration. 92 
This suggests TEMPO undergoes a fixed number of degradation reactions afler 
which it is solely involved in the redox cycle of the substrate oxidation. 
It was decide to continue with the system defined above to probe the substrate 
specificity of the reaction. 
2.4.3 Substrate specificity 
An assessment of the substrate specificity of the LM system detailed above was 
performed in an attempt to define its utility and generality. The members of the 
substrate panel to be tested were selected with a view to challenging the system with 
substrates of varying steric properties. Challenging the LM system with these 
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substrates would provide an opportunity to gauge the usefulness of this reaction and 
address concerns regarding the possible lack of generality of the system. Substrates 
35, 41 - 50 were tested and the results detailed in Table 3 observed. 
HN_OR3 	lacasse, pH4.5 buffer 	 N_OR3 
TEMPO 







35 Ph Me H 50 >99% 
41 Ph Et H 51 >99% 
42 Ph Me Mc 52 >99% 
43 pOH-Ph Me H 53 14% 
44 pOH-Ph Me Me 54 >99% 
45 pBr-Ph Ph H 55 51% 
46 Cyclohexyl Me H 56 25% 
47 Cyclohexyl •Me Me 57 79% 
48 Me 58 >99% 
49 Fl 59 >99% 
Table 3: Screen to establish substrate specificity of LM system. 
As Table 3 indicates, the results of the substrate specificity experiments suggest that 
the reaction system has a broad scope, with a wide range of substrates tolerated. The 
reaction is not limited to hydroxylamines but shows hydroxylamine methyl ethers 
may be oxidised. Interesting, no evidence for the oxidation of the phenolic 
functionality of compounds 43 and 44 is observed although the wild-type activity of 
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laccase would suggest they may be vulnerable to oxidation. Analysis of the initial 
survey was performed by GC-MS. Standard samples allowed for the development of 
definitive analytical methods and an indication of the nature of by-product was 
possible. Clearly a fuller characterisation of a number of the reactions, to ensure 
conclusive identification of the reaction product would be desirable and was 
performed for a selection of the reactions detailed in Table 4. 
• 	 Hydroxylamine 
Starting material 
Oxime product Oxime identification 
35 50 GC-MS, LC-MS, NMR 
44 54 GC-MS, LC-MS, NMR 
46 56 GC-MS, LC-MS, NMR 
Table 4: LC-MS and NMR analysis of oxidation product. 
Whilst confidence in the Livi system developed for the oxidation of hydroxylamine 
derivatives had been established a further level of development was considered 
crucial. A preparative scale reaction, with full characterisation of the reaction 
products, was performed to test the utility of this reaction for the preparation of 









Figure 30: Preparative scale product ofoxiine 50 using the LM system. 
0.3g of fully characterised 50 was obtained in 89% yield from the LM system 
reaction (see 7.13, page 147). 
The LM system detailed above represents a novel reaction for the oxidation of 
hydroxylamine derivatives, an area which has received little attention in the 
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literature. The reaction conditions are relatively mild and inexpensive and the 
substrate specificity has been shown to have no major limitations. To probe whether 
an even broader range of functionality may be successfully oxidised using the LM 
system compound 60 was tested. The reaction was found to be compatible with a 
tertiary nitrogen centre and the corresponding nitrone 61 was observed via GC-MS. 
NH 
60 	 61 
Figure 31: NN-Dibenzylhydroxylamine and nitrone analogue. 
With the LM system for hydroxylamine derivative oxidation in hand, further 
expansion of the range of the reaction was envisaged. A large proportion of the 
hydroxylamine derivatives employed were chiral and thus an enantioselective 
oxidation would be not only possible but highly attractive. A large number of 
enzymatically catalysed reactions exhibit excellent enantioselectivity. The chiral 
environment of the majority of enzyme active sites, derived from the single 
enantiomer nature of most amino acids, explains this phenomenon. However, as 
reported in the literature and the substrates tested above, this is not the case for the 
LM system. To confirm this fact the enantioselectivity of the oxidation with respect 








Figure 32: GC trace of oxidation reaction of 47. Non-enantioselective oxidation of 
47 to a mixture of geometric isomers of the corresponding oxime 57 is illustrated 
(GC Method 1). 
This result is most simply explained by the fact that the substrates do not interact 
with the laccase directly but via the mediator. The mediators do not offer the 
possibility of enantio-discrimination when oxidising the substrates. In extending this 
theory it is obvious that if an enantioselective oxidation is desired using the LM 
system the mediator must oxidise the substrate in an enantioselective fashion. By 
analogy to the enzyme active site it may be postulated that a single enantiomer chiral 
mediator may oxidise the hydroxylamine derivative in an enantioselective manner. 
2.4.4 Further mediator investigations 
In an attempt to further improve the rate of oxidation the identity of the optimum 
mediator was further probed. With a view not only to rate improvement but also to 
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future specialisation of the LM system, a number of TEMPO analogues 62 - 64 were 
tested to investigate whether substituted TEMPO mediators would exhibit 
comparable activity to the parent mediator. These experiments would provide an 
indication as to whether more complex nitroxyl radical mediators could be viable 
mediators. This was of interest as elaboration of a TEMPO core could afford chiral 
mediators, and therefore possibly, enantioselective oxidation mediators. Table 5 










Polystyrene supported TEMPO 64 
Figure 33: Substituted TEMPO analogues. 




Table 5: Survey of substituted TEMPO analogues. 
With a view on cost and availability, none of the substituted TEMPO analogues 
presented decisive reasons for replacing TEMPO, although the fact that these 
mediators were active was an indication that substituted TEMPO analogues could be 
viable mediators. A further experiment was performed to investigate whether 
enantioselective oxidations employing homochiral mediators would be viable. 
Clearly the 4-substitued ring structures could not afford mediators with single 
enantiomer configuration close to the nitroxyl radical. Any chirality could only be 
practically introduced by further elaboration of the 4-positon, distant from the active 
oxidising species at position 1. It was felt that, to maxiniise the chances of transfer of 
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chirality, single enantiomer chirality should be located close to the active oxidising 
moiety in the mediator molecule. However this focus was balanced with an attempt 
to test a single enantiomer mediator rapidly. To address this issue a substituted - 
analogue of PROXYL, 3-carbomoyl-PROXYL 65, was also investigated, as a 
resolution of the racemic mediator could provide single enantiomer mediator in short 




Figure 34: 3-carbomoyl-PROXYL 65. 
A number of literature preparations of single enantiomer TEMPO analogues have 
been published. 93,94  All involve lengthy synthetic routes or extensive 
recrystallisations, implying low yields and were thus unattractive. The use of single 
enantiomer mediators to attempt to affect the enantioselective oxidation of a single 
hydroxylamine enantiomer was not pursued not only for this reason but the intrinsic 
flaws suffered by the laccase:mediator system in the context of a deracemisation, the 
ultimate goal of the project. As detailed in Chapter 5, a key issue is the fact that the 
oxidising mediator and any reducing agent will both be in the bulk solution and 
therefore interact with each other in a redox cycle. 
2.5 	Laccase conclusions 
Consideration of the inherent limitations of the laccase:mediator system with regard 
to a deracemisation system led to a change of focus in terms of the stereoselective 
oxidation portion of the research. Whilst the laccase:mediator system was ultimately 
unsuited to a role in a deracemisation system, a novel oxidation system for 
hydroxylamines was defined. This system was demonstrated to be reproducible, 
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effective and, in the use of atmospheric oxygen as the bulk oxidant, environmentally 
friendly. 
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3 	Monoamine oxidase 
In an attempt to identity a highly stereoselective hydroxylamine oxidation catalyst 
attention turned to the amine oxidase class of enzymes. Work within the laboratory 
had identified an amine oxidase with highly stereoselective oxidation activity for 
secondary amines. 63  The concept was to test, and if necessary, modify and optimise 
this enzyme in an attempt to identify a viable stereoselective hydroxylamine 
oxidation catalyst. 
3.1 	Amine oxidases 
Amine oxidases catalyse the oxidation of amines to the corresponding ketones or 
aldehyde, ammonia and hydrogen peroxide. An imine intermediate is produced 
(Figure 35). As is readily apparent this reaction can be regarded as being analogous 
to the desired reaction with a hydroxylamine, the oxime being the achiral 
intermediate produced as opposed to an imine. 
enzyme 	 + 	H20 
RCH2NH2 + H + 02 	 RCH=NH2 RCHO + NH 3 
H202 
Figure 35: Amine oxidase general wild-type activity. 
Amine oxidases may be divided into two general groups based on the cofactor they 
possess. Type I amine oxidases are copper dependent and use 2,4,5-
trihydroxyphenylalanine quinine (TPQ) as a cofactor. The type II amine oxidases, of 
which monoamine oxidases (MAO) are the most abundant, use flavin as the co-
factor. There is a significant body of literature associated with MAO enzymes 15  due 
to the fact that they are implicated in human oxidative deamination pathways, 
especially of certain neurotransmitters. This has led to great interest in the MAO 
enzymes and inhibitors from a medical treatment standpoint. 16,11  MAO inhibitors 
have been used clinically both for the treatment of Parkinson's disease 98  and as 
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antidepressants 99,  and continue to be important targets for pharmaceutical research, 
development and sales. 100 
Due to the collective experience gained within the Turner Group' 01,102  the research 
into hydroxylamine activity and optimisation was concentrated solely on a flavin-
containing monooxidase. 
3.2 	Flavin containing amine oxidases 
The utility of MAO inhibitors, and the reason for much of the research into them, is 
based on the fact that MAO regulates neurotransmitter levels. This fact was first 
discovered when tuberculosis patients dosed with isoniazid showed improvements in 
mood. As this was an unforeseen, albeit fortunate, side-effect further research was 
initiated that discovered isoniazid was inhibiting MAO. 103 
Subsequent work has investigated the nature of MAO enzymes in humans. Two 
different MAO enzymes are present in humans, type A (MAO-A) and type B (MAO-
B). A number of experimental, results lead to the unravelling of this fact. Key to the 
understanding that there are two different MAO enzymes in humans was the 
observation that MAO-A is inhibited by clorgyline 66 whilst MAO-B was inhibited 
by deprenyl 67.104  Conclusive evidence of the presence of two different MAO 
enzymes was obtained from cDNA cloning experiments, which allowed the isolation 
of MAO-A and MAO-B from human liver.' 05 






Figure 36: MAO-A inhibitors. 
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The MAO-A and -B enzymes exhibit high amino acid sequence identity and the 
subunit molecular weights differ by only 1.7 kDa, 59.7 kDa and 58 kDa respectively. 
Both enzymes contained the pentapeptide Ser-GIy-Gly-Cys-Tyr. 106 This is known to 
be critical in FAD binding; it was found that the FAD is bound by Cys-406 in MAO-
A and Cys-397 in MAO-B. Research on MAO-A and MAO-B has established that 
they are integral proteins of the outer membrane of mitochondria and this fact has led 
to difficulty in preparing soluble, functional membrane proteins. 
The three-dimensional structure of MAO-B has been solved. 107  This success has also 
led to the solving of the MAO-A structure through a single crystal isomorphous 
replacement technique. 105 The crystal structure showed the enzyme is dimeric. The 
proposed structure is postulated to be the quaternary structure in vivo, as the dimer 
was observed in two different geometries, triclinic and orthorhombic. 
An irreversible inhibitor was successfully co-crystallised in the active site of MAO-B 
and this has provided an insight into the active site location and geometry. 
109  The 
inhibitor was an analogue of the MAO-B inhibitor 67, and was bound covalently to 
the N5 of flavin on the re-face in a solvent inaccessible position. The binding area is 
a cavity of volume 420K and is a hydrophobic environment due to aromatic and 
aliphatic amino acids that line it. The recognition site for the substrate amino group is 
an aromatic cage formed by two tyrosine residues, 398 and 435. The tyrosine 
aromatic rings are seen to be rotated slightly towards the flavin. These aromatic rings 
are clearly important to the function as it has been shown that mutating one or other 
of the tyrosines to serine resulted in inactivation.' 10 On the other hand mutations to 
















Figure 37: Representation of pargyline suicide inhibitor covalently attached to FAD 
and bound in the active site of MAO-B. 109 MAO-B active site residues are shown in 
black (aromatic side chains in ellipsoidal frame and others in rectangular boxes). 
A separate cavity, named the entrance cavity, is present in MAO-B, between the 
protein's exterior surface and the substrate binding cavity. This is lined with 
hydrophobic and aromatic residues, much as the substrate binding cavity is. Access 
to the entrance cavity from the outer surface of the protein is postulated to be 
controlled by a loop of 13 amino acids. The suggestion is that movement of this loop 
allows for substrate binding in the entrance cavity. Subsequently a transient 
movement of the residues which separates the entrance and substrate cavities occurs. 
This second step allows diffusion of the substrate into the substrate cavity. 
A further interesting attribute of the MAO-B crystal structures is that the normally 
planar FAD ring is bent around the N5-NlO axis. Additionally two aromatic amino 
acids form an aromatic sandwich about 8A apart, perpendicular in orientation to 
FAD on the re-side. 107 -Structural models of substrates bound in the active site of 
HE 
MAO-B suggested that the aromatic sandwich and flavin combine in amino 
recognition of the substrate. 
3.2.1 FAD oxidation mechanism 
The overall catalytic cycle of amine oxidation in MAO has been proposed to occur in 
three steps (Figure 38). The first of these steps is the oxidation of the substrate. This 
occurs with concurrent reduction of FAD to FADH 2 . This is followed by the 
deamination of the imine intermediate by water to produce the corresponding ketone 
or aldehyde and ammonia. This step is not enzyme catalysed, it occurs spontaneously 
in water. Lastly, the reoxidation of FADH2 to FAD occurs. This is performed with 
molecular oxygen and releases hydrogen peroxide. 
FAD reduction 
RCH2NH2 	+ E-FAD 	 - 	RCH=NH 	+ 	E-FADH2 
Deamination 
RCH=NH 	+ 	H20 	 RCHO 	+ 	NH3 
FAD reoxidation 
E-FADH2 	+02 	 E-FAD 	+ 	H202 
Figure 38: The steps in the catalytic cycle of amine oxidation catalysed by MAO. 
The exact mechanism of FAD reduction and amine oxidation has been the subject of 
debate and three pathways have been proposed: a single electron transfer (SET) 
a nucleophilic pathway 112  and a direct hydrogen atom transfer (HAT) 
pathway. " 3 Conflicting evidence has been presented but the SET pathway has been 
the generally accepted version for MAO catalysed a-carbon oxidation of amines and 
N-cyclopropylamines inactivators have been used to probe this.' 14 It was 
demonstrated that an amine radical cation is formed which is proposed to undergo 
rapid ring opening to form a highly reactive primary carbon centred radical. The 
41 
carbon centred radical is thought to be responsible for inactivation of the enzyme and 
this was probed by the use of 14C labelled N-cyclopropylamine. This was 
demonstrated to react with MAO in a 1:1 stoichiometric ratio at the flavin or at an 
active site cysteine residue.' IS 
FADH• 	FADt-12 





NI-2 	K I RCH=+N HRCH2NH2 	RCH3N 	 C  
rn 	 r x. ( 	X LZX 	
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RCH-NH2 
Figure 39: The possible SET mechanisms for amine oxidation catalysed by a FAD 
dependent MAO. 
Evidence for the existence of radical species during the amine oxidation step has 
been provided by EPR experiments, with clear evidence for a tyrosyl radical 
observed. 116  This is believed to be located on a tyrosine residue close to the active 
site and the tyrosyl radical is thought to be in equilibrium with the flavosemiquinoine 
of FAD. 
More recently support for the polar nucleophilic mechanism has been forthcoming.' ' 
Support for this mechanism has been based on structural data which indicates that no 
amino acid residues that could act as acids or bases are in close proximity to the 




1* 1 r NH2 
CH 






Figure 40: Nucleophilic (polar) mechanism. 
Using stopped flow spectroscopy experiments it has been shown that the substrate is 
influential in the FADH2 reoxidation step. 115  A binary or ternary complex has been 
shown to be present in the catalytic cycle. This complex can consist of reduced 
enzyme, oxygen and product or reduced enzyme, oxygen and substrate. 119 
The release of the intermediate imine from the enzyme complex, as opposed to 	- - 
hydrolysis within the active site, has been demonstrated. 120  Experiments with N-
methylbenzylamine confirmed the release of the imine, the amine was oxidised in 
1% v/v water in benzene and oxidised products were examined by GC. The release 
of an imme rather than the hydrolysed product is of course essential if a MAO 
enzyme is to be employed in a deracemisation system. The extensive work in the 
Turner group with amine deracemisation systems clearly confirms the generality of 
the imine release. 
3.3 MAO-N 
A number of amine oxidases have been discovered in microorganisms' 21  and a type 
II amine oxidase enzyme (MAO-N) which oxidises mono-amine substrates compared 
to the previously reported di- or polyamines has been identified. 122  This enzyme was 
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discovered from but ylamine- induced cultures of Aspergillus niger and further 
research has allowed purified recombinant MAO-N expressed in E. co/i to be 
obtained.  123  This allows for relatively simple expression of large amounts of the 
enzyme and the substrate specificity indicates that the MAO-N enzyme is useful in 
transformations of small molecule, chiral amines.  61  The human monoamine oxidase 
MAO-B is the most closely related enzyme to MAO-N for which a three-
dimensional structure is available. There is 24% sequence identity and 43% sequence 
similarity between the two amino acid sequences. Previously a sequence alignment 
of MAO-B and MAO-N had been carried out by M. Alexeeva' °2 and this has 
provided some insight into some of the key residues in the MAO-N enzyme. 
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Figure 41: Representation of pargyline suicide inhibitor covalently attached to FAD 
and bound in the active site of MAO-B. 109 MAO-B active site residues are shown in 
black (aromatic side chains in ellipsoidal frame and others in rectangular boxes). 
Aligned amino acids in MAO-N are shown in red and the 246 aligned residue is 
shown in blue. ")2 
3.3.1 Homology model of MAO-N 
This alignment data has led to investigations into the active site of the MAO-N 
enzyme and confirmation that the 246 residue is at the heart of the active site. The 
use of an alignment strategy between MAO-B and MAO-N has been taken a step 
thrther. A three dimensional homology model of MAO-N has been developed using 
the three dimensional structure of MAO-B of which the crystal structure has been 
solved. The related MAO-N sequence was overlaid over this model and the potential 
energy of the system minimised using the CHARMM (Chemistry at HARvard 
Molecular Mechanics) force field system.' 24 
As a result of the previous work in the group a good deal of information is available 
regarding the MAO-N variants and the handling of them. A number of researchers, 
within the Turner group and industrial partners, have studied the MAO-N enzyme 
and undertaken significant development work on it. Programs of research have been 
focused on hilly characterising the enzyme, improving, the expression system, 
evolving novel activities' 25  and probing the effects of residue changes. In addition, 
using the enzyme as a stereoselective catalyst in deracemisation systems has been 
achieved for a variety of structurally diverse amines. 63  This presents a good basis to 
commence investigation of the enzymes in terms of their ability to accept 
hydroxylamines as substrates and utility in a hydroxylamine deracemisation. The 
research program described herein has concentrated on expanding the utility of the 
MAO-N enzyme by employing it in deracemisations of hydroxylamines and 
hydroxylamine derivatives. 
3.4 	MAO-N Hydroxylamine Results and Discussion 
Previous work by other researchers had resulted in a number of MAO-N variants 
being available in the laboratory (Table 6). These variants had been created in a 
number of research programs designed to produce variants with higher activity 
towards chiral amines and had also resulted in variants with broader substrate 
specificity. The enzyme variants and the genes encoding for them were generously 




Enzyme name from wild- Source 
gene name 
type 
MAO-Nwt mao-Mn' n/a M.Alexeva 
N336S 
MAO-NI mao-NJ M.Alexeva 
M348K 
mao-N.! + 
MAO-N2 mao-N2 R. Carr 
1246M 
,nao-N2 + 
MAO-N51 ,nao-N51 T384S R. Can 
D385N 
,nao-N2 + 
MAO-N5D nzao-N5D T384N R. Cart 
1)3 85 S 
Table 6: MAO-N variants available. 
The genes were inserted into a pETI 6b expression vector and an expression system 
in E. co/i 13L21 (DE3) was in place. The pET16b vector inserts a 6x His tag at the N 
terminus end of the protein, resulting in the ability to purify the MAO-N enzymes 
using Ni chelation chromatography. 
3.4.1 Ilydroxylamine activity investigation 
The stereoselective oxidation of hydroxylamine 35 was selected to be the reaction 
that would be attempted initially. There were a number of reasons for this choice; 35 
was easily synthesised from acetophenone and was easily obtained in high purity. 
The key rationale was that this substrate was the hydroxylamine analogue of a-
methylbenzylamine 24. The MAO-N enzymes had been demonstrated to turnover 
this substrate and it was felt that the structural similarity meant that this substrate was 
a good foundation to base the research upon. 
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HO, NH 	 NI-i2 
35 	 24 
Figure 42: Initial test substrates for MAO work. 
A programme was envisaged in which the ability of the enzyme to turnover the 
substrate and the associated rates, enzyme stability and necessary purification would 
be characterised and optimised. The group of available MAO-N enzymes was 
rationalised to reduce the workload and ensure optimum use of resources. MAO-
N513, MAO-NI and MAO-Nwt were selected as the three enzymes to take forward 
into this investigation. MAO-N51) had been demonstrated to be highly active 
towards secondary amines. MAO-NI had been evolved specifically to have high 
activity for ct-methylbenzylamine. MAO-Nwt was tested as all the other variants had 
been engineered to have improved activity towards secondary .amines. There was no 
guarantee that this engineering process had not caused the mutants to become 
inactive towards hydroxylamines. It was therefore decided to test the wild-type with 
a view to conducting engineering experiments on this if necessary. 
3.4.2 Screening for hydroxylamine activity 
A plate-based colony screen for oxidation activity was employed to gain an overview 
of the activity of the variants towards the substrate. This process allowed for a rapid 
screening system as purification of the MAO-N enzyme was not required; colonies 
expressing the enzyme were screened directly. The output of the screen is 
colorimetric and thus analysis is performed by eye. The solid phase assay relies on an 
indirect screening approach in that the hydrogen peroxide by-product from the amine 
oxidation catalysed by MAO-N is used as a reagent in a second step. Horseradish 
riii 
peroxidase (HRP) is used to catalyse the reaction of the hydrogen peroxide with 









brown insoluble product 
. 
soluble yellow substrate 
Figure 43: Plate-based screen concept. 
The 3,3'-diaminobenzidine (DAB) reagnt 68 was found to be optimum for 
screening MAO-N variant activity against amines and was employed for this screen 
















Figure 44: Dye formation reaction in plate-based screen. 
The polymeric final product 69 is insoluble in the assay medium and thus does not 
diffuse from the site of production. This is crucial so that individual colonies 
producing the colour can be identified. The DAB and its product do not inhibit the 
HI 
action of MAO-N nor does it react with the amine substrates. The DAB screen does 
suffer form a general background oxidation which results in an orange to brown 
darkening of the whole plate over an extended period of days (Figure 44). Colonies 
that darken extremely slowly and are obscured by this background may be regarded 
as having  so little activity as to be classifiable as negative anyway. 
Figure 45: Example of solid-phase assay plate darkening. Sector A) has inactive 
colonies, B) moderately active colonies and C) active colonies present. 
To test whether the DAB would be suitable a plate was produced containing only 
hydroxylarnine 35 and the assay components. No coloriinetric reaction occurred 
apart from the slow background darkening observed with the screen in all 
applications. Screening of MAO-N5D, MAO-NI and MAO-Nwt expressing colonies 
was carried out. Negative control plates, with colonies transformed with pET16b 
plasmid without an insert and positive control plates, with a-methylbenzylamine 24 
as the substrate were employed for comparison (Table 7). 
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Variant 	. Substrate Activity 
MAO-NSD 24 High 
MAO-N5D 35 None 
MAO-NI 24 High 
MAO-NI 35 None 
MAO-Nwt 24 Very low 
MAO-Nwt 35 None 
pET16b control 24 None 
pETl6b control 35 None 
Table 7: Plate-based screen results for hydroxylamine 35 activity screen. 
It is apparent from Table 7 that no activity is observed for either MAO-N variant 
against hydroxylamine 35. Two different courses of action were followed in an 
attempt to address this difficulty. Firstly, the use of a second, more sensitive screen 
was attempted. The rationale behind this was that very low levels of activity may 
have been missed due to the limitations of the plate-based screen. Previous work in 
the group had demonstrated that low level activity could be the foundation of a 
program of enzyme engineering which led to novel variants exhibiting high levels of 
desired activity. Thus identifying a variant with very low activity could be valuable. 
Secondly, a different hydroxylamine substrate was tested. The reason for this was 
that dismissing the ability of an enzyme to turnover a class of substrates on the basis 
of the failure of a single example would be premature. 
A liquid-phase assay, performed in a 96-well microtitre plate was employed to re-
assay the MAO-N variants for activity against hydroxylamine 35. This assay 
employed the same concept as the solid-phase assay, in terms of producing a 
colorimetric product via HRP catalysed reaction with H202. The difference is that the 
substrate is soluble in the aqueous buffer and thus is suitable for a spectrophotometer 
based screen. The 96-well plate coupled with an UV/Vis spectrophotometer allow for 
time-point data collection and thus rate data to be produced. The sensitivity of the 
instrument allows for lower activities to be observed and recorded compared with the 
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plate-based screen. This screen was used to test both hydroxylamine 35 and 46. 
Flydroxylamine 46 is the analogue of the amine which was found to be most active in 
the work of Carr in the group previously. It was thus chosen as a second substrate to 
test, however no activity was observed. 
HNOH HWOH 
rac-35 rac-46 
Figure 46: Hydroxylamines tested initial MAO screening. 
At this juncture it appeared that the possibility that the MAO-N variants would 
display activity against hydroxylamine substrates had to be dismissed. In a final 
attempt to confirm this (S)-35 was tested for activity. By analogy with all the amine 
substrates, this is the enantiomer that the MAO-N variants would be expected to be 
highly active towards. No activity was observed. 
HNOH 
(S)-35 
Figure 47: Hydroxylamine analogous to most active amine. 
Two routes forward presented themselves. Firstly; to attempt to engineer a MAO-N 
variant that did display the desired properties. Secondly; to attempt to modify the 
substrates to some extent to allow them to be turned over by the MAO-N enzyme. 
3.4.3 Inhibitory action of hydroxylamines 
Before embarking on a process of enzyme engineering of a MAO-N variant in an 
attempt to access activity toward hydroxylamines the theoretical possibility of 
activity had to be established. A key consideration was whether MAO-N was 
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intrinsically unsuited to a role of hydroxylamine oxidation. A number of experiments 
established that it was. 
To check whether hydroxylamines had an inhibitory effect upon MAO-N variants a 
simple experiment was performed. A plate-based screen of MAO-NI expressing 
colonies against a mixture of 10mM cx-methylbenzylamine 24 and 10mM 1-
phehylethy1hydroxylamine 35 was performed. No activity was observed. This 
confirmed that the hydroxylamine had an inhibitory effect. The experiment was 
repeated in a liquid-phase assay and the result confirmed. The mechanism of 
inhibition was not filly established however some information was elucidated. 
The inhibition appeared to be irreversible. MAO-NI enzyme solution was incubated 
with 10mM hydroxylamine 35 and then purified via Ni chelation to the His tag. The 
purified enzyme was then incubated with 10mM cz-methylbenzylamine 24 and no 
activity observed. A variation of this reaction was performed in which MAO-NI, 
purified and subsequently supported on Eupergit resin, was incubated with 10 mM 
hydroxylamine 35. The resin was filtered off, washed with copious amounts of pH 
7.4 phosphate buffer and then tested for activity against cx-methylberizylanine. No 
activity was observed. 
A number of possibilities arise for the mechanism of inhibition including covalently 
binding in the active site pocket, possibly to the N5 of flavin, as with the inhibitor 
pargyline (Figure 41). Analysis of the flavin post incubation with hydroxylamine was 
carried out. The flavin UV curves were found to be very similar with no discernable 
differences (Figure 48). LC-MS analysis of the fiavin solution was inconclusive with 
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Figure 48: UV curves of MAO-N per- and post- incubation with hydroxylamine 35. 
As a result of the experiments described above it was decided to abandon attempts to 
engineer a MAO-N variant that exhibited activity towards a hydroxylamine substrate. 
The results above, coupled with literature data uncovered indicating that 
hydroxylarnine acts as a MAO inhibitor 126,  suggested that it would be futile to pursue 
this line of investigation. 
3.5 	MAO-N Hydroxylamine ether Results and Discussion 
As detailed above, a second approach to be problems described would be to attempt 
to modify the substrates and assess whether they were viable as MAO-N substrates. 
To this end it was decided to investigate whether 'capping' the hydroxyl 
functionality would alleviate the problems found thus far. Two hydroxylamine 
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ethers, 47 and 48, were thus synthesised 127  and assayed against MAO-N5D colonies 
(Table 8). It was decided to concentrate on a single MAO-N variant, MAO-N5D for 
these experiments. 
3.5.1 Screening for hydroxylamine ether activity 
HNOMe 	 H 
N tMe 
47 	 48 
Figure 49: Hydroxylamine ether substrates screened. 
• 	
Variant Substrate Activity 
MAO-N51) 24 Very high 
MAO-N5D 47 High 
MAO-N5D 48 High 
Table 8: results of plate-based screen of hydroxylaniine ether substrates. 
As Table 8 illustrates the concept of capping the hydroxyl functionality appears to 
have successful to an extent. It was decided to further probe the possibility of 
hydroxylamine ether turnover by using a liquid phase assay screen for greater 
sensitivity and accuracy and to broaden the panel of substrates to be tested (Figure 
50). 
54 
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Figure 50: Expanded pane] of hydroxylamine ether substrates for screening. 
Assessment of the rate data produced was based on relative rates referenced to a 
standard substrate, cz-methylbenzylarnine 24 (Table 9). This was to allow 
comparability and standardisation between any subsequent studies. The various CEE 
preparations used throughout the project would be very unlikely to contain the same 
amount of enzyme; however relative rates will always be comparable. 
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Table 9: Relative rate of substrate turnover using ivlAO-N51). 
A number of substrates are turned-over by MAO-N5D at rates which are moderate 
but rival the rates observed for a number of amines. The substrates tested were 
analogous to those amines which were most active. This means that there is a 
different profile to the structure of active amine as hydroxylamine ethers. 
Hydroxylamine 47 was selected to be investigated to a fuller extent and .Michealis-
.Menten kinetic calculations were performed using GraphPad Prism 4 soflware.' 28 
This was to gain accurate kinetic data for a hydroxylamine substrate. Once again a-
methylbenzylamine 24 was used as a comparison (Table 10). 
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Catalytic 
Substrate VM S. 
k.. (mm') KM (m14) efficiency 24 (jLmolIminImg) 
 Km 
(min' mM') 
MAO-51) 0.81±1x10 2 45.3±0.5 155±0.12 12.76 
Published data' ° ' 
MAO-5D 0.78±8x 10' 43.4±0.4 3.52±0.19 12.33 
Substrate 
47 - 
MAO-51) 0.18±3x10 2 10.2±0.8 5.66±0.24 1.80 
Table JO: Mic heal is-Menten kinetic data for hydroxylamine ether 47. 
The data shows that the hydroxylarnine ether 47 is a reasonable substrate for the 
MAO-N5D, when compared with a substrate known to be suitable for 
deracemisat ion experiments. 
The kinetic data demonstrates that the MAO-51) enzyme is a poorer system for the 
oxidation of the model hydroxylamine ether than for the model amine. The KM, the 
concentration of substrate at half has risen. This indicates a lower affinity for 
the substrate from the enzyme. This change in K 1 means that the reaction will 
decelerate sooner in the ease of the hydroxylamine ether 47 than the amine. The 
lowering of the k03  indicates that the turnover is slower compared with the amine 
substrate. When these two factors are combined it is apparent that the catalytic 
efficiency of the enzyme towards the hydroxylamine ether model substrate is an 
order of magnitude lower than for the model amine. This data confirms the un-
quantified observations that the assay systems provided as described above. 
Although the enzyme was demonstrably slower at affecting the oxidation of the 
hydroxylamine ether model compound than the amines tested it retained enough 
activity to still be potentially viable as a deracemisation catalyst. 
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3.5.2 Kinetic resolution of a hydroxylamine ether 
Attention now turned to whether the MAO-N5D could be a viable catalyst for the 
deracemisation of hydroxylarnine ethers. This is a very different question from 
whether it turns over the substrate. Critically, is the oxidation stereoselective? If not 
then the novel MAO-N oxidation discovered is of little value. In the case of the 
oxidation of hydroxylamines ethers to oximes a further detail must be considered 
which is not relevant for the amine to imine or hydroxylamine to oxime analogues. 
The oxime product may exist in both cis and trans geometric isomers, therefore 
investigation of the stereoselectivity of the oxidation must be coupled with 
investigation of geometry of the product. 
A kinetic resolution of hydroxylamine ether 47 was performed using the .MAO-N5D 
enzyme variant. This experiment was designed to answer a number of questions. 
Firstly, was the MAO-N51) enzyme, in a whole-cell system, a viable catalyst for a 
gram scale resolution of rac-45? Secondly, was the reaction high yielding and did it 
produce highly an enantioenriched product? Thirdly, what enantiomer of 47 
remained at the completion of the reaction? Finally, what geometric isomer of the 
oxime product 57 was formed? 
The resolution was perfornied on 1.2g scale and proceeded smoothly overnight 
(Figure 51). Gratifyingly the use of a whole-cell preparation was found to be 
effective with little of the work-up difficulties that can occur. This allowed for a 
simple preparative procedure to be used, with no enzyme purification step required. 
The two products of the resolution were isolated by column chromatography and 
analysed. 
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Figure 51: Kinetic resolution of N-methoxycyc lohexylethylamine 47. 
The geometry of the oxime was determined by ' NMR NOSEY spectroscopy and 
found to be trans. A NOE interaction between the OMe and Me protons was 
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Figure 52: GC confirmation of oxime 57 geometry. 
The remaining enantiomer of hydroxylamine ether 47 was found to be (R)- 
configuration. This was determined by GC analysis of a derivative. The remaining 
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hydroxylamine ether 47 was hydrogenated with H2 gas and Pd/C catalyst overnight. 
The resulting amine was derivatised with triflic anhydride and the resulting mono-
triflate analysed by chiral GC. Comparison with an authentic sample indicated that it 
was (R)-configuration (Figure 53). This is as expected as it is in agreement with the 
fact the MAO-N is known to oxidise amines in a highly (5)-selective manner. 
[mVl 
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Figure 53: Chiral GC analysis of hydroxylamine ether 47 enantiopurity. 
The reaction detailed above represents a novel bio trans formation of a hydroxylamine 
ether. The use of a MAO enzyme to transform a non-amine substrate is an interesting 
development, expanding the utility of the MAO-N enzyme. The resulting chiral 
product is produced in excellent e.e. and the oxime product is produced as a single 
geometric isomer, both in high yield. 
ZE 
3.5.3 Molecular modelling of active species in MAO-N 
With the information regarding the geometry of the oxime product in hand, an 
investigation of the active site of the enzyme was conducted using a 3D computer 
homology model. 129  The (S)-hydroxylamine substrate was docked into the active site 
and an energy minimisation protocol applied (Figure 54). The basis for the modelling 
experiments is the three dimensional homology model of MAO-N described in 
section 3.3.1. Into the active site of this model was docked the substrate 47 and the 




Figure 54: Hydroxylamine ether (S)-47 docked in MAO-N active site model. Green 
lines indicate closest contacts. 
The illustration of the active site indicates a number of key features. The nitrogen 
atom of the substrate is located close in space to the N5 of the flavin, with the C-N 
bond aligned perpendicular to the flavin ring plane. This is a result which closely 
mimics that observed for similar modelling experiments performed with amine 
substrates, without having been fixed as part of the model parameters. 
The model indicates that a void is available in the active site into which the methoxy 
ether moiety may be located. Clearly the need to position this subsituent is a factor 
that differs completely from the experiments with amine substrates. Residue 245 
appears to be close contacting to the methoxy methyl in this model. Whilst a model 
derived at some length from a solved crystal structure clearly has limitations in terms 
of accuracy, it is pleasing to note that the substrate appears to fit the active site and 
be located in a fashion analogous to amine substrates modelled previously. 
Additionally, attempts to successfully dock the (R) analogue were unsuccessful with 
major steric hindrances being displayed. 
Turning to the configuration of the oxime products, further molecular modelling was 
undertaken. This was in order to try and gain an insight into whether the oxime 
product configuration (cis or trans) was likely to be determined by the active site 
geometry. It was decided that the configuration of the active site was to be 
maintained from the previous experiment and the two possible oxime substrates 
docked separately into this active site. Clearly it is possible that the active site 
geometry alters as the oxidation reaction occurs, however it was felt that an 
indication as to whether the geometry of the active site would be crucial could be 
achieved by simply docking each oxime into the geometry derived from the previous 
experiments. Figures 55 and 56 illustrate the results of docking the two oxime 










Figure 56: trans-57 oxime docked into active site model. Green lines indicate closest 
contacts. 
As can readily be seen, the production of solely trans product can understood with 
respect to the active site geometry. The cis product must be heavily disfavoured for a 
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number of reasons. The methoxy methyl closely contacts the W430 residue and is 
sterically hindered due to this. Additionally the cis configuration leads to the location 
of the methoxy methyl group directly between the N5 of flavin and the substituent 
nitrogen atom undergoing oxidation. This would seem unlikely to occur as hydrogen 
atom transfer is postulated to occur between these sites (see Figure 40). 
Conversely, the trans product fits the active site in a fashion that allows for 
unimpeded access between the flavin and substrate reactive sites and the position of 
the non-reactive portions of the molecule closely match those of the hydroxylamine 
ether substrate before oxidation. Gratifyingly, the data from the molecular modelling 
experiments is in close agreement with the data derived from laboratory experiments. 
3.6 MAO-N Conclusion 
In terms of establishing a deracemisation system for hydroxylamine the MAO-N 
variants are not viable as stereoselective oxidation catalysts. However, by capping 
the hydroxyl functionality as a methyl ether activity has been demonstrated. This 
activity has been shown to be of such a level that the construction of a 
deracemisation system is possible, as the activity is within an order of magnitude of 
amine substrates that have been deracernised previously. Crucially, the high 
enantioselectivity of the oxidation has been demonstrated; a prerequisite to a 
successful deracemisation. The whole-cell system has been shown to be effective and 
this allows for a simple experimental procedure. Common problems associated with 
whole-cell systems such as work-up difficulties have not been observed to any great 
extent. The experimental program was now taken forward in two different directions; 
firstly, improving the biocatalyst through enzyme engineering and secondly, 
development of a complementary reduction system to allow for a deracemisation. 
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4 	Biocatalyst modification 
With a naturally derived biocatalyst in hand it is possible to perform a wide variety 
of synthetic reactions successfully, however, industrially relevant applications for 
biocatalysts often involve substrates or conditions which do not correspond to the 
wild-type environment of the biocatalyst. This may be because the specific substrate 
is not encountered by the wild-type enzyme, the substrate is not turned over by the 
wild-type enzyme or the reaction conditions do not correspond to the conditions that 
the wild-type enzyme operates in. The problems identified above can lead to 
difficulties in employing a biocatalyst. Modification of the biocatalyst may be 
attempted to overcome the factors which prevent successful exploitation of a 
biocatalyst system. 
Broadly, there are two different techniques to produce an effective biocatalyst from 
one which is ineffective. One may leave the active enzymatic components of the 
biocatalyst unchanged but modify the method by which they are delivered to the bulk 
reaction medium. Secondly, one may modify the enzyme(s). 
4.1 	Modifying biocatalyst delivery form 
Modifying the delivery of the enzyme to the bulk reaction solution may solve 
difficulties associated with the use of the purified enzyme as the biocatalyst. The use 
of purified enzyme is, of course, perfectly possible. The positive factors associated 
with this method include the fact that the catalyst is known to be pure, is frilly 
characterised and should be consistent batch-to-batch. The amount of catalyst added 
can be known to a high degree of accuracy and downstream purification is not 
normally difficult. There are a number of significant disadvantages with employing 
purified enzymes in a reaction. When considering a simple transformation, the 
limiting factor in terms of time and the highest costs are often associated with 
enzyme purification. If a biocatalysis system comprises more than one enzyme in the 
same pot then this problem is only exacerbated. The stability of many enzymes can 
be compromised when they are purified, and are thus no longer exposed to the 
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mixture of biomolecules present in the whole-cell. This may manifest itself in 
degradation of the enzyme or a lack of solubility in standard solution media. 
Rather than purified protein being employed, the enzyme may be delivered within 
the wild-type host or by addition of the organism which was used as the expression 
host - a whole-cell system. This has been reported as successful on numerous 
occasions. ' 30 As is often the case, the use of a whole-cell system is a balance of 
factors, positive and negative. A key benefit of using the whole-cell is the removal of 
the enzyme purification step. A further advantageous element that whole-cell 
systems may have is the ease at which the cells can be removed form the reaction 
medium due to there relatively large size and stability. 131  A clear advantage with the 
whole-cell system becomes evident if the biocatalysis system to be used consists of 
more than one enzyme. If all the required enzymes can be expressed in a single 
organism then the use of a whole-cell can be very efficient and impressive.' 32 An 
additional benefit is that whole-cell systems are often active in non-conventional 
solvents such as organic solvents or ionic liquids. 133  This is in contrast to most 
purified enzymes. Clearly there are also a number of difficulties that can be found 
when employing a whole-cell system. Downstream processing can be lengthy and 
difficult. Whole-cells have a complex mixture of cellular products which can teach 
into the bulk solution and disrupt purification of the desired products.' 4 Another 
factor is that whole-cell systems may contain alternative metabolic pathways which 
process the reaction substrate to undesired products. The fact that batches of whole-
cells may differ also leads to the possibility of inconsistence across reaction batches. 
The use of a solid support matrix of some nature to stabilise the enzyme is an 
alternative to whole-cells. Many commercialised enzyme systems involve the use of 
a solid-support for the active enzyme species. Purified or semi-purified enzymes may 
be placed on a solid support. This technique often increases the stability of the 
enzyme with respect to solvent and temperature. It also aids in the recovery and reuse 
of the enzyme as removal from the bulk solution is simplified. It has been found that 
the substrate profile of an enzyme can be altered by the use of a solid support 135.  A 
range of supports have been reported including hollow fibres' 36,  ceramics' 37,  
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resins' 38,  glass  139,  nanocomposites' 4° and within monolithic reactors. 141  The concept 
c of a solid supported enzyme system has been extended to other solids such as cross- 
linked enzyme crystals (CLECS)' 42 and cross-linked enzyme aggregates (CLEAS).' 43 
The modification of the method of delivery of the biocatalyst offers much scope for 
the development of a viable biocatalysts reaction. On occasions where the enzyme in 
question does not intrinsically exhibit the desired properties then modification of the 
enzyme itself may be either necessary or desirable. 
4.2 	Modifying the structure of the biocatalyst 
The second area that may be explored is the modification of the enzyme itself, at the 
amino acid level. This may be achieved by making changes at the genetic level 
which, in turn, alter the enzyme. Alternatively direct chemical modification of the 
enzyme may be performed. At this level the substrate specificity, substrate turnover 
rates and the stability of the enzyme may all be affected. Whilst only 
experimentation will show whether the effects are positive or negative in terms of the 
desired characteristics of the enzyme, efficient experimental design can maximise the 
possible benefits to be realised for this fundamental alteration of the enzyme. 
Direct chemical modification may be broadly divided into two, specific and non-
specific side chain-modification. Non-specific modification refers to the covalent 
modification of the side-chain of a number of amino acid residues. The modification 
may be limited to a single amino acid type or residue but crucially there is no control 
as to the specific site residue that is modified. It may be one, some or all at varying 
positions on each enzyme molecule, thus a heterogeneous enzyme mixture is often 
formed. Non-specific side-chain modification has resulted in altered properties of a 
ribonuclease, glucose oxidase and lipases amongst others. 31)  Specific site chemical 
modification exploits the fact that each amino acid residue is located in a different 
environment along the protein chain, thus with care a specific residue site may be 
covalently modified. A serine protease, fatty acid binding protein and papain have 
been modified in this more controlled fashion. 30 
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The approach to modifying enzymes at the genetic level can be from two directions. 
One may modify residues in a random way and select for desired characteristics. 
Subsequently one may attempt to deconvolute the modification in residues that lead 
to the change in properties, if this knowledge is desired. 144  The term 'directed 
evolution' has been coined for an experimental program following this course. 
Alternatively one may modify known residues and observe the results, in a process 
known as 'rational design' .145  It is of course possible to marry together elements 
from both techniques. 146  Both methods require the modification to be performed at 
the DNA level and thus having the enzyme gene in hand is pre-requisite for the use 
of either of the methods. The limitation of the vast majority of these genetically 
based techniques is that the only variation is between the 20 commonly naturally 
occurring amino acids. Elegant techniques have been described for the introduction 
of non-natural amino acids 147  but the pool of naturally occurring amino acids has 
provided enough diversity for nearly all successful protein engineering programs 
thus far. 
4.2.1 Directed evolution 
Directed evolution is a term used to describe the use of Darwinian evolutionary 
concepts to alter the properties of biocatalysts. 148 It comprises mutation of the gene 
encoding the potential enzyme and selection on the basis of the desired functional 
changes. The directed evolution experiment thus comprises the generation of a 
library of mutant genes and the subsequent screening and selection for desired 
characteristics. A number of iterations of this cycle may be followed. The two 
distinct parts of this evolutionary process are both under a degree of experimental 
control. Firstly, random mutagenesis of the encoding gene. The frequency of 
mutation, whilst not precisely controlled using the techniques which have become 
standard, may be calibrated. In turn the rate has been found to be relatively 
reproducible. This means that the researcher may be confident of the approximate 
rate of mutation. 149  The crucial factor allowing a high degree of control is that the 
selection pressure place upon the mutants is determined by the researcher. This 
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means that the researcher may direct the evolutionary course of the enzyme in 
question; hence the name 'directed evolution'. The great benefit of directed evolution 
with respect to rational design experiments is that no prior knowledge of either the 3-
dimensional protein structure or the mode of catalytic action is required. 
4.2.1.1 Generation of libraries of variants 
The initial step of the directed evolution protocol is the generation of a library of 
variants. This library of genes will contain all the different variants to be exposed to 
the selection pressure in the second stage of the experiment. As the library of variants 
is constructed in a pseudo-random fashion a large number of variants are required. 
This is because many of the mutations will produce variants that are unlikely to 
survive the selection pressure. All variant genes that do not encode for proteins with 
improved properties being screened for, with respect to the wild-type, will be 
rejected at the screening stage. The random nature of the mutagenesis means that this 
is likely to be the majority of variants, as many mutations will not affect the catalytic 
properties of the enzyme or be deleterious. A number of techniques for constructing 
the libraries of variant genes are available including PCR based techniques' 50 , gene 
shuffling' 5 1 ,  chemical modification' 52  and mutator-strain 
Error prone polymerase chain reaction (epPCR) is a modification of the standard 
PCR procedure in which the fidelity of the PCR reaction is deliberately 
undermined. 150  The PCR conditions are tuned to ensure that during each replication 
cycle the products are not faithfully copied. The mutated PCR products are then 
cloned into an expression vector and the resulting library can be screened for the 
desired change in the function of the protein. epPCR employs the early generation of 
PCR DNA polymerases which have a significant propensity for misincorporation of 
nucleotides. These have been superseded by high fidelity enzymes for most PCR 
applications. Increasing the concentration of magnesium chloride or manganese 
chloride or varying the relative concentrations of the four dNTPs also leads to lower 
fidelity. The presence of Mn 2  along with an over representation of dGTP and dTTP 
in the amplification reaction leads to error rates of I to IOnt/kb.' 54 The epPCR 
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technology has been refined to the extent that a number of commercial suppliers 
supply kits including detailed instructions to achieve defined mutagenesis rates. The 
ease by which mutations can be generated by epPCR and the control of the mutation 
rate makes this method powerful; however there are some disadvantages to the 
techniques. 
The amplification nature of the PCR means that a mutation introduced early in the 
reaction will dominate. The mutated daughter molecules are amplified during the 
remaining PCR cycles and will be over represented in the final library compared with 
a mutation that is introduced in the final PCR cycle. This problem can be reduced by 
a combination of pooling multiple reactions and reducing the number of 
amplification cycles per reaction. 
A further significant problem is that of mutational bias. epPCR is not random, in the 
true unbiased sense, and must be regarded as pseudo-random. Transitions (purine 
:purine or pyrimidine:pyrimidine) mutations are more common than transversion 
(purine:pyrimidine interchanges). Secondly, epPCR only introduces single nucleotide 
mutations which can lead to a bias in the amino acid that the mutant DNA encodes. 
The degeneracy of the genetic code means that single point mutations in codons can 
result in only a limited number of alternative amino acids. The result of this bias is 
that some amino acid changes are much more likely to occur than others. 
A further disadvantage is the fact that after an epPCR is complete the mutant DNA 
products must be cloned into a vector prior to screening. This is disadvantages from a 
practical standpoint, increasing the time required to construct a library 
DNA shuffling (Figure 57) allows the recombination of genes from different sources 
or genes containing different point mutations. 1.51  This recombination method mimics 
naturally occurring evolutionary processes in which mutations are incorporated. The 
foundation of the DNA shuffling process is the digestion of genes and their 
subsequent recombination. The overall effect of DNA shuffling, and its variations, is 
to combine fragments of different genes into a single DNA molecule. The digested 
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pool of DNA fragments is subjected to repeated cycles of PCR. By careful control of 
the extent to which the initial genes are digested, the number of possible 'crossover 
points' at which DNA sequence from one parental gene changes to DNA sequence 
from another, may be controlled. 155  This basic DNA shuffling technique has been 
refined and developed into more efficient DNA shuffling protocols. 156 
Random chimeragenesis on transient templates (RACI-IITT) is a variation of DNA 
shuffling (Figure 57))57 The fragments are created and then reassembled by 
annealing together along a parental template strand. Following this step the 
mismatched sections are removed then fragments extended and ligated together 
resulting in a recombined gene. The benefit of the RACHITT technique is that many 
crossovers are possible, however it is necessary for the overlapping regions between 
fragments to be removed by exonuclease digestion. This can add both time and 
unwanted variables to the reaction. In addition the RACI-IITT method is limited to 
incorporation of sequence elements that are similar to the template as they must 
anneal to this parental template. 
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Figure 57: DNA shuffling techniques. 
Incremental truncation for the creation of hybrid enzymes (ITCHY) is a technique 
developed for shuffling parental genes with low sequence homology. 158 The 
difficulty in this case is that the low sequence homology leads to severe difficulties 
in strand extension or annealing to a parental template. ITCHY overcomes this as it 
is based on the direct ligation of libraries of fragments generated from two DNA 
template sequences. The two fragments are processed differently; one fragment is 
digested with exonuclease III and S I nuclease from the 5 '-end of the gene. These 
fragments are ligated to fragments of a second template that have been digested from 
the opposite, 3'-end. The ligation step occurs in after digestion at arbitrary sites. The 
control of the digestion is poor and this has lead to the ITCHY method being 
modified to overcome the lack of control difficulties with the process. The 
phosphates of the DNA are replaced with phosphothioate bonds in a process named 
thio-ITCHY. ' 59  Incorporation of random, exonuclease resistant, phosphorothioate 
linkages into the DNA determine the length of the truncated fragments that are 
ligated. The other benefit with the thio-ITCHY method is the inherent problem of 
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out-of-frame shift products can be addressed as the phosphorothioate linkages can be 
used to ensure that the digestion fragments remain in frame when ligated.' 60 Further 
developments in combining portions of genes with little homology have been 
reported such as Diversa Corporation's Tunable GeneReassembly TM technology.' 61 
As with all PCR based mutagenesis techniques a final cloning step, into an 
expression vector, is required for DNA shuffling experiments. This can lead to a 
bottleneck in the experiment. 
A mutator-strain of Ecu/i, XLI -Red, has been developed as a commercial product 
and has been shown to be a reproducible method for introducing random mutations 
into a cloned gene. 162  XLI-Red is deficient in three of the primary DNA repair 
pathways in Ecu/i, namely ,nutS, rnutD and mutT.' 63 These genes are knocked out in 
the XLI -Red strain and thus the repair pathways dependent •upon them are 
inoperable. MittS is one of the genes responsible for correcting mismatched DNA 
base-pairs after replication has occurred; its role is to recognise a base pair mismatch 
and to recruit other proteins involved in the mismatch repair pathway.' 64 MutD gene 
encodes for a subunit of DNA polymerase III, subunit a, which is responsible for 
proof-reading (3'-5' exonuclease activity), 165 thus DNA polymerase Ill is still 
operating but without proof-reading capability. MutT encodes for 8-oxodGTPase 
which ensures that no 8-oxoGTP is available for incorporation into DNA. 166  These 
three deficiencies ensure that XLI-Red is an efficient mutator of cloned DNA. 
However the fundamental disadvantage of the XLI-Red strain is that DNA mutation 
is not confined to the cloned DNA of interest but the entirety of the genetic material 
in the host strain. This includes the remainder of the plasmid in which the parental 
gene is cloned and the genomic DNA of the E. co/i. The indiscriminate mutation can 
lead to a number of difficulties for the directed evolution process. Firstly, enzyme 
variants may be lost as the bacterial host becomes too sickly to survive. Thus these 
variants are lost before the screening stage without having been subjected to a 
selection pressure based on the enzyme properties. In addition mutations of the 
expression vector can lead to viable enzyme variants not being expressed and thus 
failing the selection pressure. Alternatively mutations to the promoter region can lead 
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to an increase in enzyme expression levels leading to a positive hit at the selection 
stage. On inspection these are found to be expression mutants and not mutant 
enzymes with improved characteristics. 
4.2.1.2 Selection of mutants with desired characteristics 
After the creation of a large library of variants a robust and rapid method of 
screening is required. The random nature of the mutants formed in the first stage of a 
directed evolution experiment means that for the system to be effective at identifying 
mutants with the desired properties a large number of variants need to be screened. 
This in turn necessitates the development of high-throughput screening methods to 
allow the experiment to be conducted over a realistic time-scale. Initial high-
throughput screening, followed by more accurate and intensive analysis of putative 
positive hits is the. most effective method of identifying mutants of interest. A 
number of techniques are available to achieve this high-throughput screening. 167,168 
Crucial to the high-throughput nature of the screen is the fact that the enzyme 
variants are not isolated and purified before screening. It is therefore the case that 
what is screened is the ability of colonies to perform the conversion being studied. 
Careful use of negative and positive controls should ensure that the reason that 
positive hits display the desired characteristic is due to the fact that an enzyme 
variant of interest has been created. There are three main methods to screen the 
colonies; direct analysis of products, life-or-death and colour/fluorometric output. 
A life or death selection system is constructed so that only clones which perform the 
transformation of interest are viable. No active enzyme and the cells die. Thus, after 
a suitable period of time all the viable colonies should perform the transformation of 
interest and all other, non-viable mutants are dead. 169  This should, theoretically, 
reduce false positives to zero. A number of disadvantages have been identified with 
respect to life-or-death screens. The development of the screen can be lengthy and 
cumbersome. Due to the multiple metabolic pathways present within standard 
screening organisms, such as E. co/i, it can be complex to develop a strain that isn't 
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viable without the enzyme activity being studied. Knocking out multiple genes is 
often necessary and this can be difficult. A further problem can manifest itself during 
the screening process itself Knock-out strains may mutate and recover knocked-out 
gene products or develop replacement pathways. This leads to false positives and 
will only be discovered when analysis of the mutant enzyme, or its encoding DNA, is 
performed. 
The direct analysis of products involves determining if a colony produces the desired 
chemical product of the transformation being studied. This screening method may be 
regarded as the most direct method of screening, because one is detecting the 
presence of a desired product. There are numerous methods of detecting and 
analysing a chemical product, however for the purposes of high-throughput screening 
chromatography such as FIPLC , CE or GC 170,17  and mass spectrometry / GC-MS 172 
are the most viable, although techniques such as 'H-NMR' 73 and FT-1R' 74 have been 
employed. The reason for this is two-fold. These methods may be developed to have 
short run times, so that each sample does not take too much time to analyse. 
Secondly, the equipment used for chromatography and mass spectrometry is 
amenable to automation. This allows a large number of samples to be processed in a 
relatively short time. 
The analysis of reaction products can be extended to investigating the 
enantioselectivity of a reaction. Isotopically labelled compounds have been used to 
determine enantioselectivity of a panel of nitrilase enzymes. 75 The reaction of 15N-3-
hydroxyglutaronitrile 75 pseudo-prochiral enantiomers can be used to assay the 
enantioselectivity of nitrilases using mass spectrometry (Figure 58). Isotopically 
labelled pseudo racemic substrates have also been used in high throughput screening 














Figure 58: Determination of the enantioselectivity of nitrilase enzymes using 
isotopically labelled pseudo-enantiomers of a prochiral substrate. 
Difficulties with direct analysis of products are found. Samples can require 
preparation before they are suitable for delivering to the analytical equipment, 
involving intervention by the researcher. Although systems can be developed which 
do allow rapid sample turnover, this method is not as efficient in sample throughput 
with respect to the other screens described and generally direct product analysis is 
the most time-consuming method to screen large libraries of variants. In addition all 
samples must be analysed, thus there is not a method for dismissing negative hits 
before analysis on the instruments. This contrasts with life-or-death screens. 
A colorirnetric screen offers many advantages and for this reason many high 
throughput assays are based on the use of chromogenic (or fluorogenic) substrates. A 
high quality colorimetric screen combines many advantages; the equipment 
employed means a high numbers of variants may be screened, the development of 
the analytical method is usually simple, no organism engineering is required and the 
system is often transferable to other chemical transformations of interest. 
The colorimetric output of a screen may be linked to a number of different events. It 
may be proportional to the disappearance of a substrate, if the substrate of interest 
has a colorimetric or fluorometric output. The appearance of a desired colorimetric 
product may also occur. Most commonly the generation of a by-product of the 
76 
reaction of interest is detected. 174  The formation of a detectable product may also 
require further reagents or catalysts in the assay mixture. 
The colorimetric output of a screen may be detected by a number of different 
methods, of varying complexity, cost and speed. The simplest, and Often most 
efficient in terms cost and development time, is the use of the human eye. Plates of 
colonies with varying colour output may be surveyed and those exhibiting the 
desired output selected. The downsides associated with this method of hit selection 
are that no accurate numerical data is associated with the hit, in terms of colour 
density, rate of colour formation, etc. Secondly the problem of human fallibility, 
most especially the possible lack of objectivity, can be manifested. Bias, in terms of 
'wanting something to work' and fallibility, in terms of problems such as tiredness, 
can influence selection adversely. The use of basic imaging technology, such as 
filtered digital cameras can allow for more accurate screening. 78 
A recent development in colorimetric screening is the release of a digital imaging 
spectrophotometer called Kcat Technology. ' 79 ' 80 Kcat Technology allows the high 
throughput solid phase assay of microbial libraries by the analysis of each 
microcolony on a plate. Each microcolony is analysed simultaneously at a very high 
resolution (75pm/pixel). The benefit of this technology is that for each pixel it is 
possible to plot a kinetic profile and thereby rank in order the relative performance of 
hits identified in the screen, which is not facile with a regular plate based screen. The 
technology also allows for highly confluent plates to be screened, and thus more 
variants per unit time. clearly the manual selection of a specific microcolony from a 
highly confluent plate must be considered if this experimental path is to be followed. 
To overcome the bottleneck of manual selection and picking a number of packages 
are available combining robotic arm pickers, cameras and control 
Calibration and experimental design can be lengthy but once the experiments are 
running automation of the process offers significant opportunities for high-
throughput screening. 
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Most fluorogenic and chromogenic screens have been designed to be performed in 
parallel on microtitre or agar plates. The implication of this is that these screening 
methods are usethl and applicable for screening several hundred thousand variants. 
This is a significant number; however it is still small with respect to the total number 
of possible variants that library creation techniques can produce. A key technique 
that has been developed to address the desire to screen many millions of variants is 
fluorescence activated cell sorting (FACS) (Figure 59). 182 Using flow cytometry, up 
to 109  variants can be analysed in a practical time period. 183  A screen is developed in 
which an optical output occurs for a desired functionality of a cell. This may, for 
instance, be the conversion of a substrate or alteration in the expression levels of a 
protein. The use of Green Fluorescent Protein (GFP) coupled is one method 
described to produce an optical output for a FACS system .184 The mass of cells is 
forced to travel past a sensing point one cell at a time. As the cells move in 
suspension past a sensing point the optical property is measured and any cells that 
fall within predefined parameters may be collected. This is achieved by the 
cytometer machine which charges the steam of cells at the point when the flow has 
become a droplet. The sorted cell droplet now carries a charge that is different to the 
bulk stream and may then be deflected into a collection hopper by the application of 
a controlled electrical field. As a fUrther refinement the physical properties of each 
cell can be analysed. This allows dead cells to be discarded and prevents attempts to 
grow-up unviable cells. The equipment to perform FACS is relatively expensive and 
specialist however today they are a mainstream instrument and with an optimised 
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Figure 59: FACS system. 
In conclusion, there are various technologies available that can be used in a screen. 
Each method has benefits and drawbacks and the most appropriate method should be 
selected individually for each case to best suit the conditions of the screen. 
Furthermore it is imperative that the method chosen is high throughput and is 
sensitive enough to monitor the production of product or products to maximise the 
numbers of candidates that can be examined. 
4.2.1.3 Directed evolution - Conclusion 
The combination of a well-defined procedure to create a library of variants coupled 
with a selection procedure which effectively discriminates between the variants is 
crucial for a successful directed evolution experiment. The technology and 
techniques exist for this and, as such, a directed evolution program is a viable 
method for the production of novel enzyme variants. The crucial factor associated 
with direct evolution is that it is a 'results-orientated' technique. This means that a 
successful outcome, in terms of improving a property of an enzyme, is the sole focus. 
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Naturally, this may lead to negative consequences. If a positive hit is found 
containing multiple mutations, with respect to the parental variant, then 
deconvoluting the effect of each mutation is not possible without further work. If no 
information about the enzyme structure is available then rationalising why mutations 
have altered a property is also very difficult. It must be remembered there can be no 
guarantee that improved variants identified are the optimum variant possible, merely 
that they exhibit the characteristics screened for. 
4.2.2 Rational design 
Rational design is the term used to describe the creation of variants in a non-random 
fashion. Whilst the name rather unfairly suggests that directed evolution is an 
irrational approach to the question of producing enzymes with improved proprieties, 
the term rational design does emphasise that the make •up of the variant library is 
entirely dictated by the researcher. The fact that mutations are produced at defined 
positions on the gene, and thus the enzyme, means that variant libraries are generally 
much smaller. At the extreme the library may contain only a single variant. This, in 
turn, means that lower-throughput screening systems are required. The benefit of a 
rational design process is that one may investigate the effect that a specific residue 
change has, additionally if directed evolution produces a variant with a mutation at a 
specific residue, then investigation as to whether the optimum residue at that position 
has been found can be performed. A specific variation of a rational design 
experiment which can prove to be very powerful is saturation mutagenesis. 
4.2.2.1 Saturation mutagenesis 
To ensure a library of variants had the maximum possible diversity it is necessary to 
fully randomise each nucleotide within the encoding gene. This equates to 4" variants 
where n = the number of nucleotides in the gene. This number is incomprehensively 
large and is simply impossible to achieve, as is even attempting to fully randomise at 
each amino acid residue. The effect of this is that if an improved variant is 
discovered it is incredibly unlikely that any experimental procedure will have 
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ensured that all possible amino acids at that particular residue will have been 
screened and assessed. Saturation mutagenesis is a technique which allows the 
researcher to investigate all possible amino acids at a defined residue position. The 
technique may also be used to investigate whether putatively important residues, 
perhaps predicted by a homology model or structural data, have an effect on the 
properties of the enzyme variants. 
The 3 nucleotides that encode the position of interest are substituted for NNS, where 
N represents any of the 4 DNA bases and S either G or C. This achieves the situation 
of having all 20 amino acids represented whilst reducing the occurrence of a stop 
codon. Clearly a stop codon is undesirable at any residue on the gene, as it will result 
in a truncated product. The use of a INNS codon does alter the degeneracy of the 
genetic code; however production of all 20 amino acid variants is theoretically still 
achieved. A statistical analysis of the resulting possible gene products (Equation 1)101 
demonstrates that 147 colonies are required to ensure a 99% probability of all 
possible mutations. 
P = I 
P = % probability (defined as 99%) 
N= number of colonies required 
V = total possible number of combination 
Equation I: Required library size for saturation mutagenesis screening. 
Clearly, a saturation mutagenesis experiment can be expanded to comprise the 
saturation mutagenesis at a number of •positions simultaneously, with the 
corresponding increase in the library size and thus required number of colonies. 
The standard technique for performing saturation mutagenesis is the use of a PCR 
protocol. Two oligonucleotide primers are designed to encode the NNS sequence 
along with flanking regions of complementary sequence to allow hybridisation of the 
primer to the template. These primers are in the region of 30 nucleotide bases long. A 
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PCR amplification is carried out. The PCR products are then ligated into a 
transformation vector. After transformation and growing up of the host the genes 
vectors are recovered, digested and the gene pool cloned into an expression vector. 
Site directed saturation mutagenesis may also be performed using a commercial 
system, Stratagene's Quickchange kit. 185 The advantage with this method is there is 
no need to purify the mutated fragment of DNA from the PCR reaction and has the 
added benefit of no requirement for ligating PCR products into a plasmid. Once 
again two oligonucleotide primers are designed to encode the NNS sequence along 
with flanking regions of complementary sequence to allow hybridisation of the 
primer to the template. These primers are of the region of 30 nucleotide bases long. 
A PCR is performed with these primers, the cycle times and temperatures designed 
to allow the primers to extend completely around the plasmid. The PCR product 
mixture is exposed to Dpn I endonuclease. Dpn I specifically digests the methylated 
DNA of hemimethylated DNA. The template DNA used the PCR is methylated by 
the dam gene from E. co/i whilst PCR products are ünmethylated so only the 
template DNA is degraded. The final step is to address the fact that the PCR products 
are nicked and not completely circularised, transformation into a specific E. co/i 
strain ensures the 'nick' is repaired (Figure 60). 
PM 
desired mutation site 
parental 	 primers with mutations -20mers 
pliid 
primers annealing 
12-18 cycles in PCR 
Digestion of parent DNA by Dpnl 
(i) nick repair 
(ii) transform into E.coU0 
Library of site variants 
Figure 60: Stratagene's Quikchange system. 
A development of the saturation mutagenesis techniques outlined above is the Gene 
Site Saturation Mutagenesis (GSSM) technology of Diversa Corporation. 186  This is a 
system which, to some extent, bridges the gap between the directed evolution and 
rational design concepts. The GSSM system allows each codon in the parental gene 
to be mutated to all other possible codons in turn. This system is very powerful in 
terms of identifying residues key to the property of interest, so called 'hot spots'. As 
with directed evolution, knowledge of important residues before the experiment is 
unnecessary. The difficulties associated with deconvoluting which mutations have 
been effective within the multiple mutations sometimes observed in a directed 
evolution experiment are overcome. The proprietary nature' 87  of the technology does 
mean that the opportunity to exploit this technique is limited. 
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4.2.2.2 Screening 
As demonstrated above, the library size for the simplest saturation mutagenesis 
experiment need not necessarily be large. This means that the need for high-
throughput screening is less urgent, however methods detailed for directed evolution 
experiments can often be employed for saturation mutagenesis experiments also. A 
smaller number of variants to screen does lend itself to more detailed and labour 
intensive analysis. Screening of purified enzymes becomes viable, as does direct 
product screening using lower throughput methods. 
4.2.2.3 Rational Design - Conclusion 
Rational design is a technique which allows a much greater degree of control in 
terms of the variants produced compared with directed evolution. Probing of active 
site residues and assessing the effect of exact residue changes becomes possible. The 
negative side of this is that prior knowledge of the mode of action and structure of 
the parental enzyme is necessary to make any experiments worthwhile, this is in 
contrast to directed evolution. In addition, as such a narrow range of mutation is 
studied, a large amount of resources can be dedicated to experiments that ultimately 
do not alter the enzyme properties in the desired fashion. 
4.3 	Biocatalyst modification - Conclusion 
Biocatalyst modification techniques most be considered as complementary to each 
other. A successful program may well involve a directed evolution program, further 
optimisation using rational design procedures and optimisation of the actual 
biocatalyst form used in scaled-up reactions. It is crucial to define what is required of 
the biocatalyst and then focus on employing the most relevant methods to achieve 
this; these will vary on a case by case basis. 
4.4 Directed evolution of MAO 
In an attempt to improve the catalytic properties of the MAO-N variants towards the 
hydroxylamine and hydroxylamine ether substrates of interest a programme of 
directed evolution was undertaken. The investigation would focus on trying to 
identify mutants with higher activity towards the substrates. Drawing from the 
experience of directed evolution programs that had been performed on the MAO-N 
enzyme previously, serendipitous benefits such as a broadening of substrate 
specificity or an increase in enzyme stability may be observed. Monitoring of these is 
an important factor. 
4.4.1 Library creation 
As described above, a number of different protocols exist by which a mutant library 
can be generated. The E. co/i mutator strain XLI -Red was selected as the agent to 
create a nzao5D mutant gene library for a number of reasons. Previous experience in 
the laboratory meant that the use of this technique was well understood. An 
advantage of the method over others is that it is not resource intensive, in terms of 
time, money and labour. Perhaps the strongest driving force was the fact that the 
previous use of the XLI -Red system in our laboratory ' °1 ' °2 had lead to successful 
isolation of MAO mutants with improved properties. 
As a baseline, to assist with designing the mutation experiment, it has been 
experimentally measured that in XLI -Red the mutation rate is typically 1 
mutationl5xlo6 bp/generationlcell.' 53 in addition it has been experimentally 
measured that with a pBluescript the mutation rate was 1 mutation per 2kb after 30 
generations.' 63  Whilst these figures provide a general guide to mutation rates it must 
be noted that it is based on a standard plasmid control experiment. This does not 
reflect the actual circumstances, in terms of growth cycles, growth conditions and 
plasmid to be used in the series of experiments described herein. There is no 
substitute for experimentally determining the mutation rate under the conditions that 
are proposed to be used. The conditions employed for the construction of random 
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mutation libraries in the experiments presented in this report are chiefly based on 
work previously performed in our laboratory with various mao gene libraries. 
The mao gene is 1489 base pairs in length, so assuming an error rate comparable 
with the rate observed with pBluescript then it would take just over 22 generations 
for a single base mutation to the mao gene to be introduced. Experimentally, 
however, the optimum conditions were found to be 4 cycles of transformation and 
inoculation, corresponding to approximately 36 - 48 generations. 
It was decided that a number of mutant libraries were to be created and screened, the 
essential difference between them was the parental mao gene employed at the start. 
The libraries created were; 
RLrnao-IV5D I 
The gene mao-N5D encoding for the MAO enzyme which demonstrated activity 
towards the hydroxylamine substrates 47 and 48 (Chapter 3) was used as the parental 
gene for the construction of this library, for the obvious reason that it demonstrated 
the activity desired and so was the ideal start point for a program of directed 
evolution. : 
RL.n,ao-N5D 2 
As above, a repeat in all respects. 
RL,nao-N 
The mutant mao genes available in the laboratory had been subjected to various 
mutation protocols in an attempt to improve the activity towards amine substrates. It 
may be the case that the mutations introduced were deleterious with respect to 
activity towards hydroxylaniine substrates. For this reason, the wild-type man gene, 
maoN, was used as the starting point for the construction of this mutant library. 
4. RLmao-N2 
This parental mutant contained two of the five mutations present in the mao-IV5D, 
N336S and M348K. This mutant was a product of the directed evolution experiments 
that ultimately lead to the mao-N5D mutant. This mutant library was created by, and 
acquired from, Dr R. Speight, Ingenza Ltd. 
The RLmao-N, RLmao-IV5DI and RLmao-N5D2 mutant libraries were constructed 
in the same fashion. XLI-Red competent cells were transformed with the parental 
mao gene in pET-16b plasmid using a modified version of the manufacturer's 
protocol. The transformed cells were used to inoculate IOml of LB containing 
lOOgIml ampicillin. The cells were grown for 18 hours after which ImI of culture 
was removed for isolation of the plasmid DNA. This procedure gave the first 
generation library of mutants. The plasmid DNA was then re-submitted to the same 
procedure a total of four times. This protocol was designed to balance two critical 
parameters; the number of mutations per mao gene and the mutation to an inefficient 
mutator strain. 
Clearly, the more generations ofXLl-Red allowed to form, the greater the likelihood 
of a mutation in the mao gene. This must be balanced with the fact that too many 
XLI-Red generations and one may find multiple mutations in the mao gene. 
Alternatively, but even more problematically, genomic mutation of the XL1-Red 
may lead to the re-emergence of, or the formation of alternative, DNA repair 
pathways. This in turn leads to cells which do not introduce mutations to the parental 
mao gene and reproduce far more efficiently than those that do. They out-compete 
the mutator cells with the result that the non-mutating strain dominates the cultures. 
An investigation into whether the protocol above did produce mutations at an 
acceptable rate was performed. Plasmid •DNA from the RLniao-N5D I library 
generated by XLI-Red was used to transform BL2I (DE3) star E. coli competent 
cells and grow-up on lOOpg/ml ampicillin plates. 10 colonies were selected and the 
plasmid DNA isolated and analysed by DNA sequencing (Table 11). 
M. 
• Clone - Rlmao-N5D 1. Mutation in gene Effect of mutation 
1' n/a n/a 
2 None None 
3 A408G Thrl36Thr 
4 G167A Arg56Lys 
5 A337 deletion frame shift 
6' n/a n/a 
7 (3845, T846 deletion frame shift 
8' n/a n/a 
9 C1 345T His449Tyr 
10 161(3 Ser2lAla 
Sequencing tailed 
Table 11: Mutations introduced into ,nao-N5D in 10 random clones of RLniao-N5D1 
library. 
As illustrated in Table II the library creation protocol outlined above produces a 
wide variety of mutations. Translations, transversions and deletions are present. In 
addition it most be noted that a number of clones had no mutations in the mao gene. 
No other portion of the plasmid was sequenced. 
The protocol described above represents the optimisation of the difficult balance 
between the various parameters when using a mutator strain library creation system 
and has produced libraries in which most plasmids contain a single base-pair 
mutation in the parental mao gene. 
4.4.2 Library screening 
The variant libraries created were separately screened against two substrates, 
hydroxylamine 46 and its methyl ether derivatives 47. These two substrates were 
chosen with different goals in mind. Hydroxylamine ether 47 was a reasonable 
substrate for MAO-N51), as demonstrated in Chapter 3. The purpose for screening 
the libraries against this substrate was to investigate whether a mutant with enhanced 
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rate could be isolated. The screening against hydroxylamine 46 was a far more 
ambitious program, designed to investigate whether any of the inactive MAO-N 
variants could be successfully evolved to exhibit activity against a hydroxylamine. It 
should be noted that inhibitory action had been demonstrated for hydroxylamines 
against MAO-N5D, (Chapter 3), and thus this program had the target of 
fundamentally altering the relationship between the MAO-N enzymes and the 
substrate. 
HN OH 	 NN OMe 
46 	 47 
Figure 61: Initial screening substrates for directed evolution experimental 
programme. 
Plasmid DNA from the libraries generated by XLI-Red was used to transform .BL2I 
(DE3) star E. coil competent cells which were then subjected to the plate-based assay 
described in Chapter 3. Control plates, consisting of E. co/i transformed with the 
parental mao gene of each particular library were assayed in parallel against 47. This 
was to have a comparison against which possible hits could be compared to assess 
whether darkening rates were quicker. 
Library No. of Plates 







RImao-NSD I 20 1992 39800 0 
RLmao-N5D 2 18 2140 38500 0 
RImao-N 18 1664 30000 0 
RLinao-N2 18 912 16400 0 
All colonies on 'A of the plate counted, result multiplied by  
Table 12: Results of screening random libraries against hydroxylaniine ether 47. 
As displayed in Table 12, the use of a directed evolution protocol was wholly 
unsuccessful in identifying a MAO-N variant that had improved activity towards 47 
compared with the original MAO-N51) mutant. Activity was retained by 
approximately 5% of colonies, indicating that experimental method was sound. None 
of the active colonies produced activity greater than the control plates. The possible 
reasons for this are manifold. To take an optimistic, but unrealistic, view it could be 
claimed that the reason no improved variants were found was because the enzyme is 
fully optimised towards the substrate - in other words every possible mutation to the 
mao genes leads to a less active enzyme product. This fact could only be ascertained 
by producing every single mutant individually and assaying them but is unlikely 
compared with other possible explanations. 
Flawed experimental procedure may have led to the difficulties in a isolating an 
improved variant. Although the sequencing of a small sample of clones (Table 11) 
indicated that a range of mutations had been introduced into the parental mao genes, 
perhaps this was an unrepresentative sample and a large number of unmutated 
parental genes remained in the library DNA pool. As described in Chapter 3, there 
are also known limitations with the plate-based assay procedure, specifically 
regarding the homogeneity of the assay across the plate. It is entirely possible that a 
more active variant was located in a region that was not subjected to the optimum 
assay conditions compared with the control 'plate and thus was missed. The final 
consideration is that the libraries happened not to contain the variants that would 
have higher activity towards the substrate 47, simply a case of bad luck. The design 
of the experiment and the number of variants screened represent a viable and 
worthwhile attempt to isolate variants displaying higher activity towards 
hydroxylainine ether 47, however the results were disappointing. Further generation 
of new libraries and screening them was not attempted as other avenues were 
available to explore. 
The same libraries were screened against hydroxylamine 46 (Table 13). This was in 
an attempt to isolate variants which turned over a substrate that had proven to be an 
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inhibitor of the parental enzyme variants. This goal was extremely ambitious and, as 
such, the risk of it failing was large and obvious. 
Library No; of Plates 







RLn,ao-MD 1 18 2440 43900 
RLmao-N5D 2 18 476 8600 2 
RLrnao-N 18 2012 36200 0 
RLrnao-N2 10 1204 12000 0 
All colonies on ¼ of the plate counted, result multiplied by 4 
Table 13: Results of screening random libraries against hydroxylamine 46. 
The plasmid DNA from the 3 hits isolated was separately retransformed and re-
assayed, i hit, RLmao-N5D 2HB appeared to darken significantly faster than the other 
two, which on re-assaying did not appear to darken significantly. The one possible 
hit was taken fonvard and the CE from a 1 OmL culture used to perforill a liquid 
phase assay experiment as per Chapter 3 (Table 14). 
Sample OD / 510 at t 60 mins 
RL1iao-N5D 2HB CFE sample I Baseline 
R5mao-N5D 2113 CFE sample 2 Baseline 
.RLnzao-N5D 21-lB CFE sample 3 Baseline 
Table 14: Liquid-phase assay results for positive hit RLmao-IV5D 2HB. 
A SDS-PAGE gel confirmed that protein of the correct mass was being over-
expressed and thus the possible activity proved to be illusionary when more detailed 
examination of the variant was undertaken. This starkly highlights the usethlness of  
control plate of the parental variant produced and assayed in parallel with the 
screening experiment. If the inactive parental variant is observed to gradually darken 
over time, inactive variants which darken at the same rate can and will be ignored. 
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The fact that an active variant was not isolated is not terribly surprising and no 
further libraries were generated or screened 
4.4.3 Directed evolution conclusion 
The use of a directed evolution protocol to discover improved MAO-N enzyme 
variants did not prove to be successful. Whilst the system had proved very effective 
within the laboratory for altering and improving the characteristics of the MAO-N 
enzymes with respect to various classes of amines, this was not the case for the 
hydroxylamine derivatives of interest. Simply put, the MAO enzyme is a monoamine 
oxidase, not a hydroxylamine oxidase, and so the enzyme is already operating 
outside of its normal parameters - further improvement of the activity was not 
achievable. 
In an attempt to investigate whether improvement of the MAO-N51) activity towards 
hydroxylarnine derivatives could be made, attention was turned to the other main 
method of engineering an enzyme; site specific mutagenesis 
4.5 	Site specific mutagenesis 
In an attempt to improve the catalytic properties of the MAO-N variants towards the 
hydroxylamine and hydroxylamine ether substrate of interest a programme of site 
specific saturation mutagenesis was undertaken. The investigation would focus on 
trying to identify mutants with higher activity towards the substrates. The location of 
residues that may alter the MAO-N activity towards hydroxylamines and 
hydroxylamine ethers were investigated using the computer homology model 
described earlier (Chapter 3). 
4.5.1 Selection of residue 245 
As described previously, molecular modelling studies suggested that residue 245 of 
MAO-SD may have an influence on the catalytic activity of MAO-SD with respect to 
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substrate 47. Residue 245 was a close-contacting residue when the substrate was 
docked into the active site. The decision was made to perform site specific 
mutagenesis upon this residue. Previous work within the group had shown, as 
expected, that the close contacting residues in the active site region could be very 
influential with regards to catalytic activity. Indeed the MAO-SD variant included a 
mutation at position 246. 
4.5.2 Residue 245 saturation mutagenesis library creation 
Site directed saturation mutagenesis at position 245 was performed using Stratagene 
Quickchange protocol described above. The two oligonucleotide primers were 
designed to introduce an NNS codon in the mao5D gene, encoding for amino acid 
position 245 in the MAO-SD enzyme (Figure 62). 
Forward primer: 5'-GGATGCATGGACTGCNNSATGAGTTATAAGTTCA-3' 
Reverse primer: 5'-TGAACTTATAACTCATSNNGCAGTCCATGCATCC-3' 
Figure 62: Oligonucleotide primers designed for the NNS saturation mutagenesis 
library at amino acid residue 245 in MAO-SD 
Completion of the Quickchange protocol led to approximately 500 colonies on 4 
plates being produced. Before screening of the saturation mutagenesis library 
commenced the distribution of the library had to be ascertained. The library must be 
shown to be representative in terms of codons present and, more importantly, it must 
be shown the experiment had actually worked and that a library of mutants had been 
created. 
10 colonies were selected at random (clones TESAT 1.1 - TESAT 1.10) and the 
nucleotide sequence at the 245 position analysed by DNA sequencing. The two key 
points of this sequencing were to ascertain that firstly, there was not an over-
representation of the parental TTG codon and secondly, that a range of alternative 
codons were present. This was the case, as illustrated in Table 15 
oil 
Clone - TESAT1. 245 Codon Amino acid 
I GTC Val 
2 ACC- Thr 
3 GTC Val 
4 AAG Lys 
5 TCG Ser 
6 ATO Met 
7 CGG Mg 
8 ACG Thr 
9 TTG Leu 
10 TGC Cys 
Table 15: Sequencing of 10 clones (TESATI.! - TESATI.10) of 245 saturation 
mutagenesis library generated by the Quickchange kit. 
4.5.3 Screening of residue 245 saturation mutagenesis library 
The plasmid DNA library was used in the transformation of E. coli B.L21 (DE3) 
competent cells giving and grown-up on plates as per Chapter 7, Experimental 
Section. 155 colonies and 120 colonies grew on plates TESATIPI and TESATIP2 
respectively. As 147 colonies were required to have a >99%  probability of each 
possible mutant being represented, 275 colonies represents an acceptable sampling 
number. The membranes were then assayed against (rac)-47. After 19 hours, 6 
colonies were significantly deeper brown-coloured than the remainder of the 
colonies. In addition all colonies on a plate of solely the parental clone appeared 
paler. This control was employed to ensure large amounts of time and resources were 
not employed on re-selecting the parental clone if it turned out to be the optimum 
codon. The 6 colonies were picked and separately grown in LB containing I OOpg/ml 
ampicillin. The plasmid DNA of the 6 positive colonies was separately and 
simultaneously taken forward to two experiments. 
Firstly, the plasmid DNA of each positive clone was re-transformed into E. co/i 
131_2I (DE3) competent cells and re-grown on plates for a second assay test. Each 
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plate consisted of colonies with the same, initially positive, plasmid transformed in 
them. Thus all colonies on the plate should darken. When re-assayed and compared 
with the parental control plate, 5 plates were assigned as positive, the sixth was 
unclear and indeterminate, and thus work was discontinued on this clone. Secondly 
the plasmid DNA was sequenced at the 245 site. All six plasmids were found to have 
ATG, encoding for mcthionine, at the NINS site. The ATG codon has a I in 32 
chance of occurring amongst the NNS library; therefore in the library size screened 
here it should be expected to occur on average 8.6 times ((1/32) x 275). it may be 
expected that on average a further 2 hits would be identified, however the screen is 
necessarily non-precise and a colony 'slipping through the net' is not unexpected or 
unreasonable. The close match of the predicted and observed numbers of optimum 
colonies is pleasing. 
The optimum residue at position 245 would appear to be methionine as described 
above. This represents a single base change from the TTG parental leucine codon 
and the enzyme is named MAO-N6, the gene rnao6. The leucine to methonine 
change is not a dramatic alteration of the environment at this amino acid position. 
Leucine Methionine 
Figure 63: Leucine to methonine change 
Both are uncharged residues under standard physiological conditions and both are 
hydrophobic. The key side-chain difference is that leucine has a larger side chain 
volume than methionine (Figure 63). The linearity of the side chain of methonine 
differs from the branched nature of leucine. The change from leucine to methionine 
results in removal of a -1-methyl branch in the amino acid side group. It may be 
postulated that the enzyme active site is affected by hydrophobic exclusion and Van 
der Vaals interactions between the enzyme's active site and the substrate, thus the 
steric nature of the side chain may be crucial. 
In addition to selecting clones which appeared to have the fastest reaction rates a 
number of inactive clones were selected and investigated. There were a number of 
reason for this; as a re-check that the library contained different codons at the 245 
site, to investigate whether inactive clones consistently contained certain residues 
and to ensure that the putative optimal residue, methonine, did not appear. This 
would give increased confidence in the screen and that the ATG mutant was indeed 
worthy of further investigation (Table 16). 
• 	Clone—TESAT1NA. 
- 	
45 Codon Amino acid 
'fl'C Phe 
2 CCG Pro 
3 TAC Tyr 
41 n/a n/a 
5 FTC Phe 
6' n/a n/a 
Sequencing reaction failed 
Table 16: Inactive mutants from 245 saturation mutagenesis experiment. 
Pleasingly, the inactive mutants selected showed a consistency, in that they may all 
be regarded as residues that would sterically hinder the 245 site, as compared with 
the 245 methonine and leucine mutants which have been demonstrated to be active. 
Clearly, this rationale is not the only explanation as to why these mutants may be 
inactive. The enzyme may not fold into the active form with these residues present, 
there may have been a problem associated with protein expression for these 
particular clones that is wholly unrelated to the 245 residue change. Additionally, it 
is possible that the assay was faulty in some aspect and these clones were in fact 
active, and misidentified as inactive. No system can be devised that is infallible, 
however the assay and mutagenesis system has been proven to be robust and the 
methonine mutant, MAO-6, was taken forward for further investigation. 
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4.5.4 Effect of methonine mutation 
In an attempt to gain an insight into what effect the L245M mutation may have had 
upon the MAO enzyme a further round of molecular modelling was undertaken. 
MAO-6 structure was subjected to the same modelling conditions as for the MAO-
SD experiment, with the same substrate, (S)-47, docked in the active site. The active 






Figure 64: Hydroxylamine ether (S)-47 docked in MAO-N6 active site model. Green 
lines indicate closest contacts. 
It can be seen that the modification of the leucine 245 residue to methonine has 
caused the pocket into which the methoxy ether moiety is located to increase in 
volume (cf. Figure 55). It would appear from these studies that a modification of the 
active site configuration occurs with the L245M mutation. It may be speculated that 
the alteration of the active site volume allows for the more rapid entry and exit to the 
active site by the substrate. Clearly this contention is speculation to some degree. The 
suggested configuration of the active site relies on a number of assumptions. The 
original model is merely a homology model of MAO-N, derived from alignment with 
the known crystal structure of MAO-B. In turn this model has been subjected to 
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energy minimisation protocols which, whilst well described and extensively used, are 
necessarily predictions rather than fact. A crystal structure of the MAO-6 mutant is 
required to conclusively understand the structure and mechanism both of the parental 
MAO-5D and mutant MAO-6 enzymes. Acquiring a crystal structure of any of the 
MAO mutants is outside the scope of this investigation. 
The MAO-6 was subjected to a further level of investigation and screened against a 
number of hydroxylarnine substrates, in parallel with the MAO-SD, to assess the 
extent to which improvements in the catalytic properties of the enzyme had been 
achieved (Table 17). The plate-based screen necessarily lacks fine detail in terms of 
catalytic rates and does not provide any sort of data output that may be used for 
accurate comparison. 
Substrate I 10mM MAO-SD activity I % MAO-6 activity .I % 
24 100 98 
48 17.4 19.9 
47 15.6 18.4 
70 13.1 15.8 
74 3.5 3.6 
72 3.4 3.7 
42 1.2 1.6 
72 0.6 <0.5 
44 <0.5 <0.5 
46 <0.5 <0.5 
73 <0.5 <0.5 
Table 17: Substrate conversion rate, relative to MAO-SD with cx-methylbenzylamine 
24 at 100%. Analytical threshold 0.5%. 
As Table 17 indicates the MAO-6 mutant shows a slightly modified profile with 
respect to MAO-SD in terms of relative activities. There remains no free 
hydroxylamine activity, as discussed in Chapter 3 this is unsurprising, however an 
alteration in the relative rates for a number of substrates is observed. The key point to 
note is that there are no major differences between the activities of the two mutants; 
substrates remain in the same order of relative activity and the absolute values do not 
different greatly. This indicates that the effect of replacing the leucine with a 
inethonine is not dramatic; rather it subtly alters the active site, and provides a degree 
of rate enhancement for substrates already proven to be active with the parental 
MAO-SD mutant. The alteration to a methonine residue does not allow for any of the 
panel 44, 46 and 73 that were not substrates to become so; specificity does not 
appear to be altered. One may speculate that a small increase in the rate at which the 
substrate may enter and leave the active site is achieved with the leucine to 
methonine substitution. As specificity is not altered the 245 residue does not appear 
to have a crucial role in the active site configuration and catalytic action. An analysis 
of the kinetic properties of MAO-6, compared to MAO-SD, turning-over a model 
substrate may assist in elucidating this, and is presented below. These results also 
indicate that the plate-based assay is perhaps more sensitive than thought, as a rate 
improvement of 18% was successfully detected. This provides extra confidence in 
the use of the plate-based screen at the top of a hierarchical screening system. 
The kinetics of the enzyme reactions were probed using Micheal is-Menten studies as 
per Chapter 3. The experimental procedure was exactly the same and the data for the 




kw (min") KM (mM) 
(ILmol/min/mg) k, / K 
24 (miii mfW) 
MAO-SD 0.78±8x10 2 43.4±0.4 3.52±0.19 12.33 
MAO-6 0.74±2x10 2 41.1±0.3 3.49±0.11 11.78 
HNOMO 
47 
MAO-SD 0.18±3xIW2 10.2±0.8 5.66±0.24 1.80 
MAO-6 0.20±2xIO 2 11.1±0.4 4.23±0.12 2.92 
Table 18: Comparison of kinetic properties of MAO-51) and .MAO-6 mutants. 
Interestingly the parental gene (nuw5D) for this portion of work was constructed in 
an attempt to optimise the MAO-N for a wide range of secondary amines. Saturation 
mutagenesis of position 246 was undertaken and methionine was found to be the 
optimum residue, using a similar protocol to that described above. The mutated 
residue was originally isoleucine and so the more active mutant and the mutation that 
occurred followed a pattern very similar to the results described above. 
4.5.5 Residue 246 saturation mutagenesis library creation 
The fact that the parental gene for this optimisation experiment has already 
incorporated a mutation derived from a previous experimental program, focusing on 
secondary amine substrates, leads to the possibility that the MAO-N6 contains a 
deleterious mutation at 246, (lie niethonine residue that was introduced, replacing the 
isoleucine. Returning the 246 residue to the original, wild-type isoleucine and 
comparing the result to the double methionine product would both be possible and 
interesting. The resources, in terms oftime and money, involved for this however are 
comparable to performing a saturation mutagenesis experiment. Therefore it was 
decided to perform a further saturation mutagenesis experiment. With residue 245 as 
HE 
methionine, residue 246 was subjected to a saturation mutagenesis protocol. The 
experiment was performed as above 
The two oligonucleotide primers were designed to introduce an NNS codon in the 
mao6 gene, encoding for amino acid position 246 in the MAO-N6 enzyme (Figure 
65). 
Forward primer: 5 '-GGATGCATGGACTGCATGNNSAGTTATAAGTTCA-3' 
Reverse primer: 5 '-TGAACTTATAACTSNNCATGCAGTCCATGCATCC-3' 
Figure 65: Oligonucleotide primers designed for the NNS saturation mutagenesis 
library at amino acid residue 246 in MAO-6 
Completion of the Quickchange protocol led to approximately 430 colonies on 4 
plates being produced. Before screening of the saturation mutagenesis library 
commenced the distribution of the library had to be ascertained. 
10 colonies were selected at random (clones TESAT3.1 - TESAT3.10) and the 
nucleotide sequence at the 246 position analysed by DNA sequencing. The two key 
points of this sequencing were to ascertain that firstly, there was not an over-
representation of the parental ATG codon and secondly that a range of alternative 
codons were present. This was the case, as illustrated in Table 19. 
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CIôñe - TESAT3. 246 Codoñ Amino acid 
AAG Lys 
2 ACC - 	 Thr 
3 ACG Thr 
4 TGC Cys 
5 TCG Set 
6 GTC Val 
7' n/a n/a 
8 CCC Pro 
9 TTG Leu 
10 GTC Val 
Sequencing reaction tailed 
Table 19: Sequencing of 10 clones (TESAT3.1 - TESAT3.10) of 246 saturation 
mutagenesis library generated by the Quickchange kit. 
4.5.6 Screening of residue 246 saturation mutagenesis library 
The plasmid DNA library was used in the transformation of E. co/i BL2I (DE3) 
competent cells giving and grown-up on plates as per Chapter 7, Experimental 
Section. 100 colonies and 195 colonies grew on plates TESAT3PI and TESAT3P2 
respectively. The membranes were then assayed against (rac)-45. After 18 hours, 3 
colonies were significantly deeper brown-coloured than the remainder of the 
colonies. In addition all colonies on a plate of solely the parental clone appeared 
paler. This control was employed to ensure large amounts of time and resources were 
not employed on re-selecting the parental clone if it turned out to be the optimum 
codon. The 3 colonies were picked and separately grown in LB containing I 00ig/ml 
ampicillin. The plasmid DNA of the 3 positive colonies was re-transformed and re-
assayed. All three appeared as positive hits once more, however 2 hits turned dark 
noticeably faster than the other, additionally none of the three hits appeared top be 
darkening appreciably quicker than the parental control plate. 
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When sequenced the DNA of the three plasmids were found to contain two different 
sequences, corresponding to the two different darkening rates observed, as shown in 
Table 20. 
Clone - TESAT3J-JIT. 246 Codon Amino acid 
ATG Met 
2 ATG Met 
3 1 TTG Leu 
Darkened appreciably slower than both hits 1 & 2 and parental gene ,naoó control plate 
Table 20: Codon for position 246 in 3 saturation mutagenesis hits. 
ATG, encoding for methionine at the 246 site, appears to be optimum and this 
explains why the positive hits did not out-perform the control plate - the parental 
codon encodes for the optimum amino acid at this residue. 
To frilly explore the 245/246 pair of residues a double saturation mutagenesis 
experiment is required. This is because the two experiments above only investigate 
40 of the possible 400 residue pairings possible. A single Quickchange reaction is all 
that is necessary to perform a double residue saturation rnutagenesis library if the 
residues are adjacent. A NNS / NNS library is constructed using primers just as for 
the single site saturation mutagenesis, with two NNS codons present instead of one. 
Screening is more challenging as V (total possible number of combinations) is 
increased from 32 for a single amino acid change to 1024 (32 
2
)for a double amino 
acid change, thus a 99% probability of representing all possible combinations 
requires 4695 clones. Unfortunately it was not viable to perform the experiment due 
to time constraints. 
4.5.7 Saturation mutagenesis - Conclusion 
The use of a site saturation mutagenesis protocol has lead to the discovery of an 
enzyme mutant, MAO-6, which has improved catalytic performance against the 
model hydroxylamine ether 47. A conservative amino acid change, with respect to 
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the charge and hydrophobicity properties of the residue, has led to a modest rate 
enhancement. The improved properties should not be overstated, only a moderate 
rate enhancement is observed and no broadening of specificity was achieved. The 
experimental program detailed above does illustrate that the combination of in silico 
modelling and subsequent site directed mutagenesis is a viable and valuable method 
for addressing enzyme engineering problems. 
4.6 	Biocatalyst modification - Conclusion 
The enzyme engineering program described above has resulted in the identification 
of a MAO-N variant with moderately improved catalytic properties. A number of 
hydroxylamine ether substrates are now turned over faster than with the MAO-N5D 
variant which formed the starting point of the investigation. The substrate specificity 
has not broadened and activity against hydroxylamines has not been achieved. The 
MAO-N6 variant does provide a possible catalyst for the deracemisation of 
hydroxylamine ethers when used in combination with a compatible reduction system. 
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5 	Reduction of oximes 
As detailed in Chapter 1, for a successful deracemisation process to be formulated an 
in situ, non-stereoselective counterpart to the stereoselective transformation is 
required. In most cases this will be a reduction to complement a stereoselective 
oxidation, although the reverse is possible, for instance in the case of sulfoxide 
deracemisation. 
A number of systems for the reduction of oximes have been described in the 
literature, and these may be broadly classified into three groups, namely hydride 
reductions, hydrogenations and others. The reduction reactions result in the 
formation of one, or a mixture of two, products. The C=N double bond may be 
reduced to form the hydroxylamine. This is the reaction course necessary for the 
reduction method to have utility in the hydroxylamine deracemisation systems. The 
N-O bond may be cleaved, in addition to reducing the C=N bond. This results in an 
amine as the product of the reaction. Clearly this result renders the oxime reduction 
system useless, with respect to a deraceinisation, thus careful tuning and optimisation 
of the reduction reaction is critical 
5.1 	Hydride reductions of oximes 
The use of sodium cyanoborohydride to reduce a wide variety of oximes to the 
corresponding hydroxylainine has been demonstrated in the literature. The yields of 
these reactions are generally excellent and this method may legitimately be regarded 
as the standard method of synthesising racemic substituted hydroxylamines! Related 
borohydrides display a spectrum of activity; sodium triacetoxyborohydride has been 
reported to be ineffective at reducing oximes t88 whilst sodium borohydride has been 
reported in the literature to produce the amine as the major product. 9 
Amine:borane complexes have been employed to reduce oximes to hydroxylamines. 
Pyridine:borane has been used to reduce oximes and O-acyl oximes to the 
corresponding hydroxylamines' °, avoiding over-reduction to amines. It is reported 
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that a crucial factor is the use of acidic conditions, 10% aqueous hydrochloric acid or 
20% ethanolic hydrogen chloride solution being used as the reaction solvent. A 
number of papers have reported the use of borane:oxazaborolidine adducts to access 
hydroxylamine products.' 89 The product distribution of these reactions demonstrates 
that careful optimisation is required as a mixture of amine and hydroxylamine 
products are often observed. A report from Kremiñski & Zaidlewicz indicated 
hydroxylamine to amine ratios ranging from 87:13 to 3:97, dependent on the borane 
adduct employed .22 
The reduction of oximes to the corresponding amines using hydride reagents has 
been described in a number of reports. The reagents used include sodium 
borohydride, lithium aluminium hydride and Superhydride. 9 The scope of the 
reaction has been extended to include the selective reduction of an oxime to afford 
single isomer products. The majority of hydride reagents produce amine products 
and are thus unsuitable for the production of hydroxylamines in high yield. 
As demonstrated •above, the use of hydride reagents offers a viable route to the 
reduction of oximes to hydroxylamines. The danger of further reduction to the 
analogous amines means that a wide survey of possible hydride reduction systems 
may be necessary to isolate an efficient system. 
5.2 	Hydrogenation 
The use of catalytic hydrogenation to reduce oximes has been reported. The systems 
employed a metal catalyst and H2 gas under pressure. Pt02 catalyst was used to 
afford a wide range of hydroxylamines in good yield." MCI in ethanol was the 
solvent system of choice and the products isolated as their oxalate salts. Other reports 
of the use of hydrogenation reactions suggest that the amine product may be formed. 
The use of Pd/C, Raney nickel and Pt02 catalysts to synthesise the amine has been 
reported. 9 The asymmetric reduction of prochiral oximes has been reported using a 
lipase/palladium catalysed system. The dynamic kinetic resolution (DKR) of a 
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number of oximes 77 to the corresponding N-acyl amines 78 via the amine 
intermediate was reported (Figure 66). 10  





Figure 66: Asymmetric transformation of oximes to N-acyl amines. 
The Pd/C catalysed reduction formed amines in good yield, no hydroxylamine 
products were reported. The high reaction yields suggest that the Pd/C catalysed 
hydrogenation yields amines cleanly. 
The literature to dale clearly suggests that the catalytic hydrogenation of oximes is 
possible but the reaction is sensitive, thus formulating a robust system to produce 
hydroxylamine products and avoid N-O bond cleavage may be difficult. 
5.3 	Other oxime reduction methods 
The use of a dissolving metal reduction has been reported for the reduction of an 
oxime. Sodium in n-propanol reduction of 79 produced 80 in 78% yield, no 
hydroxylamine product was observed. Literature reports also present the sodium 
dithionite reduction of oximes. '' This system results in good yield of the parental 
carbonyl compound, postulated to occur via the hydrolysis of the N-U cleavage 




4 	 J~r 
Na ° /n-Propanol 
NOH NH2 
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Figure 67: Sodium in n-propanol reduction of 79. 
Of more relevance to a program focussing on the synthesis of hydroxylamines is the 
hydrosilane/H reduction system, reported to reduce a number of oximes to the 
corresponding hydroxylamines in good yield.  192  Forcing conditions were required for 
a number of oximes but no significant amine by-product production was reported. 
5.4 	Results and Discussion 
5.4.1 Chemical reductions 
A program investigating the reduction of a model oxime, 13-tetralone oxime (Scheme 
68), was undertaken due to the essential nature of developing a reduction system to 
compliment the stereoselective oxidation, and thus produce a deracemisation. The 
crucial factor was to ensure that the reaction conditions would not be detrimental to 
the oxidation. As the oxidation was envisaged to be enzymatically catalysed the use 
of reaction conditions that would be tolerated by the biocatalyst was crucial and this 
was the major focus of the investigation. 
H 
We 	 N, OMe - 
58 	 48 
Figure 68: Model oxime reduction. 
As demonstrated both in this report and the literature, the use of sodium 
cyanoborohydride as a reducing agent was found to be very effective in the reduction 
of oximes. The reaction was typically performed in a methanolic hydrogen chloride 
solution, operating at as pH of between 3 and 4. Whilst it would not be expected that 
the MAO whole-cell system defined as optimum for the biotransformation would be 
viable in a strongly acidic medium this fact was confirmed before further 
development work was attempted. A whole-cell resolution as per Chapter 3 was 
performed in a number of different buffers (Table 21). 
Buffer pH 4.1 6.5 7.0 7.5 
Coñvesionat t 
0 2 43 48 
Maximum conversion for the kinetic resolution is 50% 
Table 21: Whole-cell resolution of 48 with varying buffer pH. 
As illustrated in Table 21, the whole-cell reaction was inactive at pH 4.1 and the 
activity displayed at pH 6.5 was not adequate for performing a viable deracernisation 
as the reaction rate was too slow. It would be expected that the whole-cell system 
would be the most robust and the most likely to operate under non-optimum pH, 
however this was confirmed by testing two alternatives, purified MAO-SD and 
MAO-SD on a Eupergit resin solid-support (Table 22). As predicted neither of these 
two preparations showed any activity at either pH 4.1 or pH 6. After defining the pH 
at which the enzymatic portion of the reaction operated, work turned to the nature of 
the reducing agent. 
Buffer p11 4.1 6.5 
Enzyme form Isolated Eupergit Isolated Eupergit 
• Conversion at t: 
0 0 0 0 
=18h/% 
Table 22: Test of enzyme preparations other than whole-cell. 
Four commercially available borohydride reagents were the initial panel of reducing 
agents tested. Along with sodium cyanoborohydride, sodium borohydride, 
tributylammonium cyanoborohydride and sodium triacetoxyborohydride were 
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included in the initial screen, to provide a comprehensive coverage of borohydrides 
with varying reactivity. 
• O.IM phosphate 
• 
	
buffer pH 8.0 7.0 6.0 5.5 5.0 4.5' 4.1' 
Reducing agent  
• 	 Na(CN)H 3 0% 0% 0% 0% 6% 18% 82% 
•NaBH 4 0% 0% 0% x x x x 
Na(OAc) 3H 0% 0% 0% x x x x 
'I3u3NHB(CN)H 3 0% 0% 1 	0% x x x x 
U. 1M citrate butler, 20eq., x = not performed 
Table 23: Conversion of oxime 58 using borohydride reducing agents screened in 
various p1-1 0. I M phosphate buffers. 
As illustrated in Table 23, the use of an aqueous system does not intrinsically prevent 
the successful reduction of the oxime. Whilst sodium borohyddde, known to be 
unstable in water, was ineffective both sodium cyanoborohydride and 
triacetoxyborohydride are known in the literature to be active in aqueous solutions. 
In addition, oximes are also known to be stable in aqueous solution. Thus with both 
reagent and substrate amenable to use in water it is not surprising that the use of 
aqueous buffer as the bulk solution is not an impediment. Table 23 also clearly 
illustrates the fact that the bulk p11 is a critical parameter of the reaction. Comparing 
Table 21 and Table 23 shows a mismatch in the buffer pH conditions for the two 
components of the deracemisation reaction. 
The requirement for a low p1-I medium for successful reduction of the oxime to 
hydroxylamine is postulated to be due to the fact that the nitrogen atom needs to be 
protonated to facilitate the hydride addition. The crucial parameter is thus the p.1< 0 of 
the nitrogen protonation step and thus the bulk p1-I required to ensure that protonation 
occurs; this need not be complete protonation of all the oxime due to the irreversible 
nature of the reduction. Literature data is available for a limited number of oximes 
and pKa values range from 0.44 to 1.75 for the protonation of the oxime on the 
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nitrogen atom. 193  These values clearly indicate that in a solution with a pH 
compatible with MAO-N activity, close to pH 7, the amount of oxime protonated 
will be zero. 
The contradictory nature of the optimal conditions required for the two 'half 
reactions' of the putative deracemisation resulted in the requirement that a further 
survey of possible reduction conditions was required. It was decide that the bulk 
solvent system of the reduction systems to be tested would be fixed at 0.1M pH 7.0 
phosphate buffer. All further investigations were directed at developing a reduction 
system active under these conditions. 
The fact that successful reduction systems were achieved under conditions in which 
the nitrogen atom is postulated to be protonated, suggested that attempting to develop 
a pseudo-positive charge on the nitrogen atom may be an avenue to investigate. 
Coordinating metals to the nitrogen centre may draw electron density from the 
nitrogen and allow for reduction at neutral pH. A number of metal salts were added 
to the reaction mixture. It should be noted that the metal salt additives were soluble 
to varying degrees. 
salt , LiCI Ca(OAc) 2 M902 .61­1 20 1n2 (S03 ) 4 Ce2(SO4) 3 Ln2 (SO4) 3 
Conversion 
ofoximel 0 0 0 0 67 0 
eq. 
Table 24: Use of metal salt additives with Na(CN)]-1 3 in attempted reduction of 58. 
As illustrated in Table 24, Ce2(SO4) 3 appeared to facilitate the successful reduction of 
oxime 58 to the corresponding hydroxylamine. Close investigation of the reaction 
solutions, however, revealed that the effect of the Cc salt was to lower the pH of the 
bulk solution. The buffering capacity of the phosphate buffer had been overcome and 
an acidic solution formed. This fact was confirmed when the reaction was repeated in 
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a Statlitrino apparatus. This allowed for p1-I control and, when the pH was constantly 
maintained at pH 7.0, no reduction was observed. 
The concept of coordination of the oxime to a metal centre to promote reduction at 
neutral pH was not abandoned after the disappointing results above but developed to 
attempt to remove the possibility of affecting the bulk pH. In pursuit of this a number 
of solid supported Ce complexes were tested in an attempt to access a viable 
reduction system. The rationale was that selected metal sites would be available for 
coordination to the oxime, allowing the reduction to lake place, whilst being fixed on 
a solid support. This would prevent the bulk solution pH being altered and would 
allow it to be maintained at p1-17. The complexes in question were Ce phosphonates 
on a silica support. 
Name Ce ion 
Loading of Cc 
ion / mmol Ig 
Surface area I 
m 2/g 
Particle size / 
Am 
P-l2-014c III 0.8 246 45-125 
P-09-014 Ill 1.1 n/a' 25-125 
P-04-014b ill 2.5 22 10-45 
P-12-004c IV 0.8 247 45-125 
P-09-004X IV 1.2 495 25-125 
P-09-004L IV 0.8 475 25-125 
udid Hut Supplicu 
Table 25: Properties of cerium phosphonate on silica additives. 
The catalysts are prepared from cerium salts and disodium ethyl/butyl phosphonate 
in water, to produce a catalyst containing a mixture of ethyl phosphonate and butyl 
phosphonate coordinated cerium centres on silica. 194  An initial screen was performed 
on the range of catalysts available. The preparations were selected to ensure a range 
of surface areas and Cc loadings were surveyed in case either of these parameters 
proved critical. The route to prepare these catalysts contains a final stage of washing 
the solid with water so prior to testing the catalysts they were rigorously washed with 
distilled water. This additional washing step was performed in an attempt to ensure 
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that only cerium firmly bound to the solid surface was introduced into the reaction 
mixture. Table 26 illustrates the results of this initial screen. 
• 	 .• 	 •• 	•• 
• 	
-  Name 








Table 26: Cerium phosphonate on silica additives used in attempted reduction of 58. 
The results for both P-12-004c and P-09-004X look promising upon first inspection. 
Mindful of the erroneous conclusions that the use of the cerium salt had lead to 
earlier, an inspection of the bulk solvent pH at the conclusion of the reaction was 
performed. The solution appeared acidic when analysed by universal indicator pH 
paper. The use of a StatTitrino system, as above, demonstrated that by maintaining 
the pH at 7.0 the reaction was suppressed and no conversion to the hydroxylamine 
was observed. It would appear that, even with rigorous water washing, the bulk pH is 
altered with the addition of the cerium phosphonate - silica catalysts. 
At this juncture it was decided to attempt a different solid-phase strategy. Two resins 
containing acidic sites, Dowex-MAC and Dowex 50WX2-400, were separately 
added to a 0.IM pH7 phopshate buffer solution of the substrate 58 and the p1-1 of the 
bulk solvent was monitored. Initially this experiment was performed in the absence 
of reducing agent to assess whether it would be a viable method of providing acidic 
coordination sites in the experiment without affecting the bulk pH. The bulk pH was 
found to become acidic, even after rigorous washing of the resins before use. This 
concept was therefore not used to attempt a reduction reaction. 
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The results outlined above suggested that the pursuit of a reduction system using 
sodium cyanoborohydride as the reducing agent would not be effective. Alternative 
methods of reducing the mode] oxime 58 were investigated. The next avenue 
followed was to consider whether a hydrogenation system may be effective. The use 
of H2 gas was dismissed early in the investigation. The reason for this was the focus 
of the project upon constructing a deracemisation protocol. As demonstrated earlier, 
the use of a MAO expressing whole-cell system was found to be optimal for the 
stereoselective oxidation portion of the deracemisation. The requirement that this 
system has for 02 means that it would be incompatible with a system requiring 
gaseous hydrogen. Major safety issues arise when a reaction vessel requires both 02 
and H2 gas simultaneously supplied and no firm basis of safety can be achieved. An 
alternative to the use of gaseous hydrogen in a catalytic hydrogenation reaction is to 
employ a catalytic transfer hydrogenation (CTH) system (Figure 69). This alleviates 
the danger posed by gaseous hydrogen and has been shown to be effective for the 
catalytic hydrogenation of a number of species in the literature. A crucial factor is 
that transfer hydrogenation systems have been reported which employ water as the 
bulk solvent, one of the core requirements for success in this case. 195 
+ OH2 	
Transfer Hydrogenation catalyst M 	
R, 	R2 
X 	
H + D 
X = 0, NR 
Hydrogen donor 
Figure 69: General scheme for Catalytic Transfer Hydrogenation reactions 
The hydrogenation catalysts tested were of the metal on carbon type. These metal 
catalysts have a long history of use in catalytic hydrogenation reactions and are 
easily available.' 96 They exhibit good stability on the shelf and are easily handled in 
the laboratory. They have also been employed in transfer hydrogenation reactions to 
good effect. 197  In addition to considering the catalyst, the second key component of a 
transfer hydrogenation reaction is the hydrogen source. A number of different 
hydrogen sources are available. The classic reagent used is an azeotropic mixture of 
triethylamine and formic acid, found to be a 5:2 ratio. 198 This mixture has been 
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reported to be effective for the catalytic transfer hydrogenation of amines amongst 
other substrates. Wu et al. reported that in some circumstances formic acid alone is 
more effective than the triethylamine:formic acid mixture. 195  Both these hydrogen 
sources have been tested. Ammonium formate is a variation on the use of a formate 
compound and has also been used successfully as a hydrogen source. 199 Finally 
sodium hypophosphite was tested, a hydrogen source that was specifically chosen 
not to be formate based, to provide variety to the screen. 200 
Catalyst Pd/C 




JM619 powder Hydrogeniource 
IICO2H Amine Amine Amine 
Et3N : HCO2H Amine Amine Amine 





Table 27: Major product of attempted reduction of 58 via transfer hydrogenation 
reactions. 
As illustrated in Table 27, two different results were observed with the transfer 
hydrogenation reaction. The fact that the amine product was observed in a number of 
cases indicated that a reduction occurs, but N-O bond cleavage is the effect observed. 
On other occasions starting material is recovered. At this juncture it was decided to 
pursue this line of enquiring a little further with the discovery that a Pt / C based 
catalyst was available which was specifically advertised as being suitable for the 
hydrogenation of oximes to hydroxylamines, without N-O bond cleavage to the 
amine, albeit in a gaseous hydrogen system. 20 ' This catalyst was a sulfur poisoned 
version of a standard Pt/C catalyst. Once again a number of different hydrogen 
sources were used but no conversion was observed. 
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A number of other metal / carbon catalyst were available, however they differed only 
in terms of loading and surface area with respect to the catalysts previously tested. 
No indication of the desired selectivity had been observed and so this area of 
investigation was discontinued. 
The use of an amine:borane system was investigated to establish whether this may be 
a viable method for the reduction of the model oxime under the desired conditions. A 
number of amine:borane complexes, both commercially available and synthesiséd 
within the research group 202  were tested (Figure 70). 
NH3BH3 	HNMe2 BH 3 	L 
N 
BH3 	 BH3 
81 	 82 	 83 	 84 
NMe2 	 Cl 	 OMe 
N NMe2 LU U 6N' 	 BH 3 	N 	 N 
BH3 BH3 BH 3 




N H2 H3 
B 
89 	 90 
	






3 = polystyrene 	Q = argo-pore 
Figure 70: Amine:borane reducing agents employed in attempted reduction of 58. 
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Unfortunately the use of an amine:borane complex was found to be completely 
unviable for the reduction of the model oxime to the corresponding hydroxylamine in 
pH 7.0 aqueous buffer. No indication of any reduction products was observed upon 
analysis by GC-MS and NMR and starting material was recovered. This was a 
disappointment but, considering the previous work and the conditions employed in 
literature reports, not a surprise. 
In conjunction with the research program studying laccases (Chapter 2) a number of 
hydroxylamine reductions were tested using conditions amenable to laccase activity. 
In the context of a deracemisation, what was considered was that an enantioselective 
oxidising mediator could be combined with a non-selective reduction. The coupling 
of the two 'half-reactions' in one-pot would not be viable if both reactions were in 
the solution phase. This is because a 'short circuit' could occur, with the oxidising 
agent and reducing agent forming a redox cycle between themselves, excluding the 
substrate. This is the result of the fact that the substrate oxidation catalyst is not 
located within the enzyme active site but is in solution (Figure 71). 
Mediator 	Reducing agent - ox 
Mediator ox 	Reducing agent 
At 
02 	Laccas 
	Mediator OX 	 Substrate Reducing agent - ox 
H20 	Laccase ox 	Mediatoi 
	Substrate - ox 	Reducing agent 
Figure 71: Possible 'short-circuit' cycle excluding substrate. 
A manner of addressing the 'short circuit' problem would be to mount both reducing 
and oxidising agent on a solid-phase. If a solid-phase reducing agent could be found 
to reduce the oximes derivatives to hydroxylamine derivatives under the same 
conditions then it may be possible to construct a deracemisation system. The solid-
supported amine:boranes tested above were also tested for activity under the 
conditions suitable for laccase I TEMPO oxidations. Unfortunately the reducing 
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agents in question were not active. No suitable solid-phase reducing agent could be 
discovered. Whilst sodium cyanoborohydride was found to be effective for the 
reduction of 60 under the same conditions as required for the oxidation,- the 
commercially available solid-phase analogue was found to be inactive. A number of 
solid supported amine:boranes 96-99 were available within the group 202 and these 










3 = polystyrene 
	
C) = argo-pore 
Figure 72: Solid-supported amine:boranes tested under laccase compatible 
conditions. 
The lack of a suitable solid-supported reducing agent coupled with the anticipated 
difficulty in accessing single enantiomer solid-supported mediator led to the decision 
to discontinue this line of investigation. 
At this stage a thorough assessment of oxime reduction systems and their limitations 
was conducted: The results described above indicate that standard oxime reduction 
systems are not active in pH neutral aqueous conditions and that this appears to be 
the crucial limiting factor. It may be speculated that systems that would operate 
successfully in these conditions are most likely to be biocatalytic systems. The 
investigative program was thus modified to focus on biocatalytic systems, in 
particular the use of baker's yeast. 
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5.5 	Biocatalytic reduction of oximes 
5.5.1 Baker's yeast 
The use of a biocatalytic system has been reported for the reduction of oximes. In the 
majority of cases these experiments have been associated with investigations into 
drug metabolism within the human body. The reports regarding these hepatic 
enzymes suggest that reduction to the amine product is the pathway observed .203 
Aside from this area of exploration little has been reported in the area of 
hydroxylamine synthesis via biocatalytic reduction of oximes. An intriguing area 
which has received a little attention is the use of Baker's yeast preparations to affect 
the reduction of oximes. 
Baker's yeast (Saceharornyces cerevisiae) has of course been used for culinary 
purposes for thousands of years. The use of Baker's yeast as a synthetic tool within 
the chemistry laboratory also has a long and well documented history. 204  Baker's 
yeast has been reported to be a useful reagent in the reduction of a number of 
ketones, 3-ketoesters and (x43-unsaturated systems . 205206 The synthetic utility of 
Baker's yeast is enhanced by its ease of use. Baker's yeast preparations are easily 
available, robust and are simple to store and handle. In the context of this report 
Baker's yeast represents an attractive option due to the fact that reported reaction 
conditions are usually similar to those found to be optimum for the MAO whole-cell 
preparation (Chapter 3) in addition to the reasons detailed above. 
Baker's yeast reduction of a limited number of oximes through to amines has been 
reported in a short paper. 24  Fermenting baker's yeast was used to produce a small 
number of enantioenriched amines in moderate enantiomeric excess. The use of 
baker's yeast to reduce oximes was further developed in a paper from Chimni & 
Singh .207  This contains a report of a single oxime substrate being reduced to the 
corresponding hydroxylamine. A range of reaction conditions were described, only 
one of which produced the hydroxylamine product and no yields were presented in 
the paper. The use of a baker's yeast reduction system for oxime substrates is not 
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well described; however it has the attractive feature of being most likely to require 
conditions complementary to the use of an enzymatically catalysed stereoselective 
oxidation. 
5.5.2 Baker's Yeast Results and Discussion 
The series of reactions performed with Baker's yeast were performed under strict p1-I 
control to ensure that the solutions were maintained at pH 7.0. The reduction of 
oxime58 was used as a model experiment. Baker's yeast (Sigma Chemicals) was 
tested under both fermenting and non-fermenting conditions (Table 28). 
Conditions Time Reaction products observed 
Glucose 1/1 Baker's yeast (wiw) I day Oxime 58 
Amine 98 85%:15% hydroxylamine 
Glucose 1/1 Baker's yeast (w/w) 5 days 
48 
Glucose 0.1/1 Baker's yeast 
lday 58 
(w/w) 
Glucose 0.1/I Baker's yeast 
Sdays 58 
(w/w) 
No glucose Iday 58 
No glucose 5 days 58 




Figure 73: Amine product observed in fermenting conditions. 
As can be seen it would appear that Baker's yeast under fermenting conditions does 
possess an oxime reduction activity. In an attempt to define conditions under which 
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the production of the desired hydroxylamine would be optimised, further 
experiments were performed. 
Repeated attempts to isolate hydroxylamine product were frustrated by work-up 
difficulties. Two courses of action were followed to address this fact. Firstly; an 
attempted deracemisaion experiment was performed, in an attempt to produce single 
enantiomer product and address the work-up issues of the final constructed 
deracemisation system. The MAO whole-cell system (Chapter 3) was coupled with 
the Baker's yeast conditions and an inspection of the reaction products performed. 
No desired hydroxylamine product 48 was observed. 
The difficulties in work-up were exacerbated when the two biocatalytic systems were 
combined. Filtration of the biomass was extremely difficult and lengthy. Attempts to 
remove the solid biomass via centrifugation were only marginally more successful, 
with interfacial separation of the extractive organic solvent and aqueous buffer being 
poor. In an attempt to address these difficulties both the E.co/i expressing MAO and 
the Baker's yeast were subjected to a protocol to entrap them within a calcium 
alginate bead. This modification had been reported to alleviate work-up difficulties 
without removing reductive activity of Baker's yeast . 208  The attempted reduction of 
oxime 60 with the calcium alginate entrapped Baker's yeast was then performed. No 
reduction was observed. 
Disappointingly the discovery and optimisation of a biocatalytic reduction method to 
complement the biocataiytic stereoselective oxidation was not achieved. 
5.6 	Conclusion 
The attempted reduction of oximes proved to be unsuccessful. This was wholly due 
to the stringent requirements placed upon the development of such reactions by the 
biocatalyst system previously developed (Chapter 3). Critically, the requirement for a 
aqueous pH7 bulk reaction medium prevented a successful reduction reaction. This, 
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in turn, signals the failure of the attempt to define and optimise a deracemisation 
protocol for hydroxylamines and hydroxylamine ethers. 
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6 	Conclusion and Further Work 
The results presented herein represent a concerted and lengthy experimental 
programme focussed towards producing a deracemisation system for 
hydroxylamines. A number of different avenues have been explored. An ambitious 
attempt to engineer the MAO-N enzyme which displayed no activity towards the 
substrates of interest was made. The rationale behind this was the close relationship 
between the amines known to be substrates and their hydroxylamine analogues. 
To address the difficulties posed by the unfavourable results of initial experiments 
two separate courses of action were undertaken. The modification of the substrates 
being studied led to success in discovering novel substrates for the MAO-N enzyme. 
The enantioselective oxidation of hydroxylamine ethers by MAO-N is a novel 
discovery. A further development is the engineering of a MAO-N variant which 
displayed improved catalytic activity for a model hydroxylamine ether substrate 
compared with the parental enzyme. 
A second research programme lead to the discovery of the applicability of the well 
documented laccase:mediator system to the oxidation of hydroxylamines. This 
represents a further novel discovery. A robust and simple biocatalysed process has 
been defined. 
Research into the reduction of oximes in a pH neutral, aqueous environment has also 
been performed. This area has had no success. A number of possible techniques and 
conditions have been attempted but the problem remained intractable. 
The difficulties in discovering and defining two systems, a stereoselective oxidation 
and non-selective reduction, which operate efficiently and effectively with the same 
bulk reaction conditions, has resulted in a disappointing failure to perform a 
deracemisation of a hydroxylamine substrate. 
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Possible future courses of action to develop a successful deracemisation include the 
discovery and optimisation of novel enzymes which stereoselectively convert 
hydroxylamines. Enzymes have been reported that accept hydroxylamines as 
substrates, however the synthetic utility of them remains to be investigated 3 . These, 
or new, enzymes may exhibit characteristics which are better suited to the task than 
those currently available, perhaps having greater stability in low pH solutions. The 
increased access to extremophile derived enzymes may provide opportunities in the 
future 2°9 . The discovery of oxime reducing systems which use pH neutral conditions 
would also herald a better chance of a breakthrough. 
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7 	Experimental 
Buffers and growth media are made up as per Molecular Cloning: A laboratory 
manual, 2 nd Ed., J. Sambrook, E.F. Fritsch and T. Maniatis, 1989, Cold Spring 
Harbor, Cold Spring Harbor Press. 
'H and ' 3C NMR spectra were recorded on Bruker AC250 instruments. Chemical 
shifts are reported in pads per million (ppm) and coupling constants in Hertz (Hz). 
Residual protic solvent present in the deuterated solvent was used as the internal 
standard in NMR experiments. 
Electron impact (El) nominal mass spectra were recorded on a Kratos Profile mass 
spectrometer. El accurate mass and fast atom bombardment (FAB) nominal and 
accurate mass spectra were recorded on a Kratos MS50 spectrometer. 
JR spectra were obtaining using a Jasco FT-JR 460Plus spectrophotometer. 
Frequencies are reported in wavenumbers (cm'). Compounds were measured as neat 
thin films or as Nujol mulls 
Analytical tic. was performed on aluminium backed Merck 254nm active M 60 silica 
plates. Ultraviolet light at 254nm or permanganate solution were used as developing 
agents. Column chromatography was performed on M60 silica, size 20 - 40. 
Experiments performed with maintenance of the bulk pH were performed in a 
Metrohm 718 STAT Titrino system. 
Acetophenone oxime 50 and NN-dibenzylhydroxylamine 60 were purchased from 
Sigma Aldrich. All reagents were purchased from Aldrich Chemical Company and 
used as supplied unless otherwise noted. Solvents were HPLC grade, purchased from 
Fisher Scientific and used as supplied unless otherwise noted. Laccase preparations 
were purchased from Sigma Life Sciences. 
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7.1 	Buffer and reagent recipes 
LB medium 
In I litre ofultrapure water: 20g of pre-formulated LB medium powder. 
In I litre ofultrapure water: tryptone (lOg), NaCI (log) and yeast extract (5g). 
LB agar medium 
a) LB medium (1 OOml) and agar (1 .5g). 
Soc media 
In I litre of ultrapure water: yeast extract (5g), tryptone (20g), SM NaCI (2m1), KCI 
(0- 199), 1M MgCl2 (lOmI), 1M MgSO4 (JOmI) and D-glucose (3.6g). 
SDS loading buffer 
O.SM Tris/UCI pH 6.8 (2m1), glycerol (2m1), 10% (v/v) SDS (3.2m1), fi-
mercaptoethanol (0.8m1) and 0.05% (vlv) bromophenol blue (0.4nil). 
SOS gel running buffer 5x 
In 50m1: Tris (15.1g), glycine (94g) and 10% w/v SDS. 
SOS gel staining solution 
Methanol (450m1), acetic acid (lOOmI), water (450m1) and Coomassie blue 6-250 
(500mg). 
SDS gel destaining solution 
Methanol (450m1), acetic acid (lOOmI) and water (450ml). 
Bradford reagent 
Coomassie blue 6-250 (100mg), ethanol (50m1), 85% phosphoric acid (lOOmI) and 
ultrapure water (850m1). 
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TAE (Tris acetate EUTA buffer) SOx 
Tris base (242g), acetic acid (57.1ml) and 0.5M EDTA pH 8.0 (100m!). 
7.2 	Transformation and fermentation 
Transformation of E. coil TOPIO chemically competent cells 
Plasmid DNA and a single shot of E. culi TOPIO chemically competent cells 
(Invitrogen C4040-10) were thawed on ice. 1pl of the plasmid DNA was added to the 
shot and the DNA mixed by gentle tapping before returning the tube to ice for 30 
minutes. The sample was then placed in a 42CC water bath for 30 seconds and 
quickly placed back on ice. After 2 minutes on ice SOOpI of pre-warmed Soc media 
was added and the sample was incubated at 37°C, 225rpm for 1 hour. 100p1 of the 
transformation mixture was spread onto a LB agar plate containing I OOpg/ml 
ampicillin and the plate left to grow overnight at 37°C. 
Transformation of E. co/i BL2I (DE3) chemically competent cells 
Plasmid DNA and a single shot of E. coil BL2I (DE3) chemically competent cells 
(Invitrogen C6000-03) were thawed on ice. The procedure for TOP I 0 cells was then 
followed. 
Transformation of E. co/i XLI-red chemically competent cells 
Plasmid DNA and a single shot of E. co/i XL1-red chemically competent cells 
(Stratagene 200129) were thawed on ice. 1.7pl of 3-mercaptoethanol was added to 
each shot and mixed by gentle tapping. IpI  of the plasmid DNA was then added and 
mixed by gentle tapping. The tube was returned to ice for 30 minutes. The sample 
was then placed in a 42°C water bath for 45 seconds and quickly placed back on ice. 
After 2 minutes on ice back on ice the sample had 9401jl of pre-warmed SOC media 
added the sample incubated at 37°C, 225rpm for 1 hour. lOOp] of the transformation 
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mixture was spread onto a LB agar plate containing IOOigIml ampicillin and the 
plate left to grow overnight at 37t. 
Creation of E. coil XLI-red random mutation libraries 
The remaining 900R1  of E. coli XLI-red transformation mixture (above) was added 
to 9.1ml of LB containing lOOpg/ml ampicillin and grown at 37T, 225rpm 
overnight. ImI was removed and the plasmid DNA purified. This DNA constituted 
the first cycle in preparing the random mutageneisis DNA library. This 1st  cycle 
DNA was retransformed into E. coli XLI-red and the process repeated giving the 
second cycle of variants. This protocol was repeated four times to give a DNA 
library generated from four cycles. This pool of DNA constituted a random 
mutagenesis library. 
Fermentation Of E. coil BL21 (DE3) expressing MAO-N 
A number of different protocols were employed depending on the scale of 
fermentation required. Interestingly, in all cases IPTG induction was found to be 
unnecessary, although the pET .16b plasmid used is designed to require IPTG 
expression. 
Small scale expression 
A single colony from a fresh transformation was picked and added to 1 OmI of LB 
medium containing lOOpg/ml ampicillin in a 50m] falcon tube. The culture was left 
to grow overnight at 30C. The cells were harvested by centrifugation at 10,000rpm 
for 15 minutes. The resultant supernatant was discarded and the cell pellet stored at - 
20CC. A typical fermentation yielded 0.5g of cells. 
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Medium scale expression 
A single colony from a fresh transformation was picked and added to 1 OmI of LB 
containing I OOpg/ml ampicillin in a SGml falcon tube. The culture was lefi to grow at 
30°C until OD000nm was between 0.6 and 1.0. A number of 1 litre baffled flasks 
containing 200m1 of LB medium containing 100g/ml ampicillin were inoculated 
with 200R1  of the starter culture. The fermentation was left to grow for 24 hours at 
30°C, 225rpm. The cells were harvested by centrifugation at 6000rpm for 15 minutes 
at 4°C. The resultant supernatant was discarded and the cell pellet stored at -20°C. A 
typical fermentation yielded 15g of cells. 
Large scale expression 
A single colony from a fresh transformation was picked and added to 100m] of LB 
medium containing lOOpg/ml ampicillin. The cells were left to grow at 30°C, 
225rpm until OD000nrn was between 0.5 and 0.9. At this point the lOOmL 
fermentation was added into a 10 litre batch ferinentor containing 10 litres of LB 
medium containing lOOj.tg/ml ampicillin. The cells were grown at 30°C, 225rpm 
paddle stirring overnight. The cells were harvested by centrifugation at 6000rpm for 
15 minutes at 4°C in a Sorval RCSC refrigerated centrifuge. The resultant 
supernatant was discarded and the cell pellet stored at -20°C. A typical fermentation 
yielded bOg of cells 
Preparation of CFE 
The cell pellet was thawed on ice and resuspended in the desired buffer at 5g/mL 
concentration of cells in buffer. The sample was sonicated at 10 micron amplitude on 
ice using a 30secs on 30secs off cycle. This cycle was repeated 5 times. The resulting 
homogenate was centrifuged at 20,000rpm for 1 hour at 4°C. The resultant 
supernatant was retained and the cell pellet discarded. The CFE was stored on ice 
prior to use. 
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7.3 	DNA purification and manipulation 
Plasmid purification 
I ml of fermentation broth was spun using a microcentriflige at 12,000 rpm for 10 
minutes and the resultant supernatant discarded. The manufacturer's instructions 
were then followed (Qiagen, QIA prep Spin Miniprep kit protocol). The purified 
plasmid DNA was stored at -80©C. 
DNA agarose gel 
DNA agarose gels were prepared by addition of agarose (0.4g) to TAE x I buffer 
(SOml). The mixture was melted and the molten agarose was left to cool by stirring in 
a SOC water bath. Ethidium bromide (10mg/mI) was added ( 25R1 . The gel was 
poured into a gel tray and a loading comb inserted. 
To each of the DNA samples (ISpI) to be run was added Blue Juice x 10 (2p1) (New 
England Biolabs). Each sample was loaded into a lane, as was a pre-stained DNA 
ladder (New England Biolabs) for reference purposes. The gel was run and visualised 
under liv irradiation. 
DNA gel extraction 
The desired DNA band as visualised by UV irradiation, was cut from the rest of the 
gel and weighed. The DNA was recovered from the gel following the manufacturer's 
instructions (Qiagen QiAquick gel extraction kit protocol). The recovered DNA was 
stored at -SOT. 
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DNA sequencing 
Plasmid DNA was prepared as below in a suitable PCR tube: 
Oligonucleotide primer (3.2pmol) 
ABI Prism BigDye Terminator v3.1 cycle sequencing reaction kit 4R 1 
Plasmid DNA template 	 250ng 
Ultrapure water to make up to final volume of 	 20p1 
To sequence the MAO-N gene five primers were employed. A forward and a reverse 
primer designed to sequence from each end of the gene within the pET 16b plasmid 
(Novagen). Three internal primers were also employed (design by T. Fleming, 
University of Edinburgh). These five separate sequencing reactions ensured coverage 
of the entire gene. 
Novagen T7 promoter primer 469348-3 
Start site 
5' taatacgactcactataggg 3' 
,nao-N( 169) 
Start site at MAO-N 169 nucleotide 
5' gacttgactgtagcaggcttc 3(21 iner 52%GC) 
,nao-N(5 12) 
Start site at the 512 nucleotide 
5' cgcatgacatgttctatgttcctgagt 31(32  met 46%GC) 
rnao-N(830) 
Start site at the 830 nucleotide 
5' gtccggttaggagtgttgttaatgagagag 31(30 mer 46% GC) 
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Novagen T7 terminator primer #69337-3 
3'-end of the gene 
5 gctagttattgctcagcgg 3' 
The PCR was carried out on an Eppendorf mastercycler using the program below 
1.95°C 1 minute 
HOLD 
96°C 30 seconds 
50°C 30 seconds 
60°C 4 minutes 
Repeat steps 3-5, 30 cycles 
7.4°C HOLD 
Samples were made up to a final volume of 20pl with ultrapure water and the 
sequenced by the ICMB automated sequencing service, University of Edinburgh. 
Saturation mutagenesis library creation 
The two oligonucleotide primers containing the NNS site were made up to 
iOOpmoIIRI with water and the reaction mixture below prepared: 
Reaction buffer I Ox (Stratagene 600153-82) SpI 
Plasmid DNA containing rnao5D gene (33ng/pl) 1pl 
Oligonucleotide primer— forward NNS 11.tl 
Oligonucleotide primer - reverse NNS ]PI 
dNTP mix (Sigma D-7295) 'MI 
Water 20pl 
Pth Turbo DNA Polymerase ('Ml)  (2.5U/pl) (Stratagene 600250-52) was added as 
the final step. The PCR was carried out in the following manner using an Eppendorf 
mastercycler: 
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1.95°C 1 minute 
95°C 1 minute 
55°C 1 minute 
68°C 7 minutes 
Repeat steps 2-4, 16 cycles 
6.4°C HOLD 
The PCR product was taken forward to the next stage of nick repair. 
The crude PCR product had Dpnl restriction enzyme (Ipi) (New England Biolabs 
R0176S) added and the reaction mixture gently pipetted. The mixture was then spun 
for 1 minute at 12,000 rpm in a microcentrifuge. The reaction mixture was then 
incubated at 37°C for 1 hour. 
The digested PCR product (lpl) was then added to E. co/i XLI-blue chemically 
competent cells (Stratagene) on ice. The tube was gently tapped and returned to ice 
for 30 minutes. The tube was then placed in a water bath at 42°C for 45 seconds and 
then returned to the ice. Pre-warmed SOC media (500p I) was added to each tube and 
the samples were placed at 37°C, 225 rpm for 1 hour. 100p1 of E. co/i saturation 
library transformation was spread onto LB agar plates containing lOOpg/ml 
ampicillin. And the plates incubated at 30°C overnight. After ensuring that there was 
a high enough number of transformants to ensure that all library members were fully 
represented a random selection of colonies were picked. They were grown overnight 
in LB medium (lOmL) containing lOOpg/ml ampicillin at 37°C, 225 rpm and the 
plasmid DNA isolated. The plasmid DNA was sequenced with the appropriate 
primer as above. 
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7.4 	Assay methods 
Solid phase assay 
The DNA sample to be screened was transformed into E. coil BL2I (DE3) 
competent cells. Unlike a standard transformation, a nitrocellulose membrane 
(Amersham) was placed on top of the agar in the pertri dish. The transformation was 
spread over the membrane and the plate incubated at 37°C overnight to allow the 
colonies to develop. The membrane was then removed and stored at -20°C. The 
optimal storage time at -20°C was 48 hours. The membrane was allowed to warm up 
to ambient room temperature before performing the assay. 
The following chromogenic solution was prepared; 2 DAB tablets (Sigma, D4418), 
0.iM potassium phosphate pH 7.6 (80ml), FIRP 1mg/mI (24pl) and 10mM of 
screening substrate. 2% (w/v) agarose in ultrapure water was melted and then cooled 
to 50°C in a water bath. lOmI of the chromogenic solution was rapidly mixed with 
I OmI of the molten agarose and immediately poured over the thawed nitrocellulose 
membrane. The assay was then left to develop at room temperature. 
Liquid phase assay 
The following chromogenic solution was prepared; IM aminoantipurine (37.5pI), 
2% (w/v) TBI-IBA in DMSO (SOOpl), 10mM of screening substrate, IM potassium 
phosphate buffer pH 7.6 (5m1) and ultrapure water to give a total volume of 50m1. 
5p  of 1mg/mi HRP was added to 1Opl of the purified MAO-N protein sample in a 
well of a microtitre plate. To this was added 185pl of the chromogenic solution 
giving a total volume of 200pl. The colourimetric response was monitored by the 
51 absorbance with a plate reader (Molecular Devices, Versa Max tunable 
microplate reader) at 30°C. The activity of the MAO-N sample towards the substrate 
was calculated from rate of change of the 510 absorbance. 
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The procedure above can also be performed employing CFE in place of purified 
protein. The relative rates of substrates to the control substrate 33 were obtained by 
performing the assay above in parallel on the same plate using the same protein 
sample. 
The specific activity was determined by dividing the activity measured on the assay 
by the measured soluble protein concentration from a Bradford assay of the same 
protein sample, using the equation below 
[(Activity/(r XL)) X 20 x 60 x 1x10 3 j/P = Specific Activity pmol min'mg' 
Activity 	Measured rate (OD/sec) 
Extinction coefficient of colourimetric product, 29,400 M 1 cm' 
L 	 Path length (cm) 
P 	 Protein concentration based on Bradford assay (mg/ml) 
The path length for a 200R1  volume in a the U-shaped 96-well microtitre plate 
employed for all the experiments above was measured to be 0.53cm. 10 ' 
Michaelis-Menten kinetic calculations 
A chromogenic solution was prepared with a final substrate concentration of 50mM 
substrate and serially diluted to produce solutions with substrate concentrations of 
20, 10, 8, 6, 4, 2, 1, 0.6, 0.2, 0.1 mM and 50, 20RM. Each solution was assayed as 
above using freshly prepared protein samples to ensure any loss of activity on storage 
of the protein was minimal. 
The calculated specific activities were entered into the GraphPad Prism 4 program. 
Using the Michaelis-Menten function Vmax (pmol/min/mg) and KM (mM) were 
obtained. The kcat was subsequently calculated by multiplication of Vmax by the 
molecular weight of MAO-N (55.6 kDa). 
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7. 5 MAO-N purification techniques 
Nickel affinity purification 
Gravity flow system 
A cell pellet (Ig) from a MAO-N fermentation was thawed on ice and resuspended in 
lOmL of Ni-NTA resuspension buffer (25mM Tris/FICI pH 7.8, 300mM NaCl, 1mM 
PMSF and I mM J3-mercaptoethanol). The sample was subjected to sonication and 
centrifugation as per CFE preparation (Section 6.3) to produce the CEE. Ni-NTA 
slurry (Qiagen 30210, lOmI) was applied to a sintered resin column and equilibrated 
with Ni-NTA resuspension buffer (30ml) at 4CC. The CFE was applied to the top of 
the column and passed through the column under gravity. The column was washed 
with wash buffer (Ni-NTA resuspension buffer with 60mM imidazole added, 30ml). 
The protein was then eluted with elution buffer (Ni-NTA resuspension buffer with 
200mM irnidazole added, lOmI). The eluent was collected in lmL fractions and the 
MAO-N activity for each assayed. The active fractions were pooled and then stored 
as I ml aliquot at -80CC. 
FPLC system 
A cell pellet (Ig) from a MAO-N fermentation was thawed on ice and resuspended in 
]OmL of Ni-NTA resuspension buffer (25mM Tris/HCI pH 7.8, 300mM NaCl, 1mM 
PMSF and 1mM 3-mercaptoethanol). The sample was subjected to sonication and 
centrifugation as per CFE preparation (Section 6.3) to produce the CFE. A 25cm Ni 
affinity column operated on an UPC-900 Amersham pharmica biotech FPLC and the 
column equilibrated with Ni-NTA resuspension buffer (5 column volumes) at 6'C. 
The CFE was injected onto the column. The column was washed with wash buffer 
(Ni-NTA resuspension buffer with 60mM imidazole added, 10 column volumes). 
The protein was then eluted with elution buffer (Ni-NTA resuspension buffer with 
200mM imidazole added, 10 column volumes). The eluent was automatically 
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collected in 1 mL fractions and the MAO-N activity for each assayed. The active 
fractions were pooled and then stored as imI aliquot at -80©C. 
PDIO desalting column - removal of imidazole 
An Amersham Bioscience PD-10 desalting column was equilibrated with 25m1 of 
0.IM potassium phosphate buffer pH 7.0. 2.5ml of the sample from nickel affinity 
purification was loaded onto the top of the column and the flow through discarded. 
3.5m1 of the phosphate storage buffer was applied to the top of the column and the 
flow through collected in I mL fractions. 
Ammonium sulfate precipitation - removal of imidazole 
A sample from nickel affinity purification was placed onto ice on a stirrer plate. 
Ammonium sulfate was added to the stirred solution in a stepwise fashion until 60% 
ammonium sulfate saturation (36.6g/1 00m]). The sample was centrifuged at 4000 
rpm for 20 minutes affording a yellow pellet. The supernatant was discarded and the 
MAO-N protein pellet was resuspended in 0.1 M potassium phosphate buffer pH 7.0. 
SIDS PAGE protein gel 
Analysis of the purity of protein and MAO-N expression samples was done using 
SDS PAGE. Precast gels were purchased (SDS Biorad 10-15% polyacrylamide gel) 
and New England Biolabs markers (P77085) were used as with the molecular 
weights of the standard proteins being 175, 83, 62, 47.5, 32.5, 25, 16.5 and 6.5 kDa. 
20R 1  of the protein sample was mixed with 20R1  of the loading buffer, boiled for I 
minute and centrifuged at 13,000 rpm for I minute. Each sample was loaded in a lane 
of the SDS PAGE gel and the gel was placed into the gel apparatus (Biorad) and 
submerged in SDS gel running buffer. The electrophoresis was carried out at 200V 
for approximately 75 minutes. The gel was placed into staining solution for 60 mins 
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Figure 74: Example of a SDS polyacrylamide gel of fractions from nickel affinity 
chromatography purification; molecular weight protein markers (PM), Cell-free 
extract (CFE) and fractions from nickel affinity chromatography (PP). 
The Bradford assay 
Protein concentrations were determined using the Bradford assay. The protein 
sample (20pl) had pre-mixed Bradford reagent (980tl) added. The sample was left to 
stand for 2 minutes and then the OD 595nm was measured in triplicate on a 96-well 
microtitre plate using a plate reader. The protein concentration was obtained by 
comparison with a calibration curve derived from known concentrations of BSA. 
Bradford reagent (9801.11) was added to a known BSA concentration sample (20p.il) 
(BSA standard concentrations; 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 p.glml). The sample 
was left to stand for 2 minutes and then the OD595 measured in triplicate (200Ml)  on 
a 96-well microtitre plate using a plate reader. A straight line of best fit was fitted to 
the plot of BSA concentration against OD595im. 
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Estimation of error in the Bradford assay 
A purified protein sample was measured six times by the Bradford assay method. 
The mean 01)595nm for the six measured samples was found and the standard 
deviation of the data calculated. The 95% confidence bounds were calculated from 
the mean ± 2 standard deviations from the mean. Using the upper limit and lower 
limits, a VMax range was determined. 
UV-visible spectrum of MAO-N 
The purified MAO-N sample was placed in a imi quartz cuvette and the UV-visible 
spectrum measured in a Perkin Elmer instrument, Lambda 900, UV/VIS/NIR 
spectrometer. The spectrometer was zeroed against 0.1 M potassium phosphate buffer 
p1-I 7.0 and then the UV-visible spectrum recorded from 300-750nm. 
7.6 	Formation of Calcium alginate beads 
Sodium alginate (9g) is added to growth medium (300mL) portion wise to prevent 
clumping and stirred until completely dissolved. Wet cells (250g wet weight) are 
then suspended in the alginate solution prepared in the previous step. The cell - 
alginate mixture is then added dropwise, from a height of 20 cm, into 1000 ml of 
cross-linking solution. This is achieved by using a syringe, 20 gauge needle and a 
syringe pump. The cross-linking solution is a 0.05M solution of Cad 2 in the growth 
media and is agitated on a magnetic stirrer. A bead diameter of 0.5-2 mm is achieved 
under these conditions. The resultant beads are left for 1 hour in the cross-linking 
solution. The beads are then washed with fresh calcium cross-linking solution. 
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7.7 	Synthesis of oximes 
General procedure for the synthesis of oximes 
To a mixture of the corresponding aldehyde or ketone (leq.) in THF (8OmL) and 
hydroxylamine hydrochloride (1 .2eq.) in water (30mL) was added Na2CO3 (0.6eq.) 
in water (30nTh). The reaction mixture was rapidly stirred for I 8h. To the reaction 
mixture was added EtOAc (50mL) and the organic layer separated. The aqueous 
layer was extracted with EtOAc (2 x 50mL) and the combined organic layers dried 
with MgSO4. The solvent was removed in vacuo and the residue purified to afford 
the oxime. 
1-Phenyl-propan-l-one oxime 51 
The general procedure was followed employing phenylacetaldehyde (5.0g) to afford 
5.39g of the title compound (96% yield) as a ciA:truns mixture of white crystals. 
Analytical data matched published values. 209 
m.p. 49-51°C, lit 50-51°C; 'H NMR 61 (250 MHz, CDC]-3) 1.11 (t, 3M, J7.6Hz, 
CH3), 2.76 (q, 2H, J= 7.6Hz, CH2), 7.30-7.34 (m, 3M, ArM), 7.52-7.56 (m, 2H, ArM); 
CC-MS (Method A) 10.1thins, >99.5% purity, ES (rn/z) 149 (M), 148 (base peak) 
132, 117, 104. 
I -(4-hydroxyphenyfl-ethanone oxime 53 
The general procedure was followed employing 4-hydroxyacetophenone (5.0g) to 
afford 4.84g of the title compound (87% yield). Analytical data matched published 
values. 210 
m.p. 142-144°C, lit 141-143°C; 1 NMR 611  (250 MHz, CDCI3) 2.10 (s, 3M, CH 3), 
6.79 (d, 2H, J= 8.9Hz, Ad-fl, 7.50 (d, 2H, J=8.9Hz, ArH), 9.48 (bs, 11-I, N-OH), 
10.89 (bs, IH, p-OH); CC-MS (Method A) 15.3mins, >99.5% purity, ES (rn/z) 151 
(M), 134, 119 (base peak), 110, 94. 
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I -(4-Bromo-phenyl)-phenyl-methanone oxime 56 
The general procedure was followed employing 1-(4-Bromo-phenyl)-phenyl-
methanone (5.0g) to afford 4.46g of the title compound (84% yield) as white crystals 
after recrystalisation from ether:n-hexane. Analytical data matched published 
values. 211 
m.p. 169-171 C, lit. 170-172; 'H NMR 6H  (250 MHz, CDCI3) 7.21-7.66 (m, 711, 
ArH), 7.88-7.94 (m, 2H, ArFI); CC-MS (Method A) 26.5mins, >99.5% purity, ES 
(m/z) 185, 183 (base peak), 165. 
I -Cyclohexylethanone oxime 56 
The general procedure was followed employing 1-cyclohexylethanone (10.0g) to 
afford 8.45g of the title compound (76% yield) as a colourless oil after Kugelrohr 
purification. Analytical data matched published values. 212 
CC-MS (Method A) 15.4mins, >99.5% purity, ES (ni/z) 141 (M), 124, 109, 86 (base 
peak). 
Cyclopentanone oxime 59 
The general procedure was followed employing 2-methylcyclohexanone (2.0g) to 
afford 2.15g of the title compound (91% yield) as a white crystals after 
recrystalisation form n-hexane. Analytical data matched published values. 213 
m.p. 58-60°C, lit. 57-58°C; ' 3 C NMR Sc (60 MHz, CDCI3) 24.2 (CH2CI-1 2CN), 
24.9 (CFI2CH2C=N), 26.8 (Cl-1 2 C=N), 30.4 (CH2C=N), 166.9 (C=N); CC-MS 
(Method A) 12.Omins, >99.5% purity, ES (rn/z) 99 (M, base peak), 82, 67. 
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7.8 	Synthesis of O-methyloximes 
General procedure for the synthesis of O-methyloximes 
To a mixture of the corresponding aldehyde or ketone (leq.) in THF (80inL) and 0-
methyihydroxylamine hydrochloride (1 .2eq.) in water (30mL) was added Na2CO3 
(0.6eq.) in water (30mL). The reaction mixture was rapidly stirred for 18h. To the 
reaction mixture was added EtOAc (50mL) and the organic layer separated. The 
aqueous layer was extracted with EtOAc (2 x 50mL) and the combined organic 
layers dried with MgSO4. The solvent was removed in vacuo and the residue purified 
to afford the 0-methyl oxime. 
I -Pheny!-ethanone-0-methyloxime 52 
The general procedure was followed employing acetophenone (2.0g) to afford 2.26g 
of the title compound (91% yield) as a colourless liquid after Kugelrohr purification. 
Analytical data matched published values. 214 
b.p. 87°C/5mmHg, !it. 89°C/5rninl-Ig; 'H NMR 811 (250 MHz, CDCh) 2.24 (s, 3M, 
CM1), 4.02 (s, 3M, 0CM3), 7.18-7.50 (m, 5F1, ArH); CC-MS (Method A) 5.8rnins, 
>99.5% purity, ES (rn/z) 149 (M), 118, 103,77 (base peak). 
I -(4-hydroxyphenyl)-ethanone-0-methy!-oxime 54 
The general procedure was followed employing 4-hydroxyacetophenone (2.0g) to 
afford 2.17g of the title compound (89% yield) as a white solid after recrysta!isation 
from ether. Ana!ytical data matched published values. 215 
m.p. 63-64°C, lit 64°C; 'H NMR 61 (250 MHz, CDCh) 2.21 (s, 3M, C1713), 3.98 (s, 
3M, 0CM3), 6.75 (d, 2H, J=8.9Hz, ArM), 7.46 (d, 2H, J=8.8Hz, ArH); CC-MS 
(Method A) 14.7mins, >99.5% purity, ES (mlz) 165 (M), 134 (base peak), 119. 
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1 -Cyclohexylethanone-O-methyl-oxime 57 
The general procedure was followed employing 1-cyclohexylethanone (5.0g) to 
afford 4.45g of the title compound (72% yield) as a yellow oil after Kugelrhor 
purification. 
'H NMR SH  (250 MHz, CDCI3); 1.26-1.52 (m, 7H, cyclohexyl ring), 1.77-1.99 (m, 
4R, cyclohexyl ring) 1.91 (s, 3M, cis/trans CH3), 2.27 (s, 3H, cis/trans CR3), 3.94 (s, 
3M, cis/trans OCH3), 3.96 (s, 3H, cis/trans OCR3); ' 3 C NMR 8c  (60 MHz, CDCI3) 
11.5 (cis/trans CR3), 16.3 (cis/trans CR3), 25.8 (cyclohexyl CR2) 29.6 (cyclohexyl 
C112), 36.7 (cyclohexyl CM2), 44.3 (cyclohexyl CM), 51.3 (cis/trans OCR3), 60.9 
(cis/trans OCR 3), 161.4 (cis/trans C=N), 162.0 (cis/trans CN); FT-JR (cm') 1633, 
1447, 1376, 1051; MS EI+ (m/z) 155 (M), 124, 100 (base peak), 87; Ace. Mass: 
found 155.13104, calc. 155.13101; GC-MS (Method A) Purity >99.5%, ES (rn/z) 
155.10 (M), 100.08 (base peak). 
3,4-Dihydro- IH-naphthalene-2-one-O-methyl-oxime 58 
The general procedure was followed employing 13-tetralone (5.0g) to afford 5.67g of 
the title compound (95% yield) as a colourless oil after Kugelrohr purification. 
1 NMR oH (250 MHz, CDCI3); 2.55-2.60 (dd, IH, J=6.2Rz, 3.3Hz, CF12CH2C=N), 
2.64-2.69 (dd, IH, J=6.2Hz, 3.3Hz, CH2CH2CN), 2.82-2.93 (m, 2H, CJI 2 C.li 2C=N), 
3.53 (s, 11-I, CH 2 CN), 3.78 (s, IH, CH 2C=N), 3.86 (s, 311, cis/trans 0CM3), 3.92 (s, 
3R, cis/trans 0CM3), 7.16-7.20 (m, 4H, ArH); 13C NMR & (60 MHz, CDCI3) 24.5 
(cis/trans CH 2 CH2C=N), 27.5 (cis/trans CR2CH2C=N), 28.9 (cis/trans CH 2 CFI2 C=N), 
29.0 (cis/trans CH 2 CI-1 2 C=N), 34.9 (ArCHC=N), 61.2 (OC.H3), 126.0 (cis/trans Ar), 
126.5 (cis/trans Ar), 127.1 (cis/trans Ar), 127.4 (cis/trans Ar), 128.0 (cis/trans Ar), 
128.7 (cis/trans Ar), 133.1 (cis/trans CCI-I2CH2C=N), 134.7 (cis/trans 
CCH2CH2 C=N), 137.0 (cis/trans CCR2C=N), 138.2 (cis/trans CC.l-1 2 C=N), 157.7 
(cis/trans C=N), 158.2 (cis/trans C=N); FT-jR (cm- ') 1636, 1493, 1457, 1052; MS 
El-i- (m/z) 175 (M), 143, 129, 116 (base peak), 104; Ace. Mass: found 175.09928, 
calc. 175.09971; GC-MS (Method A) Purity >99.5%, ES (m/z) 175.02 (M), 116.00 
(base peak). 
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7.9 	Synthesis of racemic hydroxylamines 
General procedure for the synthesis of racemic hydroxylamines 
Method A - formation of hydroxylamine from isolated or commercially available 
oxime 
To a solution of the oxime in MeOH (60mL), containing a trace of methyl orange, 
NaB(CN)H 3  (Seq.) was added; and then 2M HCI-ether was added dropwise with 
stirring to maintain the strong red colour for 30 mins. The reaction mixture was 
stirred overnight, and the solvent removed in vacuo. The residue was suspended in 
water (60mL) and brought to pH 10 using 6M NaOH aq. and sat. NaHCO 3 and 
extracted with EtOAc. The organic layer was dried over MgSO 4 and the solvent 
removed in vacuo. Purification of the crude product afforded the hydroxylamine. 
Method B - direct formation of hydroxylamine from ketone / aldehyde 
To a mixture of the corresponding aldehyde or ketone (leq.) in THF (80m1) and 
hydroxylamine hydrochloride (I .2eq.) in water (30mL) was added Na 2 CO3 (0.6eq.) 
in water (30mL). The reaction mixture was rapidly stirred for 18h. To the reaction 
mixture was added EtOAc (SOmL) and the organic layer separated. The aqueous 
layer was extracted with EtOAc (2 x 50mI) and the combined organic layers dried 
with MgSO4. The solvent was removed in vacuo to give the crude oxime. To a 
solution of the crude oxime in MeOH (60mL), containing a trace of methyl orange, 
NaB(CN)H 3  (Seq.) was added; and then 2M HCI-Ether was added dropwise with 
stirring to maintain the strong red colour for 30 mins. The reaction mixture was 
stirred overnight, and the solvent removed in vacuo. The residue was suspended in 
water (60mL) and brought to pH 10 using 6M NaOH aq. and sat. NaFIC0 3 and 
extracted with EtOAc. The organic layer was dried over MgSO 4 and the solvent 
removed in vacuo. Purification of the crude product afforded the hydroxylamine. 
N-( I -Phenylethyl)-hydroxylamine 35 
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Acetophenone oxime (2.00g) was treated as per Method A to afford 1.98g of the title 
compound (98% yield) as a white solid after rectystallisation from ether. Analytical 
data matched published values.' 0,22 
m.p. 71-73°C, lit. 71-72°C; 'H NMR 81 (250 MHz, CD30D) 1.67 (q, 3H, J6.9Hz, 
CH3), 4.50 (q, IH, J=6.9Hz, CU-N), 7.44-7.47 (m, 5F1, ArH). 
N-( I -Phenylpropyl)-hydroxylamine 41 
l-Phenyl-propan-1-one oxime 51 (2.0g) was treated as per Method A to afford 1.40g 
of the title compound (69% yield) as white crystals after recrystalisation of the crude 
product from petroleum ether 40/60:hexanes. Analytical data matched published 
values .216 
'H NMR S,, (250 MHz, CDCI 3); 1.07 (t, 31-1, J=7.4H1, CH3), 1.80-1.97 (m, IFI, 
CH2), 2.05-2.22 (in, 11-1, CFI 2 ), 4.11 (dd, 11-1, J=8.7, 5.5Hz, CU-N), 7.52-7.61 (m, 5H, 
An. 
-(I -Hydroxyaminoethyl)-phenol 43 
1-(4-hydroxyphenyl)-ethanone oxime 53 (0.57g) was treated as per Method C to 
afford 0.41g of the title compound (71% yield) as a pale yellow oil after Kugelrohr 
purification. Analytical data matched published values. 217 
'H NMR S, (250 MHz, CDCI3); 1.59 (d, 311, J6.41`1z, CH3), 4.19 (q, IH, J"6.4Hz, 
CFI-N), 6.88 (d, 2H, J=82Hz, ArH), 7.19 (d, 211, J=8.2Hz, ArH). 
N- [(4- Bromophenyi) -phenyl ,nethyl]hydroxylamine 45 
I -(4-Bromo-phenyl)-phenylmethanone oxime 55 (1.0g) was treated as per Method 
C to afford 0.90g of the title compound (89% yield) as a cream solid after 
recrystalisation from ether. 
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1 H NMR 611 (250 MHz, CDCI 3); 5.29 (m, 11-1, CH-N); 6.92-7.33 (m, 911, ArM); FT-
JR (cm') 1440, 1397, 1136; MS Ei+ (nVz) 279 (M), 277, 248, 245(base peak); Acc. 
Mass: found 277.01018, calc 277.01022. 
N-( 1 -Cyclohexylethyl)-hydroxylamine 46 
The general procedure was followed employing 1-cyclohexylethanone oxime 56 
(2.0g) to afford 1.70g of the title compound (84% yield) as white crystals after 
recrystallisation from petroleum ether:hexane. 
'H NMR 611 (250 MHz, CDCI3); 1.10-1.44 (m, 5.H, ring CU2 & ring CH), 1.31 (d, 
3H, 3=6.8Hz, CU 3) 1.70-1.89 (m, 6H, ring CU2), 3.23-3.32 (m, 111, CU-N); 13C 
NMR 6c (60 MHz, CD 3 0D); 12.4 (CU3), 27.7 (ring CU2), 27.9 (ring CU2), 28.9 
(ring CH2), 31.6 (ring CU2), 40.1 (ring CU), 64.3 (CU-N); FT-IR (cm -1 ) 1617, 1450, 
1294; MS EI+ (mlz) 143 (M'), 128, 69, 60 (base peak); Ace. Mass: found 
143.13095,calc. 143.13101. 
N-Cyclopentyl-hydroxylamine 49 
Cyclopentanone oxime 59 (2.0g) was treated as per Method A to afford 1.77g of the 
title compound (87% yield) as a pale yellow oil after Kugelrohr purification. 
'H NMR 6R  (250 MHz, CDCI 3 ) 1.42-1.78 (m, 811, CU 2 ), 3.45-3.50 (m, IH, CU-N); 
' 3 C NMR 6 (60 MHz, CDCI3) 24.3 (CH2CH2CU-N), 29.9 (CH2CH2CH-N), 62.8 
(CU-N); FT-IR (cm- ') 1519, 1443, 1351, 1192, 1049; MS EI+ (m/z) 101 (M), 84, 
72 (base peak), 69; Ace. Mass: found 101.08396, calc. 101.08406. 
7.10 General procedure for the synthesis of racemic 0-methyl hydroxylamines 
Method C - formation of hydroxylamine from isolated or commercially available 
oxime 
To a solution of the 0-methyl oxime in MeOH (60mL), containing a trace of methyl 
orange, NaB(CN)U 3  (Seq.) was added; and then 2M MCI-ether was added dropwise 
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with stirring to maintain the strong red colour for 30 mins. The reaction mixture was 
stirred overnight, and the solvent removed in vacuo. The residue was suspended in 
water (60mL) and brought to pH 10 using 6M NaOH aq. and sat. NaHCO 3 and 
extracted with EtOAc. The organic layer was dried over MgSO 4 and the solvent 
removed in vacuo. Purification of the crude product afforded the 0-methyl 
hydroxylamine. 
Method D - direct formation of 0-methyl hydroxylamine from ketone I aldehyde 
To a mixture of the corresponding aldehyde or ketone (leq.) in THF (80mL) and 0-
methy1hydroxylamine hydrochloride (1 .2eq.) in water (30mL) was added Na 2 CO3 
(0.6eq.) in water (30mL). The reaction mixture was rapidly stirred for 18h. To the 
reaction mixture was added EtOAc (SOmL) and the organic layer separated. The 
aqueous layer was extracted with EtOAc (2 x SOrnL) and the combined organic 
layers dried with MgSO4 . The solvent was removed in vacuo to give the crude 
oxime. To a solution of the crude oxime in MeOH (60mL), containing a trace of 
methyl orange, NaB(CN)H3 (Seq.) was added; and then 2M MCI-Ether was added 
dropwise with stirring to maintain the strong red colour for 30 mins. The reaction 
mixture was stirred overnight, and the solvent removed in vacuo. The residue was 
suspended in water (60mL) and brought to pH 10 using 6M NaOH aq. and sat. 
NaHCO3  and extracted with EtOAc. The organic layer was dried over MgSO 4 and 
the solvent removed in vacuo. Purification of the crude product afforded the 0-
methy1hydroxylamine. 
N-( I -phenylethyl)-0-Methyl-hydroxylamine 42 
I -Phenyl-ethanone-0-methyloxime 52 (1.0g) was treated as per Method C to afford 
0.90g of the title compound (89% yield) as a colourless oil after Kugelrohr 
purification. Analytical data matched published values. 214 
'H NMR ö, (250 MHz, CDCI3); 1.37 (d, 3M, J=7.3 Hz, Cl-I3), 3.44 (s, 311, OCI-1 3), 
4.11 (q, IH, J=7.3Hz, CH-N), 7.22-7.41 (m, 5F1, ArH). 
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4-( 1 -Methoxyaminoethyl)-phenol 44 
1-(4-hydroxyphenyl)-ethanone-0-methyl-oxime 54 (2.0g) was treated as per Method 
C to afford 1.94g of the title compound (96% yield) as pale yellow crystals after 
recrystalisation of the crude product for ether:hexane. 
'H NMR 8H (250 MHz, CDCI3); 1.56 (d, 3M, J=6.7Hz, CM3), 3.71 (s, 3H, OCH3), 
4.30 (q, 111, J=6.7H1, CU-N), 6.92 (d, 2H, J=8.5flz, AM), 7.37 (d, 2H, J=8.514z, 
An-I); ' 3C NMR 8, (60 MHz, CDCI3) 19.1 (CM3), 59.6 (CU-N), 62.0 (0CM3), 115.3 
(ArCH), 128.3 (ArCH), 133.4 (ArC), 155.3 (ArC-OH); FT-JR (cm') 1614, 1516, 
1454, 1374, 1242; MS E1+ (mlz) 167 (M), 135, 121 (base peak), 107; Ace. Mass: 
found 167.09469. calc. 167.09463. 
N-( I -Cyclohexylethyl)-O-methyl-hydroxylamine 47 
1-cyclohexylethanone-0-rnethyl-oxime 57 (2.0g) was treated as per Method C to 
afford l.Slg of the title compound (75% yield) as a colourless oil after Kugekrohr 
purification. 
'H NMR 6K  (250 MHz, CDCI3); 1.01 (d, 3M, J=6.5Hz, CM3), 0.88-1.09 (ni, 4H, ring 
Cl-I2), 1.10-1.34 (2H, ring CH2),1.37-1.53 (111, IH, ring CM), 1.66-1.78 (m, 4H, ring 
CH2), 2.83 (dt, 111, i, 1H, CM-N), 3.54 (s, 3H, OCH3); ' 3C NMR & (60 MHz, 
CDCI3); 14.4 (CH3), 26.2 (ring CM2), 26.4 (ring CH 2 ), 26.5 (ring CM2), 29.1 (ring 
CH2), 29.8 (ring CH2), 39.9 (ring CH), 60.4 (CH-N), 62.1 (OC.l-1 3 ); FT-JR (cm-1 ) 
2371, 1725, 1660, 1608, 1453, 1375, 1220, 1156; MS E1+ (m/z) 157 (M'), 149, 136, 
127, 111 (base peak); Ace. Mass: found 157.14666, calc. 157.14666; GC-MS 
(Method A) >99.5% Purity, ES (m/z) 157.10 (M), 74.07 (base peak). 
N-( I ,2,3,4-Tetrahydronaphthalen-2-yl)-O-rnethyl-hydroxylamine 48 
3,4-Dihydro- I H-naphthalene-2-one-O-methyl-oxime 58 (Sg) was treated as per 
Method C to afford 4.07g of the title compound (81% yield) as a colourless oil after 
distillation of the crude product. 
ME 
'H NMR 511 (250 MHz, CDCI 3 ); 1.47-1.62 (in, il-I, CH 2 CH2 CH-N), 1.92-2.03 (m, 
IH, CH2CH2CH-N), 2.50-2.60 (m, 1H, ArCH2CH-N), 2.72-2.80 (m, 2H, 
CH2CH2CH-N), 2.82-2.95 (in, IH, ArCH2CH-N), 3.21-3.32 (m, 1H, CH-N), 3.51 (s, 
3H, OCH3), 7.01 (in, 4H, ArH); 13C NMR 0ç (60 MHz, CDC],) 26.2 (CFI2CH2C-N), 
26.9 (ArCH2C-N), 32.8 (CH2CH2C-N), 55.3 (C-NH), 61.9 (OCH3), 125.1 (Ar), 125.2 
(Ar), 127.9 (At), 128.7 (Ar), 134.0 (Ar), 135.5 (Ar); FT-JR (cm-1 ) 1580, 1494, 1453; 
MS E1+ (rnlz) 177 (M), 146 (base peak), 131, 115; Ace. Mass: found 177.11549, 
calc. 177.11536; CC-MS (Method A) Purity >99.5%, ES (mlz) 177.10 (M), 129.10 
(base peak). 
N-(2-Methylcyclohexyl)-O-methyl-hydroxylamine 70 
2-Methylcyclohexanone (4.0g) was treated as per Method D to afford 3.11 g of the 
title compound (61% yield) as a colourless oil after Kugelrohr purification 
'H NMR 611 (250 MHz, CDCI3 ) 1.14 (d, il-I, J=7.2Hz, diastereomer A Cl-I 3), 1.19 (d, 
111 1=7.2Hz, diastereomer B CHI), 1.27-1.71 (in, 611, ring CH2), 1.84-2.00 (m, 211, 
CH2CH-N), 2.22-2.29 (m, 111 CHCFI3), 2.65-2.56 (m, IH, CH-N), 3.76 (s, 3H, 
OCH 3 ); 13C NMR & (60 MHz, CDCI3) 13.8 (diastereomer A CU3), 19.0 
(diastereomer B CU3), 22.03 (diastereomer A CH2CHCH3), 23.32 (diastereomer B 
CFI2CHCH3), 25.1 (diastereomer A CHCH3), 25.7 (diastereomer B CHCH3), 30.8 
(ring CU2), 31.3 (ring CU2), 34.3 (ring CH2), 60.6 (diastereomer A OCH3), 62.0 
(diastereorner A C-N), 62.4 (diastereomer B 0CH3), 65.6 (diastereomer B C-N); FT-
lit (cm- ) 1463, 1375, 1062, 1044; MS E1+ (m/z) 143 (M t , base peak), 137, 129, 
125; Ace. Mass: found 143.13115, calc. 143.13101; CC-MS (Method A) purity 
>99.5%, ES (m/z) 143.10 (M t), 86.00 (base peak). 
N-[ I -(4-Fluorophenyl)-ethyl]-O-methyl-hydroxylamine 71 
1-(4-Fluorophenyl)-ethanone (2.2g) was treated as per Method D to afford 1.62g of 
the title compound (60% yield) as a white solid after recrystalisation from 
EtOAc:hexanes. Analytical data matched published values. 218 
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MS EI+ 169 (M+), 123 (base peak), 103; Ace. Mass. found 169.09012, 
cafe. 169.09029. 
N-( 1 -methyl-2-phenylethyl)-O-methyl-hydroxylamine 72 
1-Phenylpropan-2-one (4.0g) was treated as per Method D to afford 3.28g of the title 
compound (67% yield) as a cream solid after recrystallisation from n-hexane 
m.p. 127-129°C, lit. 129-130°C; '1-1 NMR 51.1 (250 MHz, CDCI3) 1.06 (d, 3M, 
J6.4Uz, CH3), 2.58 (dd, IM, J=6.8,6.6Hz, Cl-I2), 2.81 (dd, IM, J=6.8,6.6Uz, CU2), 
3.15-3.28 (m, lU, CU-N), 3.54 (s, 3M, 0CM3), 7.16-7.31 (m, 51-1, ArH); ' 3C NMR & 
(60 MHz, C.DCI3) 17.7 (CM3), 40.1 (CM2), 57.2 (CM-N), 62.4(OCM1), 126.2 (ArCH), 
128.3 (ArCH), 129.2 (ArCH), 138.6 (ArC); FT-JR (cm') 1733, 1616, 1454, 1375, 
1031; MS El+ (m/z) 166 (MU 4 ), 134, 119, 91, 74 (base peak); Ace. Mass: found 
165.11515, cafe. 165.11536. 
2-Methoxyamino-2-phenylethanol 75 
2-Uydroxy-1-phenyl-ethanone (0.97g) was treated as per Method D to afford 0.89g 
of the title compound (75% yield) as a yellow oil after Kugelrohr purification 
'H NMR S, (250 MHz, CDCI3) 3.46 (s, 3M, J=7.41-Iz, 0CM3), 4.19 (dd, IM, J=8.7, 
5.5Hz, CU-N), 4.46 (m, 2H, CU2), 5.28 (bs, 11-I, OH), 731-7.58 (in, 5H, Ar); 13 C 
NMR 8(-,(60  MHz, CDCI 3 ) 57.4 (CU-N), 60.8 (0CM 3 ), 71.8 (CU2), 127.8 (ArCH), 
128.0 (ArCH), 143.4 (ArC); FT-IR (crn') 2550, 1484, 1249; MS E1+ 167 (M+); 
(base peak); Ace. Mass. found 167.09452, cafe. 167.09463. 
N-( 1 -Adamantan-2-ylethyl)-O-rnethyl-hydroxylamine 76 
1-Adainantan-1-yl-ethanone (1.1g) was treated as per Method D to afford 0.53g of 
the title compound (41% yield) as a pale yellow oil after Kugelrohr purification. 
'H NMR 5u (250 MHz, CDCI3) 1.07 (d, 3M, J=6.8Hz, CM3), 1.49-1.71 (m, 12M, Ad 
C112), 1.97 (s, 3M, Ad CM), 2.56 (m, IM, CM-N), 3.32 (s, 3M, OCH3); ' 3 C N.MR 5c 
(60 MHz, CDCI3) 18.8 (CM), 29.2 (Ad CM), 29.4 (Ad CM), 39.4 (Ad C), 41.1 (Ad 
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CH2), 41.5 (Ad CH2), 61.6 (OCH3), 67.2 (C-N); FT-IR (cm-1 ) 2480, 1634, 1459; MS 
El (m/z) 195 (M), 163, 148 (base peak); Ace. Mass. found 209.17801, calc. 
209.17796. 
7.11 Synthesis of enatiopure hydroxylamines 
Synthesis of enatiopure hydroxylamines 
Anhydrous magnesium sulfate (25g) was added to a solution of (R)-amine (leq.) and 
p-anisaldehyde (1.leq) in dry DCM (lSOmL) under an atmosphere of argon and 
stirred for 24 hours. The mixture was then filtered througha pad of anhydrous 
magnesium sulfate and washing with DCM (300mL). The filtrate was cooled under 
argon to 0°C and a slurry of 70-75% m-CPBA (1.2eq.) in DCM (lOOmL) added in 
several portions. After stirring for 1.5 hours the cooling was removed and stirring• 
continued at r.t. for 2.5 hours. The mixture was then filtered, the solid residue 
washed with DCM (I OOmL) and the combined filtrates washed successively with 
0.5M aqueous Na2SO3 (1 5OmL), 0.5M K2CO3 (I 5OmL) and water (50mL) then dried 
over anhydrous magnesium sulfate. The solvent was removed in vacuo, maintaining 
the water bath temperature at r.t. and the oxaziridine residue dissolved in EtOH 
(200mL). This solution was cooled to 0°C under an atmosphere of argon and 
hydroxylamine hydrochloride (I .3eq) was added portion wise. The mixture was 
stirred for 24 hours, allowing the cooling bath to warm to r.t.. Chloroform (300mL) 
was added and stirring continued for 2 hours. The mixture was filtered and the 
solvent removed in vacuo. The oily residue was taken up on water (SOmL) and 
washed with ether (2x5OmL). The aqueous phase was then treated with sat. aq . 
NaFIC03 (50mL) and re-extracted with ether (3x50m1). The combined organic 
extracts were dried over anhydrous magnesium sulphate and the filtered into a flask 
containing anhydrous oxalic acid (1 .2eq) in ether (200ml). The precipitated oxalate 
salt was collected by filtration. Drying in a desiccator overnight afforded the 
enantiopure (R)-hydroxylamine as its oxalate salt. 
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(R)-N-(] -Phenylethyl)-hydroxylamine oxalate salt (R)-35 
The general procedure was followed using crude (R)-a-methylbenzylamine (1.12g) 
to afford 0.65g of the title compound (52% yield) as a white crystals. Analytical data 
matched published values.' 9,22 
Oxalate salt laiD 2° -2.7(c 1.03, MeOH), lit. -2.9 (c 1.0, MeOB); Free base lain 20 - 
29.3 (c 4.00, CI-1C13), lit. -30.1 (c 4.25, CHCI 3 ); spectral data as for rac-35. 
7.13 Laccase mediator preparative scale oxidation 
N-(1 -Phenylethyl)-hydroxylamine oxalate salt 35 (0.343g), laccase (Trametes 
versicolor, 0.624g) and TEMPO free radical (0.118g) were dissolved in pH 4.5 
citrate buffer (90rnL) and MeCN (I 0mL). The reaction mixture was shaken at 
200rpm at 25°C in a sponge stoppered vessel. After 3 hours the reaction mixture was 
centrifuged at 4000rpm for 2mins. The reaction mixture was then decanted and 
washed with ether (2xlOOmL).The combined organic layers were dried (NaSO 4) and 
the solvent removed in vacuo to afford a cream solid. This was found to be 
substantially pure acetophenone oxime 50. The solid was washed with hexane (2 x 
5mL) to afford acetophenone oxime 50 (0.301g, 89%) as a white solid, 
7.13 Kinetic resolution ofJV-methoxycyclohexylethylamine 47 
rac-N-Methoxycyclohexylethylamine 47 (1.21g) was dissolved in pH 7.4 0.IM 
potassium phosphate buffer (20mL). To the solution was added a pellet of E. coli 
BL2I expressing MAO-N5D (2g wet weight). The pellets had been stored at -20°C 
from fermentation until use. The reaction soloution was sponge stoppered and then 
incubated at .25°C overnight with shaking (200rpm). The reaction mixture was 
centrifuged (3000rpm) for I Oniins and the supernatant decanted. The cell pellet was 
resuspended in pH 7.4 0.IM phosphate buffer (10m14 and then centrifuged 
(3000rpm) for S mins. The combined aquoues extracts were washed with EtOAc 
(3x25mL) and the combined organic layters dried over anhydrous magnesium 
sulphate. The solvent was removed in vaccuo to yield a mixture of the product oxime 
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and unconverted hydroxylamine. The residue was prificed using column 
chromotagraphy (n-hexane 70:30 EtOAc to EIOAc 30:70 n-hexane) to yield trans 1-
cyclohexylethanone-0-methyl-oxime 57 (Rf 0.59 (n-hexane 50:50 EtOAc), 0.55g, 
46% yield) and (R)-N-Methoxycyclohexylethylamine 47 (Rç 0.64 (n-hexane 50:50 
EIOAc), 0.53g, 44% yield). 
7.14 Analytical methods 
CC-MS Method A 
GC-MS analysis was performed using an Agilent 6890N Gas Chromatograph 
interfaced to an Agilent 7683 auto-iniector and sample tray. ChemStation software 
was used to record and analyse data. 
CP-Sil S CB Low Bleed/MS column, 25m x 0.25mm, df = 0.25 rim, He l8OkPa, 
splitless, lrij 275 C, Temp 50°C - 150°C, 5°C/mm, 150°C 5mm, 150— 250°C, 
10°C/mm, 250°C 5mm. 
Agilent 5973 El Mass Selective Detector, cone voltage 25V, Data was acquired in 
the kill scan mode over the range m/z 50-250. 
CC Method A 
CC analysis was performed using a Shimadzu GC-8 Gas Chromatography with 
irianula injection. Chrompack software was used to record and analyse data. 
CP-Chirasil-DEX CB column, 25m x 0.25mm, df = 0.25 jim, He 200kPa, 
lOOmL/min split, lnj 250°C, lID Det 250°C, Temp 50°C— 180°C, 10°C/mm, 180°C 
- 200°C, 20°C/mm, 200°C 10mm, cis-oxime 57 (5.00 mins), trans-oxime 57 (5.46 
mins), (l-Phenylethyl)-hydroxylammne 47 (7.52 mins). 
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CC Method B 
CP-Chirasil-DEX CB column, 25m x 0.25mm, df = 0.25 pm, He 200kPa, 
lOOmL/min split, Inj 250°C, FID Det 250°C, Temp 50°C - 180°C, 10°C/mm, 180°C 
- 200°C, 20°C/mm, 200°C 1 0mm, (R)-N-triflate-(I -Phenylethyl)-hydroxylamine 
(7.86 mins), (5)-N-triflate-( I -Phenylethy])-hydroxy]amine (8.14 mins). 
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Appendix I 
MAO-N wild type sequence 
I atg ace ice cga gac gga tac cag tgg aca ccc gag aca ggg ctc 45 
I Met Thr Ser Arg Asp Giy Tyr Gin Trp Thr Pro Glu Thr Giy Leu 15 
46 acg cag ggc gtc ccc tct cta gga gtc atc icc ccg ccc act aat 90 
16 Thr Gin Giy Val Pro Ser Len Giy Val lie Ser Pro Pro Thr Asn 30 
91 ate gaa gac acg gac aaa gat ggt cca tgg gac gtg alt gtc att 135 
31 lie Gin Asp Thr Asp Lys Asp Gly Pro Trp Asp Vat lie Val lie 45 
136 ggi gga ggg tac tgc ggg ttg act gee act agg gac ttg act gta 180 
46 Gly Gly Giy Tyr Cys Gly Len Thr Ala Thr Arg Asp Leu Thr Val 60 
181 gca ggc tic aaa acc ctt ctc etc gaa gcc cga gac cgc ata ggc 225 
61 Ala Giy Phe Lys Thr Len Len Leu Glu Ala Arg Asp Arg lie Giy 75 
226 ggc cgc tcc tgg We tct aac ate gac ggc tat cct tac gag atg 270 
76 Giy Arg Ser Trp 5cr Ser Asn lie Asp Gly Tyr Pro Tyr Giu Met 90 
271 ggc ggc aca tgg gte cac tgg cac caa tcg cac gta tgg cgc gaa 315 
91 Gly Giy Thr Trp Val His Trp His Gin Ser His Val Trp Arg Gin 105 
316 ate acg cgc tac aag atg cac aac gcc cta tca ccc tcc tic aac 360 
106 Ile Thr Arg Tyr Lys Met His Asn Ala Len Ser Pro 5cr Phe Asn 120 
361 tic icc cgc ggc gtg aat cac tic cag eta egg ace aac ccc ace 405 
121 Phe 5cr Arg Gly Val Asn His Phe Gin Len Arg Thr Asn Pro Thr 135 
406 aea tea ace tac atg act cac gaa gee gag gac gag etc etc ege 450 
136 Thr Ser Thr Tyr Met Thr His Glu Ala Glu Asp Gin Len Len Arg 150 
451 tee gea ttg eae aag tic ace aac gig gat gge ace aae gge cgt 495 
151 5cr Ala Len His Lys Phe Thr Aso Val Asp Giy Thr Asn Giy Mg 165 
496 act gte ctg ccc tic ceg cat gac atg tic tat gtt cct gag tic 540 
166 Thr Val Len Pro Phe Pro His Asp Met Phe Tyr Val Pro Gin Phe ISO 
541 agg aag tat gat gag atg tea tac tcg gag egg all gal caa ate 585 
181 Arg Lys Tyr Asp Gin Met Ser Tyr Ser Gin Arg lie Asp Gin lie 195 
586 egg gat gag ttg age cit aat gaa egg agt tel ctg gaa gcg ttt 630 
196 Arg Asp Gin Leu Ser Len Asn Gin Arg Ser Ser Leu Glu Ala Phe 210 
631 ata ttg cit tge tel ggc gga aeg ctg gag aat age tea tit gga 675 
211 lie Leu Len Cys Ser Giy Giy Thr Len Giu Asn Ser Ser Phe Gly 225 
166 
676 gaa tte ctg eat tgg tgg geg atg age gga tat aeg tat cag gga 720 
226 Glu Phe Leu His Trp Trp Ala Met Ser Gly Tyr Thr Tyr Gln Gly 240 
721 tgc atg gac tge ttg ata agt tat aag ttc aag gat ggg eag tet 765 
241 Cys Met Asp Cys Leu lie Ser Tyr Lys Phe Lys Asp Gly GIn Ser 255 
766 gea ttt geg agg agg ttt tgg gag gag geg gee ggg acg ggg agg 810 
256 Ala Phe Ala Arg Arg Phe Trp Glu Glu Ala Ala Gly Thr Gly Arg 270 
811 ttg ggg tat gtg ttt ggg tgt ceg gtt agg agt gtt gtt aat gag 855 
271 Leu Gly Tyr Val Phe Gly Cys Pro Val Arg Ser Val Val Asn Glu 285 
856 aga gat gcg geg aga gtg aeg geg agg gat ggg agg gag ftc gtt 900 
286 Arg Asp Ala Ala Arg Val Thr Ala Mg Asp Gly Arg Glu Phe Vat 300 
901 gcg aag egg gtg gtt tge act aft eec etc aat gte ttg tee aeg 945 
301 Ala Lys Mg Val Vat Cys Thr lie Pro Leu Asn Val Leu Ser Thr 315 
946 ate eag tte tea cet geg etg teg aeg gag agg ate ter get atg 990 
316 He Gin Phe 5cr Pro Ala Leu Ser Thr Glu Mg lie Ser Ala Met 330 
991 eag gea ggt eat gtg aat atg tgc aeg aag gtg eat gee gaa gtg 1035 
331 GIn Ala Gly His Val Asn Met Cys Thr Lys Val His Ala Glu Val 345 
1036 gae aat atg gat atg egg teg tgg aeg ggc aft geg tae eet ftc 1080 
346 Asp Asn Met Asp Met Mg Ser Ti-p Thr Gly lie Ala Tyr Pro Phe 360 
1081 aat aaa etg tgc tat get aft ggt gat ggg aeg act ccc geg gga 1125 
361 Asn Lys Leu Cys Tyr Ala lie Gly Asp Gly Thr Thr Pro Ala Gly 315 
1126 aae aeg eat ctg gtg tgt tte ggg aeg gat gcg aat eat ate eag 1170 
376 Asn Thr His Leu Vat Cys Phe Gly Thr Asp Ala Asn His lie GIn 390 
ll7l ecg gat gag gaegtgegg gag aegttgaaggeggttgggeagttal2iS 
391 Pro Asp Glu Asp Val Mg Glu Thr Leu Lys Ala Val Gly Gin Leu 405 
1216 geg ect ggg aca ttt gga gtg aag egg ftg gtg ttt cac aat tgg 1260 
406 Ala Pro Gly Thr Phe Giy Val Lys Mg Leu Val Phe His Asn lip 420 
1261 gtg aag gat gag ttt geg aag gge geg tgg ftc ftc tet agg cet 1305 
421 Val Lys Asp Glu Phe Ala Lys Giy Ala lip Phe Phe Ser Mg Pro 435 
1306 ggg atg gtg agt gag tgt ttg eag ggg ttg agg gag aag eat ggg 1350 
436 Gly Met Val Ser Glu Cys Leu GIn Gly Leu Mg Glu Lys His Gly 450 
1351 ggtgtggtgttt gcgaattea gat tgg gegttg ggg tgg agg age 1395 
451 Gly Val Val Phe Ala Asn Ser Asp Tip Ala Leu Gly Tip Mg Ser 465 
167 
1396 tIt ati gal ggg gcg att gag gag ggg aeg aga get get agg gtg 1440 
466 Phe lie Asp Gly Ala lie Glu Glu Gly Thr Arg Ala Ala Avg Val 480 
1441 gtg Hg gag gaa ttg gga aeg aag agg gag gtg aag get egi ttg 1485 
481 Val Leu Glu Glu Len Gly Thr Lys Arg Glu Val Lys Ala Avg Len 495 
1486 tga 1488 
496 End 
MAO-SD sequence: 
as wild-type except 	11e246 to Met, Asn336 to 8cr, Met348 to Lys, Thr384 
to Asn, Asp385 to Ser. 
MAO-6 sequence: 
as MAO-SD except 	Leu246 to Met. 
The Genetic code 
T [ 	C A C 
Ill Phe TCI' 5cr TAT Tyr TGT Cys 
TTC Phe ICC 5cr TAC Tyr ICC Cys 
T TTA Leu TCA 5cr TAA Ter TGA Ter 
- 1TGLeu TCG 5cr TAG Ter TGGTrp 
CTT Leu CCI Pro CAT His CGT Arg 
CTC Leu CCC Pro CAC His CGC Arg 
CIA Leu CCA Pro CAA GIn CGA Arg 
= CThLeu CCCPro CAG Gin CGGArg 
ATT lie ACT Thr AM' Asn AGT Ser 
AIC lie ACCThr AACAsn AGC 5cr 
A 
ATA ile ACA Thr AAA Lys AGA Arg 
- ATGMet ACG Thr AAGLys AGGArg 
- GIT Val GCT Ala GAT Asp CCI Gly 
GIC Val CCC Ala GAC Asp I 	GGC Gly 
GTA Val GCA Ala GAA Glu GGA Gly 
= GIG Val GCGAla GAGGlu GGGGly 
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Amino acid symbols and abbreviations 
• 	
Letter Code Amino acid Letter Code Amino acid 
A Ala Alanine M Met Methionine 
C Cys Cysteine N Asn Asparagine 
D Asp Aspartic acid P Pro Proline 
E Glu Giutamic acid Q Gin Glutamine 
F Phe Phenyiaianine R Mg Arginine 
G Gly Giycine S Ser Serine 
H His Flistidine I Thr Threonine 
I lie Isoleucine V Val Valine 
K Lys Lysine W Trp Tryptophan 
L Leu Leucine Y Tyr Tyrosine 
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